_unit_id,_created_at,_canary,_id,_started_at,_channel,_trust,_worker_id,_country,_region,_city,_ip,relations,step_1_select_the_valid_relations,step_2a_copy__paste_only_the_words_from_the_sentence_that_express_the_relation_you_selected_in_step1,step_2b_if_you_selected_none_in_step_1_explain_why,b1,b2,e1,e2,expdec,rel-type,sent_id,sentence,term1,term2
502832716,7/13/2014 18:49:18,,1322049107,7/13/2014 18:48:54,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[SYMPTOM],[SYMPTOM],symptoms,N/A,35,116,63,135,-1,RO-disease_has_finding,901608-FS1,"A case of a 43 year old woman with SEVERE SUSTAINED HYPERTENSION resistant to many antihypertensive drugs, frequent HYPERTENSIVE CRISIS and symptoms suggestive of pheochromocytoma (symptomatic triad) is presented.",SEVERE SUSTAINED HYPERTENSION,HYPERTENSIVE CRISIS
502832716,7/13/2014 18:52:37,,1322050701,7/13/2014 18:52:20,neodev,1,18517457,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],frequent and symptoms,N/a,35,116,63,135,-1,RO-disease_has_finding,901608-FS1,"A case of a 43 year old woman with SEVERE SUSTAINED HYPERTENSION resistant to many antihypertensive drugs, frequent HYPERTENSIVE CRISIS and symptoms suggestive of pheochromocytoma (symptomatic triad) is presented.",SEVERE SUSTAINED HYPERTENSION,HYPERTENSIVE CRISIS
502832716,7/13/2014 18:53:33,,1322051114,7/13/2014 18:52:37,clixsense,1,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],frequent,N/A,35,116,63,135,-1,RO-disease_has_finding,901608-FS1,"A case of a 43 year old woman with SEVERE SUSTAINED HYPERTENSION resistant to many antihypertensive drugs, frequent HYPERTENSIVE CRISIS and symptoms suggestive of pheochromocytoma (symptomatic triad) is presented.",SEVERE SUSTAINED HYPERTENSION,HYPERTENSIVE CRISIS
502832716,7/13/2014 19:04:42,,1322056197,7/13/2014 19:04:36,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],woman,da,35,116,63,135,-1,RO-disease_has_finding,901608-FS1,"A case of a 43 year old woman with SEVERE SUSTAINED HYPERTENSION resistant to many antihypertensive drugs, frequent HYPERTENSIVE CRISIS and symptoms suggestive of pheochromocytoma (symptomatic triad) is presented.",SEVERE SUSTAINED HYPERTENSION,HYPERTENSIVE CRISIS
502832716,7/13/2014 19:06:50,,1322057103,7/13/2014 19:06:42,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],SUSTAINED,N/A,35,116,63,135,-1,RO-disease_has_finding,901608-FS1,"A case of a 43 year old woman with SEVERE SUSTAINED HYPERTENSION resistant to many antihypertensive drugs, frequent HYPERTENSIVE CRISIS and symptoms suggestive of pheochromocytoma (symptomatic triad) is presented.",SEVERE SUSTAINED HYPERTENSION,HYPERTENSIVE CRISIS
502832716,7/13/2014 19:10:48,,1322058881,7/13/2014 19:09:35,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,[SYMPTOM],[SYMPTOM],"43 year old woman with SEVERE SUSTAINED HYPERTENSION resistant to many antihypertensive drugs, frequent HYPERTENSIVE CRISIS and symptoms suggestive of pheochromocytoma is presented.",N/A,35,116,63,135,-1,RO-disease_has_finding,901608-FS1,"A case of a 43 year old woman with SEVERE SUSTAINED HYPERTENSION resistant to many antihypertensive drugs, frequent HYPERTENSIVE CRISIS and symptoms suggestive of pheochromocytoma (symptomatic triad) is presented.",SEVERE SUSTAINED HYPERTENSION,HYPERTENSIVE CRISIS
502832716,7/13/2014 19:13:31,,1322059977,7/13/2014 19:12:27,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[CAUSES],[CAUSES],is presented.,N/A,35,116,63,135,-1,RO-disease_has_finding,901608-FS1,"A case of a 43 year old woman with SEVERE SUSTAINED HYPERTENSION resistant to many antihypertensive drugs, frequent HYPERTENSIVE CRISIS and symptoms suggestive of pheochromocytoma (symptomatic triad) is presented.",SEVERE SUSTAINED HYPERTENSION,HYPERTENSIVE CRISIS
502832716,7/13/2014 19:20:37,,1322062827,7/13/2014 19:19:12,clixsense,1,15189335,GBR,K3,Peterborough,81.156.166.189,[CAUSES],[CAUSES],frequent,na,35,116,63,135,-1,RO-disease_has_finding,901608-FS1,"A case of a 43 year old woman with SEVERE SUSTAINED HYPERTENSION resistant to many antihypertensive drugs, frequent HYPERTENSIVE CRISIS and symptoms suggestive of pheochromocytoma (symptomatic triad) is presented.",SEVERE SUSTAINED HYPERTENSION,HYPERTENSIVE CRISIS
502832716,7/13/2014 19:21:35,,1322063119,7/13/2014 19:20:47,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],with and,N/A,35,116,63,135,-1,RO-disease_has_finding,901608-FS1,"A case of a 43 year old woman with SEVERE SUSTAINED HYPERTENSION resistant to many antihypertensive drugs, frequent HYPERTENSIVE CRISIS and symptoms suggestive of pheochromocytoma (symptomatic triad) is presented.",SEVERE SUSTAINED HYPERTENSION,HYPERTENSIVE CRISIS
502832716,7/13/2014 19:26:01,,1322064778,7/13/2014 19:25:20,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",resistant to,[PREVENTS] [TREATS],35,116,63,135,-1,RO-disease_has_finding,901608-FS1,"A case of a 43 year old woman with SEVERE SUSTAINED HYPERTENSION resistant to many antihypertensive drugs, frequent HYPERTENSIVE CRISIS and symptoms suggestive of pheochromocytoma (symptomatic triad) is presented.",SEVERE SUSTAINED HYPERTENSION,HYPERTENSIVE CRISIS
502832716,7/13/2014 19:42:45,,1322071423,7/13/2014 19:42:22,instagc,1,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with SEVERE SUSTAINED HYPERTENSION frequent HYPERTENSIVE CRISIS,N/A,35,116,63,135,-1,RO-disease_has_finding,901608-FS1,"A case of a 43 year old woman with SEVERE SUSTAINED HYPERTENSION resistant to many antihypertensive drugs, frequent HYPERTENSIVE CRISIS and symptoms suggestive of pheochromocytoma (symptomatic triad) is presented.",SEVERE SUSTAINED HYPERTENSION,HYPERTENSIVE CRISIS
502832716,7/13/2014 19:51:50,,1322078623,7/13/2014 19:50:57,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SEVERE SUSTAINED HYPERTENSION HYPERTENSIVE CRISIS,n/a,35,116,63,135,-1,RO-disease_has_finding,901608-FS1,"A case of a 43 year old woman with SEVERE SUSTAINED HYPERTENSION resistant to many antihypertensive drugs, frequent HYPERTENSIVE CRISIS and symptoms suggestive of pheochromocytoma (symptomatic triad) is presented.",SEVERE SUSTAINED HYPERTENSION,HYPERTENSIVE CRISIS
502832716,7/13/2014 20:08:04,,1322095793,7/13/2014 20:07:40,elite,1,28503042,USA,OK,Oakwood,64.250.220.169,[ASSOCIATED_WITH],[ASSOCIATED_WITH],frequent and symptoms,N/A,35,116,63,135,-1,RO-disease_has_finding,901608-FS1,"A case of a 43 year old woman with SEVERE SUSTAINED HYPERTENSION resistant to many antihypertensive drugs, frequent HYPERTENSIVE CRISIS and symptoms suggestive of pheochromocytoma (symptomatic triad) is presented.",SEVERE SUSTAINED HYPERTENSION,HYPERTENSIVE CRISIS
502832716,7/13/2014 20:16:07,,1322102723,7/13/2014 20:15:38,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,35,116,63,135,-1,RO-disease_has_finding,901608-FS1,"A case of a 43 year old woman with SEVERE SUSTAINED HYPERTENSION resistant to many antihypertensive drugs, frequent HYPERTENSIVE CRISIS and symptoms suggestive of pheochromocytoma (symptomatic triad) is presented.",SEVERE SUSTAINED HYPERTENSION,HYPERTENSIVE CRISIS
502832716,7/13/2014 20:18:48,,1322105177,7/13/2014 20:18:27,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,[CAUSES],[CAUSES],frequent,Na,35,116,63,135,-1,RO-disease_has_finding,901608-FS1,"A case of a 43 year old woman with SEVERE SUSTAINED HYPERTENSION resistant to many antihypertensive drugs, frequent HYPERTENSIVE CRISIS and symptoms suggestive of pheochromocytoma (symptomatic triad) is presented.",SEVERE SUSTAINED HYPERTENSION,HYPERTENSIVE CRISIS
502832717,7/13/2014 18:47:01,,1322048061,7/13/2014 18:46:42,clixsense,1.0,19803139,NLD,11,Leiden,82.139.76.131,[TREATS],[TREATS],major autoantigen,N/A,48,0,62,21,1,RO-may_treat,908088-FS1,INSULIN PEPTIDE B9 23 is a major autoantigen in TYPE 1 DIABETES,TYPE 1 DIABETES,INSULIN PEPTIDE B9 23
502832717,7/13/2014 18:47:32,,1322048319,7/13/2014 18:47:14,neodev,1.0,18517457,GBR,"","",86.29.147.112,[TREATS],[TREATS],is a major autoantigen,N/a,48,0,62,21,1,RO-may_treat,908088-FS1,INSULIN PEPTIDE B9 23 is a major autoantigen in TYPE 1 DIABETES,TYPE 1 DIABETES,INSULIN PEPTIDE B9 23
502832717,7/13/2014 18:47:48,,1322048434,7/13/2014 18:47:35,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],autoantigen,Na,48,0,62,21,1,RO-may_treat,908088-FS1,INSULIN PEPTIDE B9 23 is a major autoantigen in TYPE 1 DIABETES,TYPE 1 DIABETES,INSULIN PEPTIDE B9 23
502832717,7/13/2014 18:55:09,,1322051808,7/13/2014 18:54:53,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],major autoantigen,N/A,48,0,62,21,1,RO-may_treat,908088-FS1,INSULIN PEPTIDE B9 23 is a major autoantigen in TYPE 1 DIABETES,TYPE 1 DIABETES,INSULIN PEPTIDE B9 23
502832717,7/13/2014 19:08:24,,1322057878,7/13/2014 19:07:48,instagc,1.0,19686223,CAN,BC,Surrey,154.20.155.106,[TREATS],[TREATS],INSULIN PEPTIDE B9 23 is a major autoantigen in TYPE 1 DIABETES,N/A,48,0,62,21,1,RO-may_treat,908088-FS1,INSULIN PEPTIDE B9 23 is a major autoantigen in TYPE 1 DIABETES,TYPE 1 DIABETES,INSULIN PEPTIDE B9 23
502832717,7/13/2014 19:13:47,,1322060109,7/13/2014 19:12:21,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],major autoantigen in,N/A,48,0,62,21,1,RO-may_treat,908088-FS1,INSULIN PEPTIDE B9 23 is a major autoantigen in TYPE 1 DIABETES,TYPE 1 DIABETES,INSULIN PEPTIDE B9 23
502832717,7/13/2014 19:28:25,,1322065698,7/13/2014 19:27:55,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[ASSOCIATED_WITH],[ASSOCIATED_WITH],major,n/a,48,0,62,21,1,RO-may_treat,908088-FS1,INSULIN PEPTIDE B9 23 is a major autoantigen in TYPE 1 DIABETES,TYPE 1 DIABETES,INSULIN PEPTIDE B9 23
502832717,7/13/2014 19:34:22,,1322067718,7/13/2014 19:33:42,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[CAUSES],[CAUSES],major autoantigen,na,48,0,62,21,1,RO-may_treat,908088-FS1,INSULIN PEPTIDE B9 23 is a major autoantigen in TYPE 1 DIABETES,TYPE 1 DIABETES,INSULIN PEPTIDE B9 23
502832717,7/13/2014 19:34:55,,1322067940,7/13/2014 19:34:04,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],is a major autoantigen in,[DIAGNOSE_BY_TEST_OR_DRUG],48,0,62,21,1,RO-may_treat,908088-FS1,INSULIN PEPTIDE B9 23 is a major autoantigen in TYPE 1 DIABETES,TYPE 1 DIABETES,INSULIN PEPTIDE B9 23
502832717,7/13/2014 19:50:07,,1322077178,7/13/2014 19:49:33,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[TREATS],[TREATS],INSULIN PEPTIDE B9 23 TYPE 1 DIABETES,n/a,48,0,62,21,1,RO-may_treat,908088-FS1,INSULIN PEPTIDE B9 23 is a major autoantigen in TYPE 1 DIABETES,TYPE 1 DIABETES,INSULIN PEPTIDE B9 23
502832717,7/13/2014 19:53:35,,1322080318,7/13/2014 19:52:52,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],autoantigen,n/a,48,0,62,21,1,RO-may_treat,908088-FS1,INSULIN PEPTIDE B9 23 is a major autoantigen in TYPE 1 DIABETES,TYPE 1 DIABETES,INSULIN PEPTIDE B9 23
502832717,7/13/2014 20:31:33,,1322115976,7/13/2014 20:29:46,gifthulk,1,21916793,GBR,"","",87.113.87.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is a major autoantigen,N/A,48,0,62,21,1,RO-may_treat,908088-FS1,INSULIN PEPTIDE B9 23 is a major autoantigen in TYPE 1 DIABETES,TYPE 1 DIABETES,INSULIN PEPTIDE B9 23
502832717,7/13/2014 20:45:37,,1322127677,7/13/2014 20:45:11,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],autoantigen,n/a,48,0,62,21,1,RO-may_treat,908088-FS1,INSULIN PEPTIDE B9 23 is a major autoantigen in TYPE 1 DIABETES,TYPE 1 DIABETES,INSULIN PEPTIDE B9 23
502832717,7/13/2014 21:16:43,,1322154497,7/13/2014 21:13:40,elite,1.0,28397222,GBR,"","",31.49.231.211,[PART_OF],[PART_OF],major autoantigen in,N/A,48,0,62,21,1,RO-may_treat,908088-FS1,INSULIN PEPTIDE B9 23 is a major autoantigen in TYPE 1 DIABETES,TYPE 1 DIABETES,INSULIN PEPTIDE B9 23
502832717,7/13/2014 21:16:44,,1322154529,7/13/2014 21:16:10,clixsense,1.0,26649250,GBR,B7,Bristol,79.71.125.97,[TREATS],[TREATS],is a major autoantigen in,n/a,48,0,62,21,1,RO-may_treat,908088-FS1,INSULIN PEPTIDE B9 23 is a major autoantigen in TYPE 1 DIABETES,TYPE 1 DIABETES,INSULIN PEPTIDE B9 23
502832718,7/13/2014 18:47:02,,1322048082,7/13/2014 18:46:23,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],effective in women with,N/A,91,24,117,49,1,RO-may_treat,908089-FS1,Studies have shown that SUBCUTANEOUS TERIPARATIDE 20 microg/day is effective in women with POSTMENOPAUSAL OSTEOPOROSIS men with idiopathic or hypogonadal osteoporosis and patients with glucocorticoid induced osteoporosis.,POSTMENOPAUSAL OSTEOPOROSIS,SUBCUTANEOUS TERIPARATIDE
502832718,7/13/2014 18:55:26,,1322051923,7/13/2014 18:55:10,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[PREVENTS],[PREVENTS],effective,N/A,91,24,117,49,1,RO-may_treat,908089-FS1,Studies have shown that SUBCUTANEOUS TERIPARATIDE 20 microg/day is effective in women with POSTMENOPAUSAL OSTEOPOROSIS men with idiopathic or hypogonadal osteoporosis and patients with glucocorticoid induced osteoporosis.,POSTMENOPAUSAL OSTEOPOROSIS,SUBCUTANEOUS TERIPARATIDE
502832718,7/13/2014 18:55:54,,1322052201,7/13/2014 18:55:41,neodev,1.0,18517457,GBR,"","",86.29.147.112,[TREATS],[TREATS],is effective,N/a,91,24,117,49,1,RO-may_treat,908089-FS1,Studies have shown that SUBCUTANEOUS TERIPARATIDE 20 microg/day is effective in women with POSTMENOPAUSAL OSTEOPOROSIS men with idiopathic or hypogonadal osteoporosis and patients with glucocorticoid induced osteoporosis.,POSTMENOPAUSAL OSTEOPOROSIS,SUBCUTANEOUS TERIPARATIDE
502832718,7/13/2014 18:59:48,,1322054054,7/13/2014 18:59:14,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],is effective in,N/A,91,24,117,49,1,RO-may_treat,908089-FS1,Studies have shown that SUBCUTANEOUS TERIPARATIDE 20 microg/day is effective in women with POSTMENOPAUSAL OSTEOPOROSIS men with idiopathic or hypogonadal osteoporosis and patients with glucocorticoid induced osteoporosis.,POSTMENOPAUSAL OSTEOPOROSIS,SUBCUTANEOUS TERIPARATIDE
502832718,7/13/2014 19:01:23,,1322054708,7/13/2014 19:01:13,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[TREATS],[TREATS],hypogonadal,da,91,24,117,49,1,RO-may_treat,908089-FS1,Studies have shown that SUBCUTANEOUS TERIPARATIDE 20 microg/day is effective in women with POSTMENOPAUSAL OSTEOPOROSIS men with idiopathic or hypogonadal osteoporosis and patients with glucocorticoid induced osteoporosis.,POSTMENOPAUSAL OSTEOPOROSIS,SUBCUTANEOUS TERIPARATIDE
502832718,7/13/2014 19:09:33,,1322058367,7/13/2014 19:08:54,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PREVENTS],[PREVENTS],effective in,N/A,91,24,117,49,1,RO-may_treat,908089-FS1,Studies have shown that SUBCUTANEOUS TERIPARATIDE 20 microg/day is effective in women with POSTMENOPAUSAL OSTEOPOROSIS men with idiopathic or hypogonadal osteoporosis and patients with glucocorticoid induced osteoporosis.,POSTMENOPAUSAL OSTEOPOROSIS,SUBCUTANEOUS TERIPARATIDE
502832718,7/13/2014 19:12:43,,1322059708,7/13/2014 19:11:48,instagc,1.0,19686223,CAN,BC,Surrey,154.20.155.106,[TREATS],[TREATS],SUBCUTANEOUS TERIPARATIDE 20 microg/day is effective in women with POSTMENOPAUSAL OSTEOPOROSIS men with idiopathic or hypogonadal osteoporosis and patients with glucocorticoid induced osteoporosis.,N/A,91,24,117,49,1,RO-may_treat,908089-FS1,Studies have shown that SUBCUTANEOUS TERIPARATIDE 20 microg/day is effective in women with POSTMENOPAUSAL OSTEOPOROSIS men with idiopathic or hypogonadal osteoporosis and patients with glucocorticoid induced osteoporosis.,POSTMENOPAUSAL OSTEOPOROSIS,SUBCUTANEOUS TERIPARATIDE
502832718,7/13/2014 19:21:40,,1322063187,7/13/2014 19:21:24,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[TREATS],[TREATS],effective,n/a,91,24,117,49,1,RO-may_treat,908089-FS1,Studies have shown that SUBCUTANEOUS TERIPARATIDE 20 microg/day is effective in women with POSTMENOPAUSAL OSTEOPOROSIS men with idiopathic or hypogonadal osteoporosis and patients with glucocorticoid induced osteoporosis.,POSTMENOPAUSAL OSTEOPOROSIS,SUBCUTANEOUS TERIPARATIDE
502832718,7/13/2014 19:44:56,,1322073132,7/13/2014 19:44:32,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],is effective in,N/A,91,24,117,49,1,RO-may_treat,908089-FS1,Studies have shown that SUBCUTANEOUS TERIPARATIDE 20 microg/day is effective in women with POSTMENOPAUSAL OSTEOPOROSIS men with idiopathic or hypogonadal osteoporosis and patients with glucocorticoid induced osteoporosis.,POSTMENOPAUSAL OSTEOPOROSIS,SUBCUTANEOUS TERIPARATIDE
502832718,7/13/2014 19:48:49,,1322076066,7/13/2014 19:48:14,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],SUBCUTANEOUS TERIPARATIDE POSTMENOPAUSAL OSTEOPOROSIS,n/a,91,24,117,49,1,RO-may_treat,908089-FS1,Studies have shown that SUBCUTANEOUS TERIPARATIDE 20 microg/day is effective in women with POSTMENOPAUSAL OSTEOPOROSIS men with idiopathic or hypogonadal osteoporosis and patients with glucocorticoid induced osteoporosis.,POSTMENOPAUSAL OSTEOPOROSIS,SUBCUTANEOUS TERIPARATIDE
502832718,7/13/2014 19:56:40,,1322083337,7/13/2014 19:55:18,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[OTHER],[OTHER],effective,is treated by,91,24,117,49,1,RO-may_treat,908089-FS1,Studies have shown that SUBCUTANEOUS TERIPARATIDE 20 microg/day is effective in women with POSTMENOPAUSAL OSTEOPOROSIS men with idiopathic or hypogonadal osteoporosis and patients with glucocorticoid induced osteoporosis.,POSTMENOPAUSAL OSTEOPOROSIS,SUBCUTANEOUS TERIPARATIDE
502832718,7/13/2014 20:05:28,,1322093192,7/13/2014 20:05:01,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[SYMPTOM],[SYMPTOM],women with,N/A,91,24,117,49,1,RO-may_treat,908089-FS1,Studies have shown that SUBCUTANEOUS TERIPARATIDE 20 microg/day is effective in women with POSTMENOPAUSAL OSTEOPOROSIS men with idiopathic or hypogonadal osteoporosis and patients with glucocorticoid induced osteoporosis.,POSTMENOPAUSAL OSTEOPOROSIS,SUBCUTANEOUS TERIPARATIDE
502832718,7/13/2014 20:11:59,,1322099094,7/13/2014 20:11:15,elite,1.0,28503042,USA,OK,Oakwood,64.250.220.169,[TREATS],[TREATS],SUBCUTANEOUS TERIPARATIDE is effective in women with POSTMENOPAUSAL OSTEOPOROSIS,N/A,91,24,117,49,1,RO-may_treat,908089-FS1,Studies have shown that SUBCUTANEOUS TERIPARATIDE 20 microg/day is effective in women with POSTMENOPAUSAL OSTEOPOROSIS men with idiopathic or hypogonadal osteoporosis and patients with glucocorticoid induced osteoporosis.,POSTMENOPAUSAL OSTEOPOROSIS,SUBCUTANEOUS TERIPARATIDE
502832718,7/13/2014 20:33:57,,1322118211,7/13/2014 20:33:00,elite,1.0,28397222,GBR,"","",31.49.231.211,[TREATS],[TREATS],is effective in,N/A,91,24,117,49,1,RO-may_treat,908089-FS1,Studies have shown that SUBCUTANEOUS TERIPARATIDE 20 microg/day is effective in women with POSTMENOPAUSAL OSTEOPOROSIS men with idiopathic or hypogonadal osteoporosis and patients with glucocorticoid induced osteoporosis.,POSTMENOPAUSAL OSTEOPOROSIS,SUBCUTANEOUS TERIPARATIDE
502832718,7/13/2014 20:47:37,,1322129291,7/13/2014 20:47:18,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],is effective in,n/a,91,24,117,49,1,RO-may_treat,908089-FS1,Studies have shown that SUBCUTANEOUS TERIPARATIDE 20 microg/day is effective in women with POSTMENOPAUSAL OSTEOPOROSIS men with idiopathic or hypogonadal osteoporosis and patients with glucocorticoid induced osteoporosis.,POSTMENOPAUSAL OSTEOPOROSIS,SUBCUTANEOUS TERIPARATIDE
502832719,7/13/2014 18:51:04,,1322049884,7/13/2014 18:50:48,neodev,1.0,18517457,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and the,N/a,21,74,47,93,-1,RO-has_manifestation,906461-FS1,"Love PE, Santoro SA: ANTIPHOSPHOLIPID ANTIBODIES: anticardiolipin and the LUPUS ANTICOAGULANT in systemic lupus erythematosus (SLE) and in non SLE disorders: prevalence and clinical significance.",ANTIPHOSPHOLIPID ANTIBODIES,LUPUS ANTICOAGULANT
502832719,7/13/2014 18:52:30,,1322050669,7/13/2014 18:52:00,clixsense,1.0,19803139,NLD,11,Leiden,82.139.76.131,[OTHER],[OTHER],clinical significance.,N/A,21,74,47,93,-1,RO-has_manifestation,906461-FS1,"Love PE, Santoro SA: ANTIPHOSPHOLIPID ANTIBODIES: anticardiolipin and the LUPUS ANTICOAGULANT in systemic lupus erythematosus (SLE) and in non SLE disorders: prevalence and clinical significance.",ANTIPHOSPHOLIPID ANTIBODIES,LUPUS ANTICOAGULANT
502832719,7/13/2014 19:03:48,,1322055788,7/13/2014 19:03:37,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[OTHER],[OTHER],ANTICOAGULANT,da,21,74,47,93,-1,RO-has_manifestation,906461-FS1,"Love PE, Santoro SA: ANTIPHOSPHOLIPID ANTIBODIES: anticardiolipin and the LUPUS ANTICOAGULANT in systemic lupus erythematosus (SLE) and in non SLE disorders: prevalence and clinical significance.",ANTIPHOSPHOLIPID ANTIBODIES,LUPUS ANTICOAGULANT
502832719,7/13/2014 19:07:26,,1322057425,7/13/2014 19:07:16,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],significance.,N/A,21,74,47,93,-1,RO-has_manifestation,906461-FS1,"Love PE, Santoro SA: ANTIPHOSPHOLIPID ANTIBODIES: anticardiolipin and the LUPUS ANTICOAGULANT in systemic lupus erythematosus (SLE) and in non SLE disorders: prevalence and clinical significance.",ANTIPHOSPHOLIPID ANTIBODIES,LUPUS ANTICOAGULANT
502832719,7/13/2014 19:11:51,,1322059318,7/13/2014 19:11:05,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",prevalence,[SYMPTOM] [MANIFESTATION],21,74,47,93,-1,RO-has_manifestation,906461-FS1,"Love PE, Santoro SA: ANTIPHOSPHOLIPID ANTIBODIES: anticardiolipin and the LUPUS ANTICOAGULANT in systemic lupus erythematosus (SLE) and in non SLE disorders: prevalence and clinical significance.",ANTIPHOSPHOLIPID ANTIBODIES,LUPUS ANTICOAGULANT
502832719,7/13/2014 19:11:57,,1322059385,7/13/2014 19:10:41,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[MANIFESTATION],[MANIFESTATION],in systemic,N/A,21,74,47,93,-1,RO-has_manifestation,906461-FS1,"Love PE, Santoro SA: ANTIPHOSPHOLIPID ANTIBODIES: anticardiolipin and the LUPUS ANTICOAGULANT in systemic lupus erythematosus (SLE) and in non SLE disorders: prevalence and clinical significance.",ANTIPHOSPHOLIPID ANTIBODIES,LUPUS ANTICOAGULANT
502832719,7/13/2014 19:12:24,,1322059587,7/13/2014 19:11:33,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in systemic lupus,na,21,74,47,93,-1,RO-has_manifestation,906461-FS1,"Love PE, Santoro SA: ANTIPHOSPHOLIPID ANTIBODIES: anticardiolipin and the LUPUS ANTICOAGULANT in systemic lupus erythematosus (SLE) and in non SLE disorders: prevalence and clinical significance.",ANTIPHOSPHOLIPID ANTIBODIES,LUPUS ANTICOAGULANT
502832719,7/13/2014 19:13:03,,1322059828,7/13/2014 19:12:34,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],and,N/A,21,74,47,93,-1,RO-has_manifestation,906461-FS1,"Love PE, Santoro SA: ANTIPHOSPHOLIPID ANTIBODIES: anticardiolipin and the LUPUS ANTICOAGULANT in systemic lupus erythematosus (SLE) and in non SLE disorders: prevalence and clinical significance.",ANTIPHOSPHOLIPID ANTIBODIES,LUPUS ANTICOAGULANT
502832719,7/13/2014 19:27:54,,1322065497,7/13/2014 19:27:21,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ANTIPHOSPHOLIPID ANTIBODIES: anticardiolipin and the LUPUS ANTICOAGULANT,n/a,21,74,47,93,-1,RO-has_manifestation,906461-FS1,"Love PE, Santoro SA: ANTIPHOSPHOLIPID ANTIBODIES: anticardiolipin and the LUPUS ANTICOAGULANT in systemic lupus erythematosus (SLE) and in non SLE disorders: prevalence and clinical significance.",ANTIPHOSPHOLIPID ANTIBODIES,LUPUS ANTICOAGULANT
502832719,7/13/2014 19:28:48,,1322065842,7/13/2014 19:28:26,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[PREVENTS],[PREVENTS],and,n/a,21,74,47,93,-1,RO-has_manifestation,906461-FS1,"Love PE, Santoro SA: ANTIPHOSPHOLIPID ANTIBODIES: anticardiolipin and the LUPUS ANTICOAGULANT in systemic lupus erythematosus (SLE) and in non SLE disorders: prevalence and clinical significance.",ANTIPHOSPHOLIPID ANTIBODIES,LUPUS ANTICOAGULANT
502832719,7/13/2014 19:33:43,,1322067493,7/13/2014 19:33:10,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and the in systemic lupus erythematosus,N/A,21,74,47,93,-1,RO-has_manifestation,906461-FS1,"Love PE, Santoro SA: ANTIPHOSPHOLIPID ANTIBODIES: anticardiolipin and the LUPUS ANTICOAGULANT in systemic lupus erythematosus (SLE) and in non SLE disorders: prevalence and clinical significance.",ANTIPHOSPHOLIPID ANTIBODIES,LUPUS ANTICOAGULANT
502832719,7/13/2014 20:00:03,,1322087630,7/13/2014 19:59:24,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ANTIPHOSPHOLIPID ANTIBODIES: LUPUS ANTICOAGULANT,n/a,21,74,47,93,-1,RO-has_manifestation,906461-FS1,"Love PE, Santoro SA: ANTIPHOSPHOLIPID ANTIBODIES: anticardiolipin and the LUPUS ANTICOAGULANT in systemic lupus erythematosus (SLE) and in non SLE disorders: prevalence and clinical significance.",ANTIPHOSPHOLIPID ANTIBODIES,LUPUS ANTICOAGULANT
502832719,7/13/2014 20:08:58,,1322096576,7/13/2014 20:08:23,elite,1.0,28503042,USA,OK,Oakwood,64.250.220.169,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and the,N/A,21,74,47,93,-1,RO-has_manifestation,906461-FS1,"Love PE, Santoro SA: ANTIPHOSPHOLIPID ANTIBODIES: anticardiolipin and the LUPUS ANTICOAGULANT in systemic lupus erythematosus (SLE) and in non SLE disorders: prevalence and clinical significance.",ANTIPHOSPHOLIPID ANTIBODIES,LUPUS ANTICOAGULANT
502832719,7/13/2014 20:17:57,,1322104306,7/13/2014 20:17:40,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],prevalence,Na,21,74,47,93,-1,RO-has_manifestation,906461-FS1,"Love PE, Santoro SA: ANTIPHOSPHOLIPID ANTIBODIES: anticardiolipin and the LUPUS ANTICOAGULANT in systemic lupus erythematosus (SLE) and in non SLE disorders: prevalence and clinical significance.",ANTIPHOSPHOLIPID ANTIBODIES,LUPUS ANTICOAGULANT
502832719,7/13/2014 20:49:22,,1322131013,7/13/2014 20:48:59,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[OTHER],[OTHER],and,n/a,21,74,47,93,-1,RO-has_manifestation,906461-FS1,"Love PE, Santoro SA: ANTIPHOSPHOLIPID ANTIBODIES: anticardiolipin and the LUPUS ANTICOAGULANT in systemic lupus erythematosus (SLE) and in non SLE disorders: prevalence and clinical significance.",ANTIPHOSPHOLIPID ANTIBODIES,LUPUS ANTICOAGULANT
502832720,7/13/2014 18:45:33,,1322047326,7/13/2014 18:45:03,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[PREVENTS],[PREVENTS],took,N/A,50,25,61,34,1,RO-may_treat,908046-FS1,He took a 1 mg tablet of DOXAZOSIN daily for mild HYPERTENSION,HYPERTENSION,DOXAZOSIN
502832720,7/13/2014 18:45:46,,1322047444,7/13/2014 18:45:26,clixsense,1.0,19803139,NLD,11,Leiden,82.139.76.131,[TREATS],[TREATS],took,N/A,50,25,61,34,1,RO-may_treat,908046-FS1,He took a 1 mg tablet of DOXAZOSIN daily for mild HYPERTENSION,HYPERTENSION,DOXAZOSIN
502832720,7/13/2014 18:52:59,,1322050840,7/13/2014 18:52:38,neodev,1.0,18517457,GBR,"","",86.29.147.112,[TREATS],[TREATS],He took,N/a,50,25,61,34,1,RO-may_treat,908046-FS1,He took a 1 mg tablet of DOXAZOSIN daily for mild HYPERTENSION,HYPERTENSION,DOXAZOSIN
502832720,7/13/2014 18:58:11,,1322053321,7/13/2014 18:57:42,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PREVENTS],[PREVENTS],took daily,N/A,50,25,61,34,1,RO-may_treat,908046-FS1,He took a 1 mg tablet of DOXAZOSIN daily for mild HYPERTENSION,HYPERTENSION,DOXAZOSIN
502832720,7/13/2014 19:01:52,,1322054945,7/13/2014 19:01:42,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[MANIFESTATION],[MANIFESTATION],HYPERTENSION,da,50,25,61,34,1,RO-may_treat,908046-FS1,He took a 1 mg tablet of DOXAZOSIN daily for mild HYPERTENSION,HYPERTENSION,DOXAZOSIN
502832720,7/13/2014 19:04:26,,1322056093,7/13/2014 19:03:02,instagc,1.0,19686223,CAN,BC,Surrey,154.20.155.106,[TREATS],[TREATS],He took a tablet of DOXAZOSIN for mild HYPERTENSION,N/A,50,25,61,34,1,RO-may_treat,908046-FS1,He took a 1 mg tablet of DOXAZOSIN daily for mild HYPERTENSION,HYPERTENSION,DOXAZOSIN
502832720,7/13/2014 19:15:07,,1322060629,7/13/2014 19:14:27,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[CONTRAINDICATES],[CONTRAINDICATES],daily for,[CONTRAINDICATES],50,25,61,34,1,RO-may_treat,908046-FS1,He took a 1 mg tablet of DOXAZOSIN daily for mild HYPERTENSION,HYPERTENSION,DOXAZOSIN
502832720,7/13/2014 19:15:12,,1322060666,7/13/2014 19:14:47,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],for,N/A,50,25,61,34,1,RO-may_treat,908046-FS1,He took a 1 mg tablet of DOXAZOSIN daily for mild HYPERTENSION,HYPERTENSION,DOXAZOSIN
502832720,7/13/2014 19:29:07,,1322065951,7/13/2014 19:28:42,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[TREATS],[TREATS],He took a 1 mg tablet of DOXAZOSIN for HYPERTENSION,n/a,50,25,61,34,1,RO-may_treat,908046-FS1,He took a 1 mg tablet of DOXAZOSIN daily for mild HYPERTENSION,HYPERTENSION,DOXAZOSIN
502832720,7/13/2014 19:34:03,,1322067589,7/13/2014 19:33:43,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],daily for mild,N/A,50,25,61,34,1,RO-may_treat,908046-FS1,He took a 1 mg tablet of DOXAZOSIN daily for mild HYPERTENSION,HYPERTENSION,DOXAZOSIN
502832720,7/13/2014 19:48:08,,1322075451,7/13/2014 19:47:25,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[TREATS],[TREATS],DOXAZOSIN HYPERTENSION,n/a,50,25,61,34,1,RO-may_treat,908046-FS1,He took a 1 mg tablet of DOXAZOSIN daily for mild HYPERTENSION,HYPERTENSION,DOXAZOSIN
502832720,7/13/2014 19:54:17,,1322080887,7/13/2014 19:53:44,clixsense,1.0,6365250,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],DOXAZOSIN daily for mild HYPERTENSION,treats,50,25,61,34,1,RO-may_treat,908046-FS1,He took a 1 mg tablet of DOXAZOSIN daily for mild HYPERTENSION,HYPERTENSION,DOXAZOSIN
502832720,7/13/2014 20:06:39,,1322094404,7/13/2014 20:06:19,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[OTHER],[OTHER],took,is treated by,50,25,61,34,1,RO-may_treat,908046-FS1,He took a 1 mg tablet of DOXAZOSIN daily for mild HYPERTENSION,HYPERTENSION,DOXAZOSIN
502832720,7/13/2014 20:06:49,,1322094617,7/13/2014 20:06:26,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[TREATS],[TREATS],for,N/A,50,25,61,34,1,RO-may_treat,908046-FS1,He took a 1 mg tablet of DOXAZOSIN daily for mild HYPERTENSION,HYPERTENSION,DOXAZOSIN
502832720,7/13/2014 20:13:32,,1322100487,7/13/2014 20:12:32,elite,1.0,28503042,USA,OK,Oakwood,64.250.220.169,[TREATS],[TREATS],took DOXAZOSIN daily for HYPERTENSION,N/A,50,25,61,34,1,RO-may_treat,908046-FS1,He took a 1 mg tablet of DOXAZOSIN daily for mild HYPERTENSION,HYPERTENSION,DOXAZOSIN
502832721,7/13/2014 18:43:00,,1322045963,7/13/2014 18:42:30,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SIDE_EFFECT],[SIDE_EFFECT],result,Na,135,49,152,70,1,RO-has_finding_site,905453-FS1,We conclude that this histopathologic feature in PALMAR LICHEN NITIDUS could be the result of the superimposition of lichen nitidus on NORMAL PALMAR SKIN resulting in a picture resembling hypertrophic lichen planus.,NORMAL PALMAR SKIN,PALMAR LICHEN NITIDUS
502832721,7/13/2014 18:44:54,,1322046983,7/13/2014 18:41:58,neodev,1.0,18517457,GBR,"","",86.29.147.112,[MANIFESTATION],[MANIFESTATION],the result of the superimposition,N/a,135,49,152,70,1,RO-has_finding_site,905453-FS1,We conclude that this histopathologic feature in PALMAR LICHEN NITIDUS could be the result of the superimposition of lichen nitidus on NORMAL PALMAR SKIN resulting in a picture resembling hypertrophic lichen planus.,NORMAL PALMAR SKIN,PALMAR LICHEN NITIDUS
502832721,7/13/2014 18:53:32,,1322051113,7/13/2014 18:53:06,clixsense,1.0,19803139,NLD,11,Leiden,82.139.76.131,[OTHER],[OTHER],resulting,N/A,135,49,152,70,1,RO-has_finding_site,905453-FS1,We conclude that this histopathologic feature in PALMAR LICHEN NITIDUS could be the result of the superimposition of lichen nitidus on NORMAL PALMAR SKIN resulting in a picture resembling hypertrophic lichen planus.,NORMAL PALMAR SKIN,PALMAR LICHEN NITIDUS
502832721,7/13/2014 19:02:26,,1322055176,7/13/2014 19:02:18,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[LOCATION],[LOCATION],LICHEN,da,135,49,152,70,1,RO-has_finding_site,905453-FS1,We conclude that this histopathologic feature in PALMAR LICHEN NITIDUS could be the result of the superimposition of lichen nitidus on NORMAL PALMAR SKIN resulting in a picture resembling hypertrophic lichen planus.,NORMAL PALMAR SKIN,PALMAR LICHEN NITIDUS
502832721,7/13/2014 19:09:33,,1322058371,7/13/2014 19:08:25,instagc,1.0,19686223,CAN,BC,Surrey,154.20.155.106,[SYMPTOM] [CAUSES],"[CAUSES]
[SYMPTOM]",this histopathologic feature in PALMAR LICHEN NITIDUS could be the result of the superimposition of lichen nitidus on NORMAL PALMAR SKIN resulting in picture resembling hypertrophic lichen planus.,N/A,135,49,152,70,1,RO-has_finding_site,905453-FS1,We conclude that this histopathologic feature in PALMAR LICHEN NITIDUS could be the result of the superimposition of lichen nitidus on NORMAL PALMAR SKIN resulting in a picture resembling hypertrophic lichen planus.,NORMAL PALMAR SKIN,PALMAR LICHEN NITIDUS
502832721,7/13/2014 19:17:34,,1322061668,7/13/2014 19:16:05,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[ASSOCIATED_WITH],[ASSOCIATED_WITH],could be the result of the superimposition on,N/A,135,49,152,70,1,RO-has_finding_site,905453-FS1,We conclude that this histopathologic feature in PALMAR LICHEN NITIDUS could be the result of the superimposition of lichen nitidus on NORMAL PALMAR SKIN resulting in a picture resembling hypertrophic lichen planus.,NORMAL PALMAR SKIN,PALMAR LICHEN NITIDUS
502832721,7/13/2014 19:18:36,,1322062038,7/13/2014 19:18:06,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[CAUSES],[CAUSES],could be the result of,[CAUSES],135,49,152,70,1,RO-has_finding_site,905453-FS1,We conclude that this histopathologic feature in PALMAR LICHEN NITIDUS could be the result of the superimposition of lichen nitidus on NORMAL PALMAR SKIN resulting in a picture resembling hypertrophic lichen planus.,NORMAL PALMAR SKIN,PALMAR LICHEN NITIDUS
502832721,7/13/2014 19:22:44,,1322063593,7/13/2014 19:20:40,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[CAUSES],[CAUSES],result of,na,135,49,152,70,1,RO-has_finding_site,905453-FS1,We conclude that this histopathologic feature in PALMAR LICHEN NITIDUS could be the result of the superimposition of lichen nitidus on NORMAL PALMAR SKIN resulting in a picture resembling hypertrophic lichen planus.,NORMAL PALMAR SKIN,PALMAR LICHEN NITIDUS
502832721,7/13/2014 19:32:02,,1322066946,7/13/2014 19:31:49,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[ASSOCIATED_WITH],[ASSOCIATED_WITH],the,n/a,135,49,152,70,1,RO-has_finding_site,905453-FS1,We conclude that this histopathologic feature in PALMAR LICHEN NITIDUS could be the result of the superimposition of lichen nitidus on NORMAL PALMAR SKIN resulting in a picture resembling hypertrophic lichen planus.,NORMAL PALMAR SKIN,PALMAR LICHEN NITIDUS
502832721,7/13/2014 19:43:53,,1322072307,7/13/2014 19:42:46,instagc,1.0,13763729,USA,"","",75.182.89.225,[CAUSES],[CAUSES],the result of,N/A,135,49,152,70,1,RO-has_finding_site,905453-FS1,We conclude that this histopathologic feature in PALMAR LICHEN NITIDUS could be the result of the superimposition of lichen nitidus on NORMAL PALMAR SKIN resulting in a picture resembling hypertrophic lichen planus.,NORMAL PALMAR SKIN,PALMAR LICHEN NITIDUS
502832721,7/13/2014 20:12:54,,1322099909,7/13/2014 20:12:23,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],PALMAR LICHEN NORMAL PALMAR,N/A,135,49,152,70,1,RO-has_finding_site,905453-FS1,We conclude that this histopathologic feature in PALMAR LICHEN NITIDUS could be the result of the superimposition of lichen nitidus on NORMAL PALMAR SKIN resulting in a picture resembling hypertrophic lichen planus.,NORMAL PALMAR SKIN,PALMAR LICHEN NITIDUS
502832721,7/13/2014 20:19:58,,1322106206,7/13/2014 20:19:32,elite,1.0,28503042,USA,OK,Oakwood,64.250.220.169,[CAUSES],[CAUSES],PALMAR LICHEN NITIDUS could be the result of NORMAL PALMAR SKIN,N/A,135,49,152,70,1,RO-has_finding_site,905453-FS1,We conclude that this histopathologic feature in PALMAR LICHEN NITIDUS could be the result of the superimposition of lichen nitidus on NORMAL PALMAR SKIN resulting in a picture resembling hypertrophic lichen planus.,NORMAL PALMAR SKIN,PALMAR LICHEN NITIDUS
502832721,7/13/2014 20:39:58,,1322123197,7/13/2014 20:37:53,elite,1.0,28397222,GBR,"","",31.49.231.211,[CAUSES],[CAUSES],the result of,N/A,135,49,152,70,1,RO-has_finding_site,905453-FS1,We conclude that this histopathologic feature in PALMAR LICHEN NITIDUS could be the result of the superimposition of lichen nitidus on NORMAL PALMAR SKIN resulting in a picture resembling hypertrophic lichen planus.,NORMAL PALMAR SKIN,PALMAR LICHEN NITIDUS
502832721,7/13/2014 20:43:54,,1322126224,7/13/2014 20:43:24,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[LOCATION],[LOCATION],on,n/a,135,49,152,70,1,RO-has_finding_site,905453-FS1,We conclude that this histopathologic feature in PALMAR LICHEN NITIDUS could be the result of the superimposition of lichen nitidus on NORMAL PALMAR SKIN resulting in a picture resembling hypertrophic lichen planus.,NORMAL PALMAR SKIN,PALMAR LICHEN NITIDUS
502832721,7/13/2014 21:40:36,,1322172843,7/13/2014 21:40:18,instagc,1.0,28301350,GBR,K4,Plymouth,89.242.63.62,[LOCATION],[LOCATION],on,N/A,135,49,152,70,1,RO-has_finding_site,905453-FS1,We conclude that this histopathologic feature in PALMAR LICHEN NITIDUS could be the result of the superimposition of lichen nitidus on NORMAL PALMAR SKIN resulting in a picture resembling hypertrophic lichen planus.,NORMAL PALMAR SKIN,PALMAR LICHEN NITIDUS
502832722,7/13/2014 18:45:01,,1322047049,7/13/2014 18:44:41,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],found out to have,not sure,85,141,92,149,-1,RO-has_definitional_manifestation,904763-FS1,"An important fraction of the patients admitted to NC, as well as to OC and ENTC, for HEADACHE and/or other complaints were found out to have MIGRAINE by means of a simple screening test.",HEADACHE,MIGRAINE
502832722,7/13/2014 18:45:19,,1322047212,7/13/2014 18:44:55,neodev,1.0,18517457,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],found out to have,N/a,85,141,92,149,-1,RO-has_definitional_manifestation,904763-FS1,"An important fraction of the patients admitted to NC, as well as to OC and ENTC, for HEADACHE and/or other complaints were found out to have MIGRAINE by means of a simple screening test.",HEADACHE,MIGRAINE
502832722,7/13/2014 18:47:49,,1322048435,7/13/2014 18:47:29,clixsense,1.0,19803139,NLD,11,Leiden,82.139.76.131,[SYMPTOM],[SYMPTOM],other complaints,N/A,85,141,92,149,-1,RO-has_definitional_manifestation,904763-FS1,"An important fraction of the patients admitted to NC, as well as to OC and ENTC, for HEADACHE and/or other complaints were found out to have MIGRAINE by means of a simple screening test.",HEADACHE,MIGRAINE
502832722,7/13/2014 19:02:37,,1322055259,7/13/2014 19:02:04,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[IS_A],[IS_A],patients admitted for HEADACHE were found out to have MIGRAINE,n/a,85,141,92,149,-1,RO-has_definitional_manifestation,904763-FS1,"An important fraction of the patients admitted to NC, as well as to OC and ENTC, for HEADACHE and/or other complaints were found out to have MIGRAINE by means of a simple screening test.",HEADACHE,MIGRAINE
502832722,7/13/2014 19:03:17,,1322055560,7/13/2014 19:03:09,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],to,da,85,141,92,149,-1,RO-has_definitional_manifestation,904763-FS1,"An important fraction of the patients admitted to NC, as well as to OC and ENTC, for HEADACHE and/or other complaints were found out to have MIGRAINE by means of a simple screening test.",HEADACHE,MIGRAINE
502832722,7/13/2014 19:04:36,,1322056156,7/13/2014 19:04:27,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],OC,N/A,85,141,92,149,-1,RO-has_definitional_manifestation,904763-FS1,"An important fraction of the patients admitted to NC, as well as to OC and ENTC, for HEADACHE and/or other complaints were found out to have MIGRAINE by means of a simple screening test.",HEADACHE,MIGRAINE
502832722,7/13/2014 19:09:34,,1322058372,7/13/2014 19:08:26,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],were found to have,N/A,85,141,92,149,-1,RO-has_definitional_manifestation,904763-FS1,"An important fraction of the patients admitted to NC, as well as to OC and ENTC, for HEADACHE and/or other complaints were found out to have MIGRAINE by means of a simple screening test.",HEADACHE,MIGRAINE
502832722,7/13/2014 19:14:30,,1322060366,7/13/2014 19:13:33,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[IS_A],[IS_A],were found,N/A,85,141,92,149,-1,RO-has_definitional_manifestation,904763-FS1,"An important fraction of the patients admitted to NC, as well as to OC and ENTC, for HEADACHE and/or other complaints were found out to have MIGRAINE by means of a simple screening test.",HEADACHE,MIGRAINE
502832722,7/13/2014 19:16:37,,1322061261,7/13/2014 19:15:53,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[SYMPTOM],[SYMPTOM],found out to have,N/A,85,141,92,149,-1,RO-has_definitional_manifestation,904763-FS1,"An important fraction of the patients admitted to NC, as well as to OC and ENTC, for HEADACHE and/or other complaints were found out to have MIGRAINE by means of a simple screening test.",HEADACHE,MIGRAINE
502832722,7/13/2014 19:27:18,,1322065278,7/13/2014 19:26:56,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[ASSOCIATED_WITH],[ASSOCIATED_WITH],have,n/a,85,141,92,149,-1,RO-has_definitional_manifestation,904763-FS1,"An important fraction of the patients admitted to NC, as well as to OC and ENTC, for HEADACHE and/or other complaints were found out to have MIGRAINE by means of a simple screening test.",HEADACHE,MIGRAINE
502832722,7/13/2014 19:27:51,,1322065484,7/13/2014 19:27:06,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[LOCATION] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]",were found out,[LOCATION] [DIAGNOSE_BY_TEST_OR_DRUG],85,141,92,149,-1,RO-has_definitional_manifestation,904763-FS1,"An important fraction of the patients admitted to NC, as well as to OC and ENTC, for HEADACHE and/or other complaints were found out to have MIGRAINE by means of a simple screening test.",HEADACHE,MIGRAINE
502832722,7/13/2014 19:32:19,,1322067045,7/13/2014 19:31:33,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[IS_A],[IS_A],and/or,na,85,141,92,149,-1,RO-has_definitional_manifestation,904763-FS1,"An important fraction of the patients admitted to NC, as well as to OC and ENTC, for HEADACHE and/or other complaints were found out to have MIGRAINE by means of a simple screening test.",HEADACHE,MIGRAINE
502832722,7/13/2014 19:38:23,,1322069297,7/13/2014 19:37:25,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],and/or other complaints have,N/A,85,141,92,149,-1,RO-has_definitional_manifestation,904763-FS1,"An important fraction of the patients admitted to NC, as well as to OC and ENTC, for HEADACHE and/or other complaints were found out to have MIGRAINE by means of a simple screening test.",HEADACHE,MIGRAINE
502832722,7/13/2014 20:17:08,,1322103634,7/13/2014 20:16:33,elite,1.0,28503042,USA,OK,Oakwood,64.250.220.169,[SYMPTOM],[SYMPTOM],HEADACHE were found out to have MIGRAINE,N/A,85,141,92,149,-1,RO-has_definitional_manifestation,904763-FS1,"An important fraction of the patients admitted to NC, as well as to OC and ENTC, for HEADACHE and/or other complaints were found out to have MIGRAINE by means of a simple screening test.",HEADACHE,MIGRAINE
502832722,7/13/2014 20:17:39,,1322104072,7/13/2014 20:17:19,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],simple screening,Na,85,141,92,149,-1,RO-has_definitional_manifestation,904763-FS1,"An important fraction of the patients admitted to NC, as well as to OC and ENTC, for HEADACHE and/or other complaints were found out to have MIGRAINE by means of a simple screening test.",HEADACHE,MIGRAINE
502832723,7/13/2014 18:44:40,,1322046880,7/13/2014 18:44:26,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,not sure,61,31,99,49,-1,RO-has_definitional_manifestation,904686-FS1,Neutrophils from patients with CYCLIC NEUTROPENIA (cyNP) and CHEMOTHERAPY INDUCED NEUTROPENIA (CHNP) mobilized [Ca2+]i similar to those from healthy donors.,CHEMOTHERAPY INDUCED NEUTROPENIA (CHNP),CYCLIC NEUTROPENIA
502832723,7/13/2014 18:46:00,,1322047564,7/13/2014 18:45:48,neodev,1.0,18517457,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/a,61,31,99,49,-1,RO-has_definitional_manifestation,904686-FS1,Neutrophils from patients with CYCLIC NEUTROPENIA (cyNP) and CHEMOTHERAPY INDUCED NEUTROPENIA (CHNP) mobilized [Ca2+]i similar to those from healthy donors.,CHEMOTHERAPY INDUCED NEUTROPENIA (CHNP),CYCLIC NEUTROPENIA
502832723,7/13/2014 19:01:46,,1322054877,7/13/2014 19:01:14,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,61,31,99,49,-1,RO-has_definitional_manifestation,904686-FS1,Neutrophils from patients with CYCLIC NEUTROPENIA (cyNP) and CHEMOTHERAPY INDUCED NEUTROPENIA (CHNP) mobilized [Ca2+]i similar to those from healthy donors.,CHEMOTHERAPY INDUCED NEUTROPENIA (CHNP),CYCLIC NEUTROPENIA
502832723,7/13/2014 19:04:48,,1322056243,7/13/2014 19:04:37,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],NEUTROPENIA,N/A,61,31,99,49,-1,RO-has_definitional_manifestation,904686-FS1,Neutrophils from patients with CYCLIC NEUTROPENIA (cyNP) and CHEMOTHERAPY INDUCED NEUTROPENIA (CHNP) mobilized [Ca2+]i similar to those from healthy donors.,CHEMOTHERAPY INDUCED NEUTROPENIA (CHNP),CYCLIC NEUTROPENIA
502832723,7/13/2014 19:09:50,,1322058518,7/13/2014 19:08:49,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],NEUTROPENIA,N/A,61,31,99,49,-1,RO-has_definitional_manifestation,904686-FS1,Neutrophils from patients with CYCLIC NEUTROPENIA (cyNP) and CHEMOTHERAPY INDUCED NEUTROPENIA (CHNP) mobilized [Ca2+]i similar to those from healthy donors.,CHEMOTHERAPY INDUCED NEUTROPENIA (CHNP),CYCLIC NEUTROPENIA
502832723,7/13/2014 19:24:14,,1322064110,7/13/2014 19:24:00,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,61,31,99,49,-1,RO-has_definitional_manifestation,904686-FS1,Neutrophils from patients with CYCLIC NEUTROPENIA (cyNP) and CHEMOTHERAPY INDUCED NEUTROPENIA (CHNP) mobilized [Ca2+]i similar to those from healthy donors.,CHEMOTHERAPY INDUCED NEUTROPENIA (CHNP),CYCLIC NEUTROPENIA
502832723,7/13/2014 19:32:04,,1322066961,7/13/2014 19:30:22,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[MANIFESTATION] [ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]
[ASSOCIATED_WITH]",from patients with,[MANIFESTATION] [ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG],61,31,99,49,-1,RO-has_definitional_manifestation,904686-FS1,Neutrophils from patients with CYCLIC NEUTROPENIA (cyNP) and CHEMOTHERAPY INDUCED NEUTROPENIA (CHNP) mobilized [Ca2+]i similar to those from healthy donors.,CHEMOTHERAPY INDUCED NEUTROPENIA (CHNP),CYCLIC NEUTROPENIA
502832723,7/13/2014 19:47:21,,1322074806,7/13/2014 19:46:43,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CYCLIC NEUTROPENIA (cyNP) CHEMOTHERAPY INDUCED NEUTROPENIA (CHNP),n/a,61,31,99,49,-1,RO-has_definitional_manifestation,904686-FS1,Neutrophils from patients with CYCLIC NEUTROPENIA (cyNP) and CHEMOTHERAPY INDUCED NEUTROPENIA (CHNP) mobilized [Ca2+]i similar to those from healthy donors.,CHEMOTHERAPY INDUCED NEUTROPENIA (CHNP),CYCLIC NEUTROPENIA
502832723,7/13/2014 20:19:30,,1322105789,7/13/2014 20:18:54,elite,1.0,28503042,USA,OK,Oakwood,64.250.220.169,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CYCLIC NEUTROPENIA (cyNP) and CHEMOTHERAPY INDUCED NEUTROPENIA (CHNP),N/A,61,31,99,49,-1,RO-has_definitional_manifestation,904686-FS1,Neutrophils from patients with CYCLIC NEUTROPENIA (cyNP) and CHEMOTHERAPY INDUCED NEUTROPENIA (CHNP) mobilized [Ca2+]i similar to those from healthy donors.,CHEMOTHERAPY INDUCED NEUTROPENIA (CHNP),CYCLIC NEUTROPENIA
502832723,7/13/2014 20:20:10,,1322106366,7/13/2014 20:19:54,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,Na,61,31,99,49,-1,RO-has_definitional_manifestation,904686-FS1,Neutrophils from patients with CYCLIC NEUTROPENIA (cyNP) and CHEMOTHERAPY INDUCED NEUTROPENIA (CHNP) mobilized [Ca2+]i similar to those from healthy donors.,CHEMOTHERAPY INDUCED NEUTROPENIA (CHNP),CYCLIC NEUTROPENIA
502832723,7/13/2014 20:45:10,,1322127342,7/13/2014 20:44:52,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[OTHER],[OTHER],and,n/a,61,31,99,49,-1,RO-has_definitional_manifestation,904686-FS1,Neutrophils from patients with CYCLIC NEUTROPENIA (cyNP) and CHEMOTHERAPY INDUCED NEUTROPENIA (CHNP) mobilized [Ca2+]i similar to those from healthy donors.,CHEMOTHERAPY INDUCED NEUTROPENIA (CHNP),CYCLIC NEUTROPENIA
502832723,7/13/2014 20:56:32,,1322137114,7/13/2014 20:53:33,elite,1.0,28397222,GBR,"","",31.49.231.211,[NONE],[NONE],N/A,Both are variations of the same disease/condition but not connected in this sentence,61,31,99,49,-1,RO-has_definitional_manifestation,904686-FS1,Neutrophils from patients with CYCLIC NEUTROPENIA (cyNP) and CHEMOTHERAPY INDUCED NEUTROPENIA (CHNP) mobilized [Ca2+]i similar to those from healthy donors.,CHEMOTHERAPY INDUCED NEUTROPENIA (CHNP),CYCLIC NEUTROPENIA
502832723,7/13/2014 20:58:25,,1322138939,7/13/2014 20:57:30,clixsense,1.0,26649250,GBR,B7,Bristol,79.71.125.97,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,61,31,99,49,-1,RO-has_definitional_manifestation,904686-FS1,Neutrophils from patients with CYCLIC NEUTROPENIA (cyNP) and CHEMOTHERAPY INDUCED NEUTROPENIA (CHNP) mobilized [Ca2+]i similar to those from healthy donors.,CHEMOTHERAPY INDUCED NEUTROPENIA (CHNP),CYCLIC NEUTROPENIA
502832723,7/13/2014 21:45:08,,1322176258,7/13/2014 21:44:55,instagc,1.0,28301350,GBR,K4,Plymouth,89.242.63.62,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,61,31,99,49,-1,RO-has_definitional_manifestation,904686-FS1,Neutrophils from patients with CYCLIC NEUTROPENIA (cyNP) and CHEMOTHERAPY INDUCED NEUTROPENIA (CHNP) mobilized [Ca2+]i similar to those from healthy donors.,CHEMOTHERAPY INDUCED NEUTROPENIA (CHNP),CYCLIC NEUTROPENIA
502832723,7/13/2014 21:45:38,,1322176734,7/13/2014 21:45:26,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,61,31,99,49,-1,RO-has_definitional_manifestation,904686-FS1,Neutrophils from patients with CYCLIC NEUTROPENIA (cyNP) and CHEMOTHERAPY INDUCED NEUTROPENIA (CHNP) mobilized [Ca2+]i similar to those from healthy donors.,CHEMOTHERAPY INDUCED NEUTROPENIA (CHNP),CYCLIC NEUTROPENIA
502832724,7/13/2014 18:42:12,,1322045515,7/13/2014 18:41:48,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[IS_A],[IS_A],image,Na,346,278,354,293,1,RO-disease_has_primary_anatomic_site,902345-FS1,"Prognosis  In most cases that begin with a small number of patches of hair loss, hair grows back after a few months to a year.[8] In cases with a greater number of patches, hair can either grow back or progress to alopecia totalis or, in rare cases, universalis.[8]  Effects of ALOPECIA AREATA are mainly psychological (loss of self image due to HAIR LOSS.",HAIR LOSS,ALOPECIA AREATA
502832724,7/13/2014 18:46:41,,1322047892,7/13/2014 18:46:10,clixsense,1.0,19803139,NLD,11,Leiden,82.139.76.131,[CAUSES],[CAUSES],Effects,N/A,346,278,354,293,1,RO-disease_has_primary_anatomic_site,902345-FS1,"Prognosis  In most cases that begin with a small number of patches of hair loss, hair grows back after a few months to a year.[8] In cases with a greater number of patches, hair can either grow back or progress to alopecia totalis or, in rare cases, universalis.[8]  Effects of ALOPECIA AREATA are mainly psychological (loss of self image due to HAIR LOSS.",HAIR LOSS,ALOPECIA AREATA
502832724,7/13/2014 18:47:40,,1322048365,7/13/2014 18:47:09,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[CAUSES],[CAUSES],due to,N/A,346,278,354,293,1,RO-disease_has_primary_anatomic_site,902345-FS1,"Prognosis  In most cases that begin with a small number of patches of hair loss, hair grows back after a few months to a year.[8] In cases with a greater number of patches, hair can either grow back or progress to alopecia totalis or, in rare cases, universalis.[8]  Effects of ALOPECIA AREATA are mainly psychological (loss of self image due to HAIR LOSS.",HAIR LOSS,ALOPECIA AREATA
502832724,7/13/2014 18:48:12,,1322048605,7/13/2014 18:47:31,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],(loss of self image due to,N/A,346,278,354,293,1,RO-disease_has_primary_anatomic_site,902345-FS1,"Prognosis  In most cases that begin with a small number of patches of hair loss, hair grows back after a few months to a year.[8] In cases with a greater number of patches, hair can either grow back or progress to alopecia totalis or, in rare cases, universalis.[8]  Effects of ALOPECIA AREATA are mainly psychological (loss of self image due to HAIR LOSS.",HAIR LOSS,ALOPECIA AREATA
502832724,7/13/2014 18:51:45,,1322050209,7/13/2014 18:51:26,neodev,1.0,18517457,GBR,"","",86.29.147.112,[CAUSES],[CAUSES],due to,N/a,346,278,354,293,1,RO-disease_has_primary_anatomic_site,902345-FS1,"Prognosis  In most cases that begin with a small number of patches of hair loss, hair grows back after a few months to a year.[8] In cases with a greater number of patches, hair can either grow back or progress to alopecia totalis or, in rare cases, universalis.[8]  Effects of ALOPECIA AREATA are mainly psychological (loss of self image due to HAIR LOSS.",HAIR LOSS,ALOPECIA AREATA
502832724,7/13/2014 18:54:30,,1322051497,7/13/2014 18:53:11,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[SYMPTOM],[SYMPTOM],due to,N/A,346,278,354,293,1,RO-disease_has_primary_anatomic_site,902345-FS1,"Prognosis  In most cases that begin with a small number of patches of hair loss, hair grows back after a few months to a year.[8] In cases with a greater number of patches, hair can either grow back or progress to alopecia totalis or, in rare cases, universalis.[8]  Effects of ALOPECIA AREATA are mainly psychological (loss of self image due to HAIR LOSS.",HAIR LOSS,ALOPECIA AREATA
502832724,7/13/2014 18:59:47,,1322054036,7/13/2014 18:58:31,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[SYMPTOM],[SYMPTOM],mainly psychological,na,346,278,354,293,1,RO-disease_has_primary_anatomic_site,902345-FS1,"Prognosis  In most cases that begin with a small number of patches of hair loss, hair grows back after a few months to a year.[8] In cases with a greater number of patches, hair can either grow back or progress to alopecia totalis or, in rare cases, universalis.[8]  Effects of ALOPECIA AREATA are mainly psychological (loss of self image due to HAIR LOSS.",HAIR LOSS,ALOPECIA AREATA
502832724,7/13/2014 19:02:55,,1322055387,7/13/2014 19:01:47,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PART_OF],[PART_OF],are due to,N/A,346,278,354,293,1,RO-disease_has_primary_anatomic_site,902345-FS1,"Prognosis  In most cases that begin with a small number of patches of hair loss, hair grows back after a few months to a year.[8] In cases with a greater number of patches, hair can either grow back or progress to alopecia totalis or, in rare cases, universalis.[8]  Effects of ALOPECIA AREATA are mainly psychological (loss of self image due to HAIR LOSS.",HAIR LOSS,ALOPECIA AREATA
502832724,7/13/2014 19:05:38,,1322056560,7/13/2014 19:05:31,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[CAUSES],[CAUSES],begin,da,346,278,354,293,1,RO-disease_has_primary_anatomic_site,902345-FS1,"Prognosis  In most cases that begin with a small number of patches of hair loss, hair grows back after a few months to a year.[8] In cases with a greater number of patches, hair can either grow back or progress to alopecia totalis or, in rare cases, universalis.[8]  Effects of ALOPECIA AREATA are mainly psychological (loss of self image due to HAIR LOSS.",HAIR LOSS,ALOPECIA AREATA
502832724,7/13/2014 19:06:25,,1322056960,7/13/2014 19:05:27,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[SYMPTOM],[SYMPTOM],Effects of,N/A,346,278,354,293,1,RO-disease_has_primary_anatomic_site,902345-FS1,"Prognosis  In most cases that begin with a small number of patches of hair loss, hair grows back after a few months to a year.[8] In cases with a greater number of patches, hair can either grow back or progress to alopecia totalis or, in rare cases, universalis.[8]  Effects of ALOPECIA AREATA are mainly psychological (loss of self image due to HAIR LOSS.",HAIR LOSS,ALOPECIA AREATA
502832724,7/13/2014 19:06:54,,1322057140,7/13/2014 19:05:29,instagc,1.0,19686223,CAN,BC,Surrey,154.20.155.106,[CAUSES],[CAUSES],"Prognosis In most cases that begin with a small number of patches of hair loss, hair grows back after a few months to a year.[8] Effects of ALOPECIA AREATA are mainly psychological",N/A,346,278,354,293,1,RO-disease_has_primary_anatomic_site,902345-FS1,"Prognosis  In most cases that begin with a small number of patches of hair loss, hair grows back after a few months to a year.[8] In cases with a greater number of patches, hair can either grow back or progress to alopecia totalis or, in rare cases, universalis.[8]  Effects of ALOPECIA AREATA are mainly psychological (loss of self image due to HAIR LOSS.",HAIR LOSS,ALOPECIA AREATA
502832724,7/13/2014 19:26:54,,1322065146,7/13/2014 19:26:39,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[SYMPTOM],[SYMPTOM],mainly,n/a,346,278,354,293,1,RO-disease_has_primary_anatomic_site,902345-FS1,"Prognosis  In most cases that begin with a small number of patches of hair loss, hair grows back after a few months to a year.[8] In cases with a greater number of patches, hair can either grow back or progress to alopecia totalis or, in rare cases, universalis.[8]  Effects of ALOPECIA AREATA are mainly psychological (loss of self image due to HAIR LOSS.",HAIR LOSS,ALOPECIA AREATA
502832724,7/13/2014 19:41:00,,1322070337,7/13/2014 19:40:12,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],ALOPECIA AREATA are mainly psychological (loss of self image due to HAIR LOSS.,N/A,346,278,354,293,1,RO-disease_has_primary_anatomic_site,902345-FS1,"Prognosis  In most cases that begin with a small number of patches of hair loss, hair grows back after a few months to a year.[8] In cases with a greater number of patches, hair can either grow back or progress to alopecia totalis or, in rare cases, universalis.[8]  Effects of ALOPECIA AREATA are mainly psychological (loss of self image due to HAIR LOSS.",HAIR LOSS,ALOPECIA AREATA
502832724,7/13/2014 20:02:11,,1322089928,7/13/2014 20:01:31,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[SYMPTOM],[SYMPTOM],ALOPECIA AREATA HAIR,n/a,346,278,354,293,1,RO-disease_has_primary_anatomic_site,902345-FS1,"Prognosis  In most cases that begin with a small number of patches of hair loss, hair grows back after a few months to a year.[8] In cases with a greater number of patches, hair can either grow back or progress to alopecia totalis or, in rare cases, universalis.[8]  Effects of ALOPECIA AREATA are mainly psychological (loss of self image due to HAIR LOSS.",HAIR LOSS,ALOPECIA AREATA
502832724,7/13/2014 20:06:25,,1322094209,7/13/2014 20:06:02,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[SIDE_EFFECT],[SIDE_EFFECT],Effects (loss of self image,N/A,346,278,354,293,1,RO-disease_has_primary_anatomic_site,902345-FS1,"Prognosis  In most cases that begin with a small number of patches of hair loss, hair grows back after a few months to a year.[8] In cases with a greater number of patches, hair can either grow back or progress to alopecia totalis or, in rare cases, universalis.[8]  Effects of ALOPECIA AREATA are mainly psychological (loss of self image due to HAIR LOSS.",HAIR LOSS,ALOPECIA AREATA
502832725,7/13/2014 18:45:22,,1322047240,7/13/2014 18:44:16,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[CAUSES],[CAUSES],due to,na,216,333,257,356,-1,RO-has_definitional_manifestation,904645-FS1,"During the course of our experience with Fontan conversion our surgical strategy has evolved to include various ablative techniques to treat macro re entrant atrial tachycardia, focal (automatic) atrial tachycardia, ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA atrial tachycardia due to accessory connections, atrial fibrillation, and VENTRICULAR TACHYCARDIA",ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA,VENTRICULAR TACHYCARDIA
502832725,7/13/2014 18:49:05,,1322049025,7/13/2014 18:48:47,neodev,1.0,18517457,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],to include,N/a,216,333,257,356,-1,RO-has_definitional_manifestation,904645-FS1,"During the course of our experience with Fontan conversion our surgical strategy has evolved to include various ablative techniques to treat macro re entrant atrial tachycardia, focal (automatic) atrial tachycardia, ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA atrial tachycardia due to accessory connections, atrial fibrillation, and VENTRICULAR TACHYCARDIA",ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA,VENTRICULAR TACHYCARDIA
502832725,7/13/2014 18:50:15,,1322049491,7/13/2014 18:50:00,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,216,333,257,356,-1,RO-has_definitional_manifestation,904645-FS1,"During the course of our experience with Fontan conversion our surgical strategy has evolved to include various ablative techniques to treat macro re entrant atrial tachycardia, focal (automatic) atrial tachycardia, ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA atrial tachycardia due to accessory connections, atrial fibrillation, and VENTRICULAR TACHYCARDIA",ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA,VENTRICULAR TACHYCARDIA
502832725,7/13/2014 18:54:26,,1322051483,7/13/2014 18:54:02,clixsense,1.0,19803139,NLD,11,Leiden,82.139.76.131,[OTHER],[OTHER],"accessory connections,",N/A,216,333,257,356,-1,RO-has_definitional_manifestation,904645-FS1,"During the course of our experience with Fontan conversion our surgical strategy has evolved to include various ablative techniques to treat macro re entrant atrial tachycardia, focal (automatic) atrial tachycardia, ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA atrial tachycardia due to accessory connections, atrial fibrillation, and VENTRICULAR TACHYCARDIA",ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA,VENTRICULAR TACHYCARDIA
502832725,7/13/2014 19:02:50,,1322055344,7/13/2014 19:02:44,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[PART_OF],[PART_OF],REENTRY,da,216,333,257,356,-1,RO-has_definitional_manifestation,904645-FS1,"During the course of our experience with Fontan conversion our surgical strategy has evolved to include various ablative techniques to treat macro re entrant atrial tachycardia, focal (automatic) atrial tachycardia, ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA atrial tachycardia due to accessory connections, atrial fibrillation, and VENTRICULAR TACHYCARDIA",ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA,VENTRICULAR TACHYCARDIA
502832725,7/13/2014 19:04:40,,1322056184,7/13/2014 19:03:44,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],and,N/A,216,333,257,356,-1,RO-has_definitional_manifestation,904645-FS1,"During the course of our experience with Fontan conversion our surgical strategy has evolved to include various ablative techniques to treat macro re entrant atrial tachycardia, focal (automatic) atrial tachycardia, ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA atrial tachycardia due to accessory connections, atrial fibrillation, and VENTRICULAR TACHYCARDIA",ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA,VENTRICULAR TACHYCARDIA
502832725,7/13/2014 19:07:46,,1322057583,7/13/2014 19:06:56,instagc,1.0,19686223,CAN,BC,Surrey,154.20.155.106,[NONE],[NONE],N/A,I cannot find any relations.,216,333,257,356,-1,RO-has_definitional_manifestation,904645-FS1,"During the course of our experience with Fontan conversion our surgical strategy has evolved to include various ablative techniques to treat macro re entrant atrial tachycardia, focal (automatic) atrial tachycardia, ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA atrial tachycardia due to accessory connections, atrial fibrillation, and VENTRICULAR TACHYCARDIA",ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA,VENTRICULAR TACHYCARDIA
502832725,7/13/2014 19:18:33,,1322062006,7/13/2014 19:18:03,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],to treat,N/A,216,333,257,356,-1,RO-has_definitional_manifestation,904645-FS1,"During the course of our experience with Fontan conversion our surgical strategy has evolved to include various ablative techniques to treat macro re entrant atrial tachycardia, focal (automatic) atrial tachycardia, ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA atrial tachycardia due to accessory connections, atrial fibrillation, and VENTRICULAR TACHYCARDIA",ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA,VENTRICULAR TACHYCARDIA
502832725,7/13/2014 19:19:41,,1322062499,7/13/2014 19:18:46,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[IS_A],[IS_A],"techniques to treat ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA due to accessory connections, VENTRICULAR TACHYCARDIA",n/a,216,333,257,356,-1,RO-has_definitional_manifestation,904645-FS1,"During the course of our experience with Fontan conversion our surgical strategy has evolved to include various ablative techniques to treat macro re entrant atrial tachycardia, focal (automatic) atrial tachycardia, ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA atrial tachycardia due to accessory connections, atrial fibrillation, and VENTRICULAR TACHYCARDIA",ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA,VENTRICULAR TACHYCARDIA
502832725,7/13/2014 19:19:50,,1322062588,7/13/2014 19:19:15,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[CAUSES],[CAUSES],"due to accessory connections,",[CAUSES],216,333,257,356,-1,RO-has_definitional_manifestation,904645-FS1,"During the course of our experience with Fontan conversion our surgical strategy has evolved to include various ablative techniques to treat macro re entrant atrial tachycardia, focal (automatic) atrial tachycardia, ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA atrial tachycardia due to accessory connections, atrial fibrillation, and VENTRICULAR TACHYCARDIA",ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA,VENTRICULAR TACHYCARDIA
502832725,7/13/2014 19:40:24,,1322070077,7/13/2014 19:39:49,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],TACHYCARDIA,N/A,216,333,257,356,-1,RO-has_definitional_manifestation,904645-FS1,"During the course of our experience with Fontan conversion our surgical strategy has evolved to include various ablative techniques to treat macro re entrant atrial tachycardia, focal (automatic) atrial tachycardia, ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA atrial tachycardia due to accessory connections, atrial fibrillation, and VENTRICULAR TACHYCARDIA",ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA,VENTRICULAR TACHYCARDIA
502832725,7/13/2014 20:11:50,,1322099016,7/13/2014 20:11:11,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],various ablative techniques to treat,n/a,216,333,257,356,-1,RO-has_definitional_manifestation,904645-FS1,"During the course of our experience with Fontan conversion our surgical strategy has evolved to include various ablative techniques to treat macro re entrant atrial tachycardia, focal (automatic) atrial tachycardia, ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA atrial tachycardia due to accessory connections, atrial fibrillation, and VENTRICULAR TACHYCARDIA",ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA,VENTRICULAR TACHYCARDIA
502832725,7/13/2014 20:17:50,,1322104209,7/13/2014 20:17:16,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,216,333,257,356,-1,RO-has_definitional_manifestation,904645-FS1,"During the course of our experience with Fontan conversion our surgical strategy has evolved to include various ablative techniques to treat macro re entrant atrial tachycardia, focal (automatic) atrial tachycardia, ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA atrial tachycardia due to accessory connections, atrial fibrillation, and VENTRICULAR TACHYCARDIA",ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA,VENTRICULAR TACHYCARDIA
502832725,7/13/2014 20:29:45,,1322114550,7/13/2014 20:28:45,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[OTHER],[OTHER],"various ablative techniques to treat macro re entrant atrial tachycardia,",N/A,216,333,257,356,-1,RO-has_definitional_manifestation,904645-FS1,"During the course of our experience with Fontan conversion our surgical strategy has evolved to include various ablative techniques to treat macro re entrant atrial tachycardia, focal (automatic) atrial tachycardia, ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA atrial tachycardia due to accessory connections, atrial fibrillation, and VENTRICULAR TACHYCARDIA",ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA,VENTRICULAR TACHYCARDIA
502832725,7/13/2014 20:36:58,,1322120672,7/13/2014 20:36:08,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],TACHYCARDIA,N/A,216,333,257,356,-1,RO-has_definitional_manifestation,904645-FS1,"During the course of our experience with Fontan conversion our surgical strategy has evolved to include various ablative techniques to treat macro re entrant atrial tachycardia, focal (automatic) atrial tachycardia, ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA atrial tachycardia due to accessory connections, atrial fibrillation, and VENTRICULAR TACHYCARDIA",ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA,VENTRICULAR TACHYCARDIA
502832726,7/13/2014 18:47:27,,1322048267,7/13/2014 18:47:02,clixsense,1.0,19803139,NLD,11,Leiden,82.139.76.131,[PREVENTS],[PREVENTS],established,N/A,86,21,103,51,-1,RO-disease_has_finding,901775-FS1,Three primary and 16 METASTATIC MELANOMA CELL LINES were established from primary and METASTATIC LESIONS of 4 patients with malignant melanoma.,METASTATIC LESIONS,METASTATIC MELANOMA CELL LINES
502832726,7/13/2014 19:02:04,,1322055017,7/13/2014 19:01:29,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],were established from,N/A,86,21,103,51,-1,RO-disease_has_finding,901775-FS1,Three primary and 16 METASTATIC MELANOMA CELL LINES were established from primary and METASTATIC LESIONS of 4 patients with malignant melanoma.,METASTATIC LESIONS,METASTATIC MELANOMA CELL LINES
502832726,7/13/2014 19:03:08,,1322055498,7/13/2014 19:03:01,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],MELANOMA,da,86,21,103,51,-1,RO-disease_has_finding,901775-FS1,Three primary and 16 METASTATIC MELANOMA CELL LINES were established from primary and METASTATIC LESIONS of 4 patients with malignant melanoma.,METASTATIC LESIONS,METASTATIC MELANOMA CELL LINES
502832726,7/13/2014 19:06:20,,1322056927,7/13/2014 19:06:12,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],primary,N/A,86,21,103,51,-1,RO-disease_has_finding,901775-FS1,Three primary and 16 METASTATIC MELANOMA CELL LINES were established from primary and METASTATIC LESIONS of 4 patients with malignant melanoma.,METASTATIC LESIONS,METASTATIC MELANOMA CELL LINES
502832726,7/13/2014 19:08:53,,1322058076,7/13/2014 19:08:18,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PART_OF],[PART_OF],established,N/A,86,21,103,51,-1,RO-disease_has_finding,901775-FS1,Three primary and 16 METASTATIC MELANOMA CELL LINES were established from primary and METASTATIC LESIONS of 4 patients with malignant melanoma.,METASTATIC LESIONS,METASTATIC MELANOMA CELL LINES
502832726,7/13/2014 19:23:41,,1322063888,7/13/2014 19:23:22,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[MANIFESTATION],[MANIFESTATION],established,n/a,86,21,103,51,-1,RO-disease_has_finding,901775-FS1,Three primary and 16 METASTATIC MELANOMA CELL LINES were established from primary and METASTATIC LESIONS of 4 patients with malignant melanoma.,METASTATIC LESIONS,METASTATIC MELANOMA CELL LINES
502832726,7/13/2014 19:24:16,,1322064121,7/13/2014 19:23:08,instagc,1.0,19686223,CAN,BC,Surrey,154.20.155.106,[PART_OF] [CAUSES],"[CAUSES]
[PART_OF]",Three primary and 16 METASTATIC MELANOMA CELL LINES were established from primary and METASTATIC LESIONS of 4 patients with malignant melanoma.,N/A,86,21,103,51,-1,RO-disease_has_finding,901775-FS1,Three primary and 16 METASTATIC MELANOMA CELL LINES were established from primary and METASTATIC LESIONS of 4 patients with malignant melanoma.,METASTATIC LESIONS,METASTATIC MELANOMA CELL LINES
502832726,7/13/2014 19:33:00,,1322067275,7/13/2014 19:32:23,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],established from,na,86,21,103,51,-1,RO-disease_has_finding,901775-FS1,Three primary and 16 METASTATIC MELANOMA CELL LINES were established from primary and METASTATIC LESIONS of 4 patients with malignant melanoma.,METASTATIC LESIONS,METASTATIC MELANOMA CELL LINES
502832726,7/13/2014 20:00:47,,1322088413,7/13/2014 20:00:08,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],METASTATIC MELANOMA CELL LINES METASTATIC LESIONS,n/a,86,21,103,51,-1,RO-disease_has_finding,901775-FS1,Three primary and 16 METASTATIC MELANOMA CELL LINES were established from primary and METASTATIC LESIONS of 4 patients with malignant melanoma.,METASTATIC LESIONS,METASTATIC MELANOMA CELL LINES
502832726,7/13/2014 20:10:49,,1322098193,7/13/2014 20:08:54,elite,1.0,28397222,GBR,"","",31.49.231.211,[CAUSES],[CAUSES],were established,N/A,86,21,103,51,-1,RO-disease_has_finding,901775-FS1,Three primary and 16 METASTATIC MELANOMA CELL LINES were established from primary and METASTATIC LESIONS of 4 patients with malignant melanoma.,METASTATIC LESIONS,METASTATIC MELANOMA CELL LINES
502832726,7/13/2014 20:19:12,,1322105501,7/13/2014 20:18:49,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],established,Na,86,21,103,51,-1,RO-disease_has_finding,901775-FS1,Three primary and 16 METASTATIC MELANOMA CELL LINES were established from primary and METASTATIC LESIONS of 4 patients with malignant melanoma.,METASTATIC LESIONS,METASTATIC MELANOMA CELL LINES
502832726,7/13/2014 20:23:00,,1322108732,7/13/2014 20:22:46,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[OTHER],[OTHER],METASTATIC METASTATIC,N/A,86,21,103,51,-1,RO-disease_has_finding,901775-FS1,Three primary and 16 METASTATIC MELANOMA CELL LINES were established from primary and METASTATIC LESIONS of 4 patients with malignant melanoma.,METASTATIC LESIONS,METASTATIC MELANOMA CELL LINES
502832726,7/13/2014 20:36:07,,1322119945,7/13/2014 20:35:33,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[PART_OF],[PART_OF],established from,N/A,86,21,103,51,-1,RO-disease_has_finding,901775-FS1,Three primary and 16 METASTATIC MELANOMA CELL LINES were established from primary and METASTATIC LESIONS of 4 patients with malignant melanoma.,METASTATIC LESIONS,METASTATIC MELANOMA CELL LINES
502832726,7/13/2014 21:02:45,,1322142705,7/13/2014 21:02:02,clixsense,1.0,26649250,GBR,B7,Bristol,79.71.125.97,[ASSOCIATED_WITH],[ASSOCIATED_WITH],established from,n/a,86,21,103,51,-1,RO-disease_has_finding,901775-FS1,Three primary and 16 METASTATIC MELANOMA CELL LINES were established from primary and METASTATIC LESIONS of 4 patients with malignant melanoma.,METASTATIC LESIONS,METASTATIC MELANOMA CELL LINES
502832726,7/13/2014 21:43:05,,1322174823,7/13/2014 21:42:50,instagc,1.0,28301350,GBR,K4,Plymouth,89.242.63.62,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,86,21,103,51,-1,RO-disease_has_finding,901775-FS1,Three primary and 16 METASTATIC MELANOMA CELL LINES were established from primary and METASTATIC LESIONS of 4 patients with malignant melanoma.,METASTATIC LESIONS,METASTATIC MELANOMA CELL LINES
502832727,7/13/2014 18:55:23,,1322051905,7/13/2014 18:54:45,clixsense,1.0,19803139,NLD,11,Leiden,82.139.76.131,[LOCATION],[LOCATION],affected,N/A,69,101,73,117,1,RO-disease_has_primary_anatomic_site,902029-FS1,BC]  Specific recommendation: ? Obtain joint fluid from the affected JOINT in all cases of suspected SEPTIC ARTHRITIS,JOINT,SEPTIC ARTHRITIS
502832727,7/13/2014 19:05:21,,1322056435,7/13/2014 19:05:15,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[SYMPTOM],[SYMPTOM],SEPTIC,da,69,101,73,117,1,RO-disease_has_primary_anatomic_site,902029-FS1,BC]  Specific recommendation: ? Obtain joint fluid from the affected JOINT in all cases of suspected SEPTIC ARTHRITIS,JOINT,SEPTIC ARTHRITIS
502832727,7/13/2014 19:06:17,,1322056888,7/13/2014 19:05:28,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PREVENTS],[PREVENTS],Obtain suspected,N/A,69,101,73,117,1,RO-disease_has_primary_anatomic_site,902029-FS1,BC]  Specific recommendation: ? Obtain joint fluid from the affected JOINT in all cases of suspected SEPTIC ARTHRITIS,JOINT,SEPTIC ARTHRITIS
502832727,7/13/2014 19:09:26,,1322058344,7/13/2014 19:09:16,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],affected,N/A,69,101,73,117,1,RO-disease_has_primary_anatomic_site,902029-FS1,BC]  Specific recommendation: ? Obtain joint fluid from the affected JOINT in all cases of suspected SEPTIC ARTHRITIS,JOINT,SEPTIC ARTHRITIS
502832727,7/13/2014 19:19:09,,1322062248,7/13/2014 19:17:26,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[LOCATION],[LOCATION],from the affected JOINT,na,69,101,73,117,1,RO-disease_has_primary_anatomic_site,902029-FS1,BC]  Specific recommendation: ? Obtain joint fluid from the affected JOINT in all cases of suspected SEPTIC ARTHRITIS,JOINT,SEPTIC ARTHRITIS
502832727,7/13/2014 19:25:11,,1322064522,7/13/2014 19:24:18,instagc,1.0,19686223,CAN,BC,Surrey,154.20.155.106,[TREATS],[TREATS],Obtain joint fluid from the affected JOINT in all cases of suspected SEPTIC ARTHRITIS,N/A,69,101,73,117,1,RO-disease_has_primary_anatomic_site,902029-FS1,BC]  Specific recommendation: ? Obtain joint fluid from the affected JOINT in all cases of suspected SEPTIC ARTHRITIS,JOINT,SEPTIC ARTHRITIS
502832727,7/13/2014 19:40:51,,1322070286,7/13/2014 19:40:25,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[LOCATION],[LOCATION],affected JOINT,N/A,69,101,73,117,1,RO-disease_has_primary_anatomic_site,902029-FS1,BC]  Specific recommendation: ? Obtain joint fluid from the affected JOINT in all cases of suspected SEPTIC ARTHRITIS,JOINT,SEPTIC ARTHRITIS
502832727,7/13/2014 19:42:59,,1322071655,7/13/2014 19:41:42,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[LOCATION],[LOCATION],JOINT SEPTIC ARTHRITIS,n/a,69,101,73,117,1,RO-disease_has_primary_anatomic_site,902029-FS1,BC]  Specific recommendation: ? Obtain joint fluid from the affected JOINT in all cases of suspected SEPTIC ARTHRITIS,JOINT,SEPTIC ARTHRITIS
502832727,7/13/2014 20:12:31,,1322099649,7/13/2014 20:12:00,elite,1.0,28503042,USA,OK,Oakwood,64.250.220.169,[MANIFESTATION],[MANIFESTATION],in all cases of suspected SEPTIC ARTHRITIS,N/A,69,101,73,117,1,RO-disease_has_primary_anatomic_site,902029-FS1,BC]  Specific recommendation: ? Obtain joint fluid from the affected JOINT in all cases of suspected SEPTIC ARTHRITIS,JOINT,SEPTIC ARTHRITIS
502832727,7/13/2014 20:46:22,,1322128258,7/13/2014 20:46:04,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[LOCATION],[LOCATION],affected,n/a,69,101,73,117,1,RO-disease_has_primary_anatomic_site,902029-FS1,BC]  Specific recommendation: ? Obtain joint fluid from the affected JOINT in all cases of suspected SEPTIC ARTHRITIS,JOINT,SEPTIC ARTHRITIS
502832727,7/13/2014 21:15:24,,1322153427,7/13/2014 21:14:54,clixsense,1.0,26649250,GBR,B7,Bristol,79.71.125.97,[SYMPTOM],[SYMPTOM],in all cases of,n/a,69,101,73,117,1,RO-disease_has_primary_anatomic_site,902029-FS1,BC]  Specific recommendation: ? Obtain joint fluid from the affected JOINT in all cases of suspected SEPTIC ARTHRITIS,JOINT,SEPTIC ARTHRITIS
502832727,7/13/2014 21:41:36,,1322173679,7/13/2014 21:41:15,instagc,1.0,28301350,GBR,K4,Plymouth,89.242.63.62,[LOCATION],[LOCATION],from the affected,N/A,69,101,73,117,1,RO-disease_has_primary_anatomic_site,902029-FS1,BC]  Specific recommendation: ? Obtain joint fluid from the affected JOINT in all cases of suspected SEPTIC ARTHRITIS,JOINT,SEPTIC ARTHRITIS
502832727,7/13/2014 21:41:51,,1322173904,7/13/2014 21:41:04,elite,1.0,28397222,GBR,"","",31.49.231.211,[LOCATION],[LOCATION],affected,N/A,69,101,73,117,1,RO-disease_has_primary_anatomic_site,902029-FS1,BC]  Specific recommendation: ? Obtain joint fluid from the affected JOINT in all cases of suspected SEPTIC ARTHRITIS,JOINT,SEPTIC ARTHRITIS
502832727,7/13/2014 21:44:40,,1322175916,7/13/2014 21:44:26,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[OTHER],[OTHER],in all cases of suspected,N/A,69,101,73,117,1,RO-disease_has_primary_anatomic_site,902029-FS1,BC]  Specific recommendation: ? Obtain joint fluid from the affected JOINT in all cases of suspected SEPTIC ARTHRITIS,JOINT,SEPTIC ARTHRITIS
502832727,7/13/2014 22:57:37,,1322239036,7/13/2014 22:56:15,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[PART_OF],[PART_OF],all cases of suspected,n/a,69,101,73,117,1,RO-disease_has_primary_anatomic_site,902029-FS1,BC]  Specific recommendation: ? Obtain joint fluid from the affected JOINT in all cases of suspected SEPTIC ARTHRITIS,JOINT,SEPTIC ARTHRITIS
502832728,7/13/2014 19:07:18,,1322057357,7/13/2014 19:06:56,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis of,N/A,83,166,99,184,1,RO-may_diagnose,906826-FS1,Thus the nitroglycerin test seems to be a useful alternative tool for diagnosis of VASOVAGAL SYNCOPE; it is equally specific but more sensitive and feasible than the ISOPROTERENOL TEST.,VASOVAGAL SYNCOPE,ISOPROTERENOL TEST
502832728,7/13/2014 19:17:34,,1322061660,7/13/2014 19:16:17,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[ASSOCIATED_WITH],[ASSOCIATED_WITH],it is equally specific but more sensitive and feasible,[ASSOCIATED_WITH],83,166,99,184,1,RO-may_diagnose,906826-FS1,Thus the nitroglycerin test seems to be a useful alternative tool for diagnosis of VASOVAGAL SYNCOPE; it is equally specific but more sensitive and feasible than the ISOPROTERENOL TEST.,VASOVAGAL SYNCOPE,ISOPROTERENOL TEST
502832728,7/13/2014 19:17:59,,1322061831,7/13/2014 19:17:17,instagc,1.0,19686223,CAN,BC,Surrey,154.20.155.106,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],the nitroglycerin test seems to be useful alternative tool for diagnosis of VASOVAGAL SYNCOPE;,N/A,83,166,99,184,1,RO-may_diagnose,906826-FS1,Thus the nitroglycerin test seems to be a useful alternative tool for diagnosis of VASOVAGAL SYNCOPE; it is equally specific but more sensitive and feasible than the ISOPROTERENOL TEST.,VASOVAGAL SYNCOPE,ISOPROTERENOL TEST
502832728,7/13/2014 19:23:17,,1322063737,7/13/2014 19:22:25,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],tool for diagnosis of,N/A,83,166,99,184,1,RO-may_diagnose,906826-FS1,Thus the nitroglycerin test seems to be a useful alternative tool for diagnosis of VASOVAGAL SYNCOPE; it is equally specific but more sensitive and feasible than the ISOPROTERENOL TEST.,VASOVAGAL SYNCOPE,ISOPROTERENOL TEST
502832728,7/13/2014 19:28:41,,1322065803,7/13/2014 19:27:56,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],the nitroglycerin test for diagnosis of VASOVAGAL SYNCOPE; is equally specific but more sensitive than the ISOPROTERENOL TEST.,n/a,83,166,99,184,1,RO-may_diagnose,906826-FS1,Thus the nitroglycerin test seems to be a useful alternative tool for diagnosis of VASOVAGAL SYNCOPE; it is equally specific but more sensitive and feasible than the ISOPROTERENOL TEST.,VASOVAGAL SYNCOPE,ISOPROTERENOL TEST
502832728,7/13/2014 19:29:21,,1322066051,7/13/2014 19:28:50,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,83,166,99,184,1,RO-may_diagnose,906826-FS1,Thus the nitroglycerin test seems to be a useful alternative tool for diagnosis of VASOVAGAL SYNCOPE; it is equally specific but more sensitive and feasible than the ISOPROTERENOL TEST.,VASOVAGAL SYNCOPE,ISOPROTERENOL TEST
502832728,7/13/2014 20:04:13,,1322091819,7/13/2014 20:02:58,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[NONE],[NONE],N/A,Is a test that tests for a similar condition,83,166,99,184,1,RO-may_diagnose,906826-FS1,Thus the nitroglycerin test seems to be a useful alternative tool for diagnosis of VASOVAGAL SYNCOPE; it is equally specific but more sensitive and feasible than the ISOPROTERENOL TEST.,VASOVAGAL SYNCOPE,ISOPROTERENOL TEST
502832728,7/13/2014 20:44:27,,1322126767,7/13/2014 20:43:57,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],tool for diagnosis,n/a,83,166,99,184,1,RO-may_diagnose,906826-FS1,Thus the nitroglycerin test seems to be a useful alternative tool for diagnosis of VASOVAGAL SYNCOPE; it is equally specific but more sensitive and feasible than the ISOPROTERENOL TEST.,VASOVAGAL SYNCOPE,ISOPROTERENOL TEST
502832728,7/13/2014 21:08:57,,1322148023,7/13/2014 21:08:25,clixsense,1.0,26649250,GBR,B7,Bristol,79.71.125.97,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,n/a,83,166,99,184,1,RO-may_diagnose,906826-FS1,Thus the nitroglycerin test seems to be a useful alternative tool for diagnosis of VASOVAGAL SYNCOPE; it is equally specific but more sensitive and feasible than the ISOPROTERENOL TEST.,VASOVAGAL SYNCOPE,ISOPROTERENOL TEST
502832728,7/13/2014 21:41:03,,1322173203,7/13/2014 21:40:03,elite,1.0,28397222,GBR,"","",31.49.231.211,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],alternative tool for diagnosis,N/A,83,166,99,184,1,RO-may_diagnose,906826-FS1,Thus the nitroglycerin test seems to be a useful alternative tool for diagnosis of VASOVAGAL SYNCOPE; it is equally specific but more sensitive and feasible than the ISOPROTERENOL TEST.,VASOVAGAL SYNCOPE,ISOPROTERENOL TEST
502832728,7/13/2014 21:42:16,,1322174190,7/13/2014 21:41:53,instagc,1.0,28301350,GBR,K4,Plymouth,89.242.63.62,[ASSOCIATED_WITH],[ASSOCIATED_WITH],equally specific,N/A,83,166,99,184,1,RO-may_diagnose,906826-FS1,Thus the nitroglycerin test seems to be a useful alternative tool for diagnosis of VASOVAGAL SYNCOPE; it is equally specific but more sensitive and feasible than the ISOPROTERENOL TEST.,VASOVAGAL SYNCOPE,ISOPROTERENOL TEST
502832728,7/13/2014 21:43:27,,1322175149,7/13/2014 21:43:10,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis of,N/A,83,166,99,184,1,RO-may_diagnose,906826-FS1,Thus the nitroglycerin test seems to be a useful alternative tool for diagnosis of VASOVAGAL SYNCOPE; it is equally specific but more sensitive and feasible than the ISOPROTERENOL TEST.,VASOVAGAL SYNCOPE,ISOPROTERENOL TEST
502832728,7/13/2014 22:52:07,,1322233877,7/13/2014 22:50:24,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[OTHER] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[OTHER]",alternative tool,n/a,83,166,99,184,1,RO-may_diagnose,906826-FS1,Thus the nitroglycerin test seems to be a useful alternative tool for diagnosis of VASOVAGAL SYNCOPE; it is equally specific but more sensitive and feasible than the ISOPROTERENOL TEST.,VASOVAGAL SYNCOPE,ISOPROTERENOL TEST
502832728,7/13/2014 22:58:19,,1322239671,7/13/2014 22:57:22,clixsense,1,16827630,GBR,A7,Birmingham,86.146.169.103,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],tool for diagnosis of VASOVAGAL SYNCOPE;,NONE,83,166,99,184,1,RO-may_diagnose,906826-FS1,Thus the nitroglycerin test seems to be a useful alternative tool for diagnosis of VASOVAGAL SYNCOPE; it is equally specific but more sensitive and feasible than the ISOPROTERENOL TEST.,VASOVAGAL SYNCOPE,ISOPROTERENOL TEST
502832728,7/13/2014 23:06:59,,1322247383,7/13/2014 23:05:08,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,N/A,83,166,99,184,1,RO-may_diagnose,906826-FS1,Thus the nitroglycerin test seems to be a useful alternative tool for diagnosis of VASOVAGAL SYNCOPE; it is equally specific but more sensitive and feasible than the ISOPROTERENOL TEST.,VASOVAGAL SYNCOPE,ISOPROTERENOL TEST
502832729,7/13/2014 18:41:58,,1322045348,7/13/2014 18:41:16,neodev,1.0,18517457,GBR,"","",86.29.147.112,[OTHER],[OTHER],in their,N/a,101,23,114,50,-1,RO-has_causative_agent,903956-FS1,"However, patients with MODERATE TARDIVE DYSKINESIA had significantly more drug free periods in their DRUG HISTORIES than did patients with mild tardive dyskinesia.",DRUG HISTORIES,MODERATE TARDIVE DYSKINESIA
502832729,7/13/2014 18:51:59,,1322050344,7/13/2014 18:51:36,clixsense,1.0,19803139,NLD,11,Leiden,82.139.76.131,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],significantly more drug free periods,N/A,101,23,114,50,-1,RO-has_causative_agent,903956-FS1,"However, patients with MODERATE TARDIVE DYSKINESIA had significantly more drug free periods in their DRUG HISTORIES than did patients with mild tardive dyskinesia.",DRUG HISTORIES,MODERATE TARDIVE DYSKINESIA
502832729,7/13/2014 18:52:16,,1322050443,7/13/2014 18:51:50,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],had significantly,N/A,101,23,114,50,-1,RO-has_causative_agent,903956-FS1,"However, patients with MODERATE TARDIVE DYSKINESIA had significantly more drug free periods in their DRUG HISTORIES than did patients with mild tardive dyskinesia.",DRUG HISTORIES,MODERATE TARDIVE DYSKINESIA
502832729,7/13/2014 18:58:29,,1322053435,7/13/2014 18:57:10,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],significantly more,na,101,23,114,50,-1,RO-has_causative_agent,903956-FS1,"However, patients with MODERATE TARDIVE DYSKINESIA had significantly more drug free periods in their DRUG HISTORIES than did patients with mild tardive dyskinesia.",DRUG HISTORIES,MODERATE TARDIVE DYSKINESIA
502832729,7/13/2014 19:05:06,,1322056344,7/13/2014 19:04:59,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[CONTRAINDICATES],[CONTRAINDICATES],more,da,101,23,114,50,-1,RO-has_causative_agent,903956-FS1,"However, patients with MODERATE TARDIVE DYSKINESIA had significantly more drug free periods in their DRUG HISTORIES than did patients with mild tardive dyskinesia.",DRUG HISTORIES,MODERATE TARDIVE DYSKINESIA
502832729,7/13/2014 19:08:01,,1322057705,7/13/2014 19:07:42,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],significantly,N/A,101,23,114,50,-1,RO-has_causative_agent,903956-FS1,"However, patients with MODERATE TARDIVE DYSKINESIA had significantly more drug free periods in their DRUG HISTORIES than did patients with mild tardive dyskinesia.",DRUG HISTORIES,MODERATE TARDIVE DYSKINESIA
502832729,7/13/2014 19:13:09,,1322059849,7/13/2014 19:12:34,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],had significantly more drug free periods,[DIAGNOSE_BY_TEST_OR_DRUG],101,23,114,50,-1,RO-has_causative_agent,903956-FS1,"However, patients with MODERATE TARDIVE DYSKINESIA had significantly more drug free periods in their DRUG HISTORIES than did patients with mild tardive dyskinesia.",DRUG HISTORIES,MODERATE TARDIVE DYSKINESIA
502832729,7/13/2014 19:24:37,,1322064253,7/13/2014 19:24:16,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[ASSOCIATED_WITH],[ASSOCIATED_WITH],significantly,n/a,101,23,114,50,-1,RO-has_causative_agent,903956-FS1,"However, patients with MODERATE TARDIVE DYSKINESIA had significantly more drug free periods in their DRUG HISTORIES than did patients with mild tardive dyskinesia.",DRUG HISTORIES,MODERATE TARDIVE DYSKINESIA
502832729,7/13/2014 19:26:24,,1322064912,7/13/2014 19:25:57,instagc,1.0,19686223,CAN,BC,Surrey,154.20.155.106,[NONE],[NONE],N/A,I cannot find any relations.,101,23,114,50,-1,RO-has_causative_agent,903956-FS1,"However, patients with MODERATE TARDIVE DYSKINESIA had significantly more drug free periods in their DRUG HISTORIES than did patients with mild tardive dyskinesia.",DRUG HISTORIES,MODERATE TARDIVE DYSKINESIA
502832729,7/13/2014 19:32:59,,1322067262,7/13/2014 19:32:25,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[ASSOCIATED_WITH],[ASSOCIATED_WITH],patients with MODERATE TARDIVE DYSKINESIA drug free periods in their DRUG HISTORIES,n/a,101,23,114,50,-1,RO-has_causative_agent,903956-FS1,"However, patients with MODERATE TARDIVE DYSKINESIA had significantly more drug free periods in their DRUG HISTORIES than did patients with mild tardive dyskinesia.",DRUG HISTORIES,MODERATE TARDIVE DYSKINESIA
502832729,7/13/2014 19:46:38,,1322074397,7/13/2014 19:46:02,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],MODERATE TARDIVE DYSKINESIA DRUG HISTORIES,n/a,101,23,114,50,-1,RO-has_causative_agent,903956-FS1,"However, patients with MODERATE TARDIVE DYSKINESIA had significantly more drug free periods in their DRUG HISTORIES than did patients with mild tardive dyskinesia.",DRUG HISTORIES,MODERATE TARDIVE DYSKINESIA
502832729,7/13/2014 19:52:51,,1322079641,7/13/2014 19:51:44,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],significantly more,n/a,101,23,114,50,-1,RO-has_causative_agent,903956-FS1,"However, patients with MODERATE TARDIVE DYSKINESIA had significantly more drug free periods in their DRUG HISTORIES than did patients with mild tardive dyskinesia.",DRUG HISTORIES,MODERATE TARDIVE DYSKINESIA
502832729,7/13/2014 20:14:51,,1322101689,7/13/2014 20:14:04,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[OTHER],[OTHER],HISTORIES,N/A,101,23,114,50,-1,RO-has_causative_agent,903956-FS1,"However, patients with MODERATE TARDIVE DYSKINESIA had significantly more drug free periods in their DRUG HISTORIES than did patients with mild tardive dyskinesia.",DRUG HISTORIES,MODERATE TARDIVE DYSKINESIA
502832729,7/13/2014 20:21:39,,1322107655,7/13/2014 20:21:18,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],significantly,Na,101,23,114,50,-1,RO-has_causative_agent,903956-FS1,"However, patients with MODERATE TARDIVE DYSKINESIA had significantly more drug free periods in their DRUG HISTORIES than did patients with mild tardive dyskinesia.",DRUG HISTORIES,MODERATE TARDIVE DYSKINESIA
502832729,7/13/2014 21:11:46,,1322150423,7/13/2014 21:10:55,clixsense,1.0,26649250,GBR,B7,Bristol,79.71.125.97,[ASSOCIATED_WITH],[ASSOCIATED_WITH],significantly more drug free periods,n/a,101,23,114,50,-1,RO-has_causative_agent,903956-FS1,"However, patients with MODERATE TARDIVE DYSKINESIA had significantly more drug free periods in their DRUG HISTORIES than did patients with mild tardive dyskinesia.",DRUG HISTORIES,MODERATE TARDIVE DYSKINESIA
502832730,7/13/2014 18:56:56,,1322052660,7/13/2014 18:55:45,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[CAUSES],[CAUSES],cause,N/A,118,55,135,89,1,RO-may_diagnose,906906-FS1,This study prospectively evaluated the accuracy of the DEXAMETHASONE AND METYRAPONE TESTS in determining the cause of CUSHING'S SYNDROME in a series of 25 unselected patients.,CUSHING'S SYNDROME,DEXAMETHASONE AND METYRAPONE TESTS
502832730,7/13/2014 18:57:07,,1322052766,7/13/2014 18:56:30,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],determining cause,na,118,55,135,89,1,RO-may_diagnose,906906-FS1,This study prospectively evaluated the accuracy of the DEXAMETHASONE AND METYRAPONE TESTS in determining the cause of CUSHING'S SYNDROME in a series of 25 unselected patients.,CUSHING'S SYNDROME,DEXAMETHASONE AND METYRAPONE TESTS
502832730,7/13/2014 19:01:28,,1322054750,7/13/2014 19:00:58,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],in determining the cause of,N/A,118,55,135,89,1,RO-may_diagnose,906906-FS1,This study prospectively evaluated the accuracy of the DEXAMETHASONE AND METYRAPONE TESTS in determining the cause of CUSHING'S SYNDROME in a series of 25 unselected patients.,CUSHING'S SYNDROME,DEXAMETHASONE AND METYRAPONE TESTS
502832730,7/13/2014 19:03:01,,1322055451,7/13/2014 19:02:34,instagc,1.0,19686223,CAN,BC,Surrey,154.20.155.106,[CAUSES],[CAUSES],DEXAMETHASONE AND METYRAPONE TESTS in determining the cause of CUSHING'S SYNDROME,N/A,118,55,135,89,1,RO-may_diagnose,906906-FS1,This study prospectively evaluated the accuracy of the DEXAMETHASONE AND METYRAPONE TESTS in determining the cause of CUSHING'S SYNDROME in a series of 25 unselected patients.,CUSHING'S SYNDROME,DEXAMETHASONE AND METYRAPONE TESTS
502832730,7/13/2014 19:04:58,,1322056291,7/13/2014 19:04:30,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[CAUSES],[CAUSES],cause of,N/A,118,55,135,89,1,RO-may_diagnose,906906-FS1,This study prospectively evaluated the accuracy of the DEXAMETHASONE AND METYRAPONE TESTS in determining the cause of CUSHING'S SYNDROME in a series of 25 unselected patients.,CUSHING'S SYNDROME,DEXAMETHASONE AND METYRAPONE TESTS
502832730,7/13/2014 19:08:50,,1322058064,7/13/2014 19:08:41,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],DEXAMETHASONE,N/A,118,55,135,89,1,RO-may_diagnose,906906-FS1,This study prospectively evaluated the accuracy of the DEXAMETHASONE AND METYRAPONE TESTS in determining the cause of CUSHING'S SYNDROME in a series of 25 unselected patients.,CUSHING'S SYNDROME,DEXAMETHASONE AND METYRAPONE TESTS
502832730,7/13/2014 19:12:08,,1322059492,7/13/2014 19:10:07,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],determining the cause of,n/a,118,55,135,89,1,RO-may_diagnose,906906-FS1,This study prospectively evaluated the accuracy of the DEXAMETHASONE AND METYRAPONE TESTS in determining the cause of CUSHING'S SYNDROME in a series of 25 unselected patients.,CUSHING'S SYNDROME,DEXAMETHASONE AND METYRAPONE TESTS
502832730,7/13/2014 19:18:04,,1322061857,7/13/2014 19:17:36,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]",determining the cause,[DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES],118,55,135,89,1,RO-may_diagnose,906906-FS1,This study prospectively evaluated the accuracy of the DEXAMETHASONE AND METYRAPONE TESTS in determining the cause of CUSHING'S SYNDROME in a series of 25 unselected patients.,CUSHING'S SYNDROME,DEXAMETHASONE AND METYRAPONE TESTS
502832730,7/13/2014 19:19:37,,1322062466,7/13/2014 19:19:07,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],in determining the cause of,N/A,118,55,135,89,1,RO-may_diagnose,906906-FS1,This study prospectively evaluated the accuracy of the DEXAMETHASONE AND METYRAPONE TESTS in determining the cause of CUSHING'S SYNDROME in a series of 25 unselected patients.,CUSHING'S SYNDROME,DEXAMETHASONE AND METYRAPONE TESTS
502832730,7/13/2014 19:22:00,,1322063295,7/13/2014 19:21:33,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],DEXAMETHASONE AND METYRAPONE TESTS in determining the cause of CUSHING'S SYNDROME,n/a,118,55,135,89,1,RO-may_diagnose,906906-FS1,This study prospectively evaluated the accuracy of the DEXAMETHASONE AND METYRAPONE TESTS in determining the cause of CUSHING'S SYNDROME in a series of 25 unselected patients.,CUSHING'S SYNDROME,DEXAMETHASONE AND METYRAPONE TESTS
502832730,7/13/2014 19:23:20,,1322063770,7/13/2014 19:23:07,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],determining,n/a,118,55,135,89,1,RO-may_diagnose,906906-FS1,This study prospectively evaluated the accuracy of the DEXAMETHASONE AND METYRAPONE TESTS in determining the cause of CUSHING'S SYNDROME in a series of 25 unselected patients.,CUSHING'S SYNDROME,DEXAMETHASONE AND METYRAPONE TESTS
502832730,7/13/2014 19:44:32,,1322072779,7/13/2014 19:44:12,instagc,1.0,13763729,USA,"","",75.182.89.225,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],determining the cause,n/a,118,55,135,89,1,RO-may_diagnose,906906-FS1,This study prospectively evaluated the accuracy of the DEXAMETHASONE AND METYRAPONE TESTS in determining the cause of CUSHING'S SYNDROME in a series of 25 unselected patients.,CUSHING'S SYNDROME,DEXAMETHASONE AND METYRAPONE TESTS
502832730,7/13/2014 19:54:27,,1322081017,7/13/2014 19:52:44,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[SYMPTOM],[SYMPTOM],DEXAMETHASONE AND METYRAPONE TESTS CUSHING'S SYNDROME,n/a,118,55,135,89,1,RO-may_diagnose,906906-FS1,This study prospectively evaluated the accuracy of the DEXAMETHASONE AND METYRAPONE TESTS in determining the cause of CUSHING'S SYNDROME in a series of 25 unselected patients.,CUSHING'S SYNDROME,DEXAMETHASONE AND METYRAPONE TESTS
502832730,7/13/2014 20:09:09,,1322096721,7/13/2014 20:08:23,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],AND,N/A,118,55,135,89,1,RO-may_diagnose,906906-FS1,This study prospectively evaluated the accuracy of the DEXAMETHASONE AND METYRAPONE TESTS in determining the cause of CUSHING'S SYNDROME in a series of 25 unselected patients.,CUSHING'S SYNDROME,DEXAMETHASONE AND METYRAPONE TESTS
502832730,7/13/2014 20:10:54,,1322098218,7/13/2014 20:10:00,elite,1.0,28503042,USA,OK,Oakwood,64.250.220.169,[CAUSES],[CAUSES],in determining the cause of,N/A,118,55,135,89,1,RO-may_diagnose,906906-FS1,This study prospectively evaluated the accuracy of the DEXAMETHASONE AND METYRAPONE TESTS in determining the cause of CUSHING'S SYNDROME in a series of 25 unselected patients.,CUSHING'S SYNDROME,DEXAMETHASONE AND METYRAPONE TESTS
502832731,7/13/2014 18:48:23,,1322048689,7/13/2014 18:48:07,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,Na,229,281,246,316,1,RO-has_finding_site,905060-FS1,"No beta (A4) amyloid plaques or CAA were found in six marmosets who were older than the injected animals, in four marmosets that had not developed spongiform encephalopathy (SE) having been injected several years previously with HUMAN BRAIN TISSUE from three younger patients with SUSPECTED OR ATYPICAL PRION DISEASE or in 10 younger marmosets who had undergone various neurosurgical procedures.",HUMAN BRAIN TISSUE,SUSPECTED OR ATYPICAL PRION DISEASE
502832731,7/13/2014 18:54:34,,1322051509,7/13/2014 18:54:20,neodev,1.0,18517457,GBR,"","",86.29.147.112,[LOCATION],[LOCATION],with,N/a,229,281,246,316,1,RO-has_finding_site,905060-FS1,"No beta (A4) amyloid plaques or CAA were found in six marmosets who were older than the injected animals, in four marmosets that had not developed spongiform encephalopathy (SE) having been injected several years previously with HUMAN BRAIN TISSUE from three younger patients with SUSPECTED OR ATYPICAL PRION DISEASE or in 10 younger marmosets who had undergone various neurosurgical procedures.",HUMAN BRAIN TISSUE,SUSPECTED OR ATYPICAL PRION DISEASE
502832731,7/13/2014 18:54:53,,1322051703,7/13/2014 18:53:54,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,229,281,246,316,1,RO-has_finding_site,905060-FS1,"No beta (A4) amyloid plaques or CAA were found in six marmosets who were older than the injected animals, in four marmosets that had not developed spongiform encephalopathy (SE) having been injected several years previously with HUMAN BRAIN TISSUE from three younger patients with SUSPECTED OR ATYPICAL PRION DISEASE or in 10 younger marmosets who had undergone various neurosurgical procedures.",HUMAN BRAIN TISSUE,SUSPECTED OR ATYPICAL PRION DISEASE
502832731,7/13/2014 19:05:32,,1322056517,7/13/2014 19:05:24,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],marmosets,N/A,229,281,246,316,1,RO-has_finding_site,905060-FS1,"No beta (A4) amyloid plaques or CAA were found in six marmosets who were older than the injected animals, in four marmosets that had not developed spongiform encephalopathy (SE) having been injected several years previously with HUMAN BRAIN TISSUE from three younger patients with SUSPECTED OR ATYPICAL PRION DISEASE or in 10 younger marmosets who had undergone various neurosurgical procedures.",HUMAN BRAIN TISSUE,SUSPECTED OR ATYPICAL PRION DISEASE
502832731,7/13/2014 19:23:05,,1322063684,7/13/2014 19:22:50,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[LOCATION],[LOCATION],developed,n/a,229,281,246,316,1,RO-has_finding_site,905060-FS1,"No beta (A4) amyloid plaques or CAA were found in six marmosets who were older than the injected animals, in four marmosets that had not developed spongiform encephalopathy (SE) having been injected several years previously with HUMAN BRAIN TISSUE from three younger patients with SUSPECTED OR ATYPICAL PRION DISEASE or in 10 younger marmosets who had undergone various neurosurgical procedures.",HUMAN BRAIN TISSUE,SUSPECTED OR ATYPICAL PRION DISEASE
502832731,7/13/2014 19:28:52,,1322065866,7/13/2014 19:27:56,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[ASSOCIATED_WITH] [CAUSES] [TREATS] [DIAGNOSE_BY_TEST_OR_DRUG] [LOCATION],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[LOCATION]
[ASSOCIATED_WITH]",from younger patients,[ASSOCIATED_WITH] [CAUSES] [TREATS] [DIAGNOSE_BY_TEST_OR_DRUG] [LOCATION],229,281,246,316,1,RO-has_finding_site,905060-FS1,"No beta (A4) amyloid plaques or CAA were found in six marmosets who were older than the injected animals, in four marmosets that had not developed spongiform encephalopathy (SE) having been injected several years previously with HUMAN BRAIN TISSUE from three younger patients with SUSPECTED OR ATYPICAL PRION DISEASE or in 10 younger marmosets who had undergone various neurosurgical procedures.",HUMAN BRAIN TISSUE,SUSPECTED OR ATYPICAL PRION DISEASE
502832731,7/13/2014 19:59:18,,1322086557,7/13/2014 19:58:33,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[LOCATION] [PART_OF],"[LOCATION]
[PART_OF]",HUMAN BRAIN TISSUE SUSPECTED OR ATYPICAL PRION DISEASE,n/a,229,281,246,316,1,RO-has_finding_site,905060-FS1,"No beta (A4) amyloid plaques or CAA were found in six marmosets who were older than the injected animals, in four marmosets that had not developed spongiform encephalopathy (SE) having been injected several years previously with HUMAN BRAIN TISSUE from three younger patients with SUSPECTED OR ATYPICAL PRION DISEASE or in 10 younger marmosets who had undergone various neurosurgical procedures.",HUMAN BRAIN TISSUE,SUSPECTED OR ATYPICAL PRION DISEASE
502832731,7/13/2014 20:23:52,,1322109545,7/13/2014 20:23:31,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],BRAIN PRION DISEASE,N/A,229,281,246,316,1,RO-has_finding_site,905060-FS1,"No beta (A4) amyloid plaques or CAA were found in six marmosets who were older than the injected animals, in four marmosets that had not developed spongiform encephalopathy (SE) having been injected several years previously with HUMAN BRAIN TISSUE from three younger patients with SUSPECTED OR ATYPICAL PRION DISEASE or in 10 younger marmosets who had undergone various neurosurgical procedures.",HUMAN BRAIN TISSUE,SUSPECTED OR ATYPICAL PRION DISEASE
502832731,7/13/2014 20:37:30,,1322121086,7/13/2014 20:36:59,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[LOCATION],[LOCATION],with,N/A,229,281,246,316,1,RO-has_finding_site,905060-FS1,"No beta (A4) amyloid plaques or CAA were found in six marmosets who were older than the injected animals, in four marmosets that had not developed spongiform encephalopathy (SE) having been injected several years previously with HUMAN BRAIN TISSUE from three younger patients with SUSPECTED OR ATYPICAL PRION DISEASE or in 10 younger marmosets who had undergone various neurosurgical procedures.",HUMAN BRAIN TISSUE,SUSPECTED OR ATYPICAL PRION DISEASE
502832731,7/13/2014 20:52:08,,1322133349,7/13/2014 20:51:32,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[LOCATION],[LOCATION],from,n/a,229,281,246,316,1,RO-has_finding_site,905060-FS1,"No beta (A4) amyloid plaques or CAA were found in six marmosets who were older than the injected animals, in four marmosets that had not developed spongiform encephalopathy (SE) having been injected several years previously with HUMAN BRAIN TISSUE from three younger patients with SUSPECTED OR ATYPICAL PRION DISEASE or in 10 younger marmosets who had undergone various neurosurgical procedures.",HUMAN BRAIN TISSUE,SUSPECTED OR ATYPICAL PRION DISEASE
502832731,7/13/2014 21:09:41,,1322148578,7/13/2014 21:08:57,clixsense,1.0,26649250,GBR,B7,Bristol,79.71.125.97,[TREATS],[TREATS],having been injected,n/a,229,281,246,316,1,RO-has_finding_site,905060-FS1,"No beta (A4) amyloid plaques or CAA were found in six marmosets who were older than the injected animals, in four marmosets that had not developed spongiform encephalopathy (SE) having been injected several years previously with HUMAN BRAIN TISSUE from three younger patients with SUSPECTED OR ATYPICAL PRION DISEASE or in 10 younger marmosets who had undergone various neurosurgical procedures.",HUMAN BRAIN TISSUE,SUSPECTED OR ATYPICAL PRION DISEASE
502832731,7/13/2014 21:26:06,,1322162433,7/13/2014 21:23:25,elite,1.0,28397222,GBR,"","",31.49.231.211,[PREVENTS],[PREVENTS],No beta amyloid plaques were found in,N/A,229,281,246,316,1,RO-has_finding_site,905060-FS1,"No beta (A4) amyloid plaques or CAA were found in six marmosets who were older than the injected animals, in four marmosets that had not developed spongiform encephalopathy (SE) having been injected several years previously with HUMAN BRAIN TISSUE from three younger patients with SUSPECTED OR ATYPICAL PRION DISEASE or in 10 younger marmosets who had undergone various neurosurgical procedures.",HUMAN BRAIN TISSUE,SUSPECTED OR ATYPICAL PRION DISEASE
502832731,7/13/2014 21:38:58,,1322171833,7/13/2014 21:38:03,instagc,1.0,28301350,GBR,K4,Plymouth,89.242.63.62,[SYMPTOM],[SYMPTOM],with,N/A,229,281,246,316,1,RO-has_finding_site,905060-FS1,"No beta (A4) amyloid plaques or CAA were found in six marmosets who were older than the injected animals, in four marmosets that had not developed spongiform encephalopathy (SE) having been injected several years previously with HUMAN BRAIN TISSUE from three younger patients with SUSPECTED OR ATYPICAL PRION DISEASE or in 10 younger marmosets who had undergone various neurosurgical procedures.",HUMAN BRAIN TISSUE,SUSPECTED OR ATYPICAL PRION DISEASE
502832731,7/13/2014 21:41:48,,1322173894,7/13/2014 21:41:24,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],having been injected,N/A,229,281,246,316,1,RO-has_finding_site,905060-FS1,"No beta (A4) amyloid plaques or CAA were found in six marmosets who were older than the injected animals, in four marmosets that had not developed spongiform encephalopathy (SE) having been injected several years previously with HUMAN BRAIN TISSUE from three younger patients with SUSPECTED OR ATYPICAL PRION DISEASE or in 10 younger marmosets who had undergone various neurosurgical procedures.",HUMAN BRAIN TISSUE,SUSPECTED OR ATYPICAL PRION DISEASE
502832731,7/13/2014 22:55:52,,1322237183,7/13/2014 22:52:50,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[SIDE_EFFECT],[SIDE_EFFECT],with,n/a,229,281,246,316,1,RO-has_finding_site,905060-FS1,"No beta (A4) amyloid plaques or CAA were found in six marmosets who were older than the injected animals, in four marmosets that had not developed spongiform encephalopathy (SE) having been injected several years previously with HUMAN BRAIN TISSUE from three younger patients with SUSPECTED OR ATYPICAL PRION DISEASE or in 10 younger marmosets who had undergone various neurosurgical procedures.",HUMAN BRAIN TISSUE,SUSPECTED OR ATYPICAL PRION DISEASE
502832732,7/13/2014 18:45:47,,1322047440,7/13/2014 18:45:20,neodev,1.0,18517457,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/a,276,323,298,338,1,RO-has_manifestation,906151-FS1,"ANT1, TWINKLE and POLG genes affect mtDNA stability and are involved in autosomal dominant PEO, while mutations in POLG are responsible for numerous clinical presentations, including autosomal recessive PEO, sensory ataxic neuropathy, dysarthria and ophthalmoparesis (SANDO), SPINO CEREBELLAR ATAXIA and epilepsy (SCAE) or ALPERS SYNDROME",SPINO CEREBELLAR ATAXIA,ALPERS SYNDROME
502832732,7/13/2014 19:04:29,,1322056120,7/13/2014 19:02:56,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SIDE_EFFECT],[SIDE_EFFECT],affect,N/A,276,323,298,338,1,RO-has_manifestation,906151-FS1,"ANT1, TWINKLE and POLG genes affect mtDNA stability and are involved in autosomal dominant PEO, while mutations in POLG are responsible for numerous clinical presentations, including autosomal recessive PEO, sensory ataxic neuropathy, dysarthria and ophthalmoparesis (SANDO), SPINO CEREBELLAR ATAXIA and epilepsy (SCAE) or ALPERS SYNDROME",SPINO CEREBELLAR ATAXIA,ALPERS SYNDROME
502832732,7/13/2014 19:07:41,,1322057525,7/13/2014 19:07:28,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],are,N/A,276,323,298,338,1,RO-has_manifestation,906151-FS1,"ANT1, TWINKLE and POLG genes affect mtDNA stability and are involved in autosomal dominant PEO, while mutations in POLG are responsible for numerous clinical presentations, including autosomal recessive PEO, sensory ataxic neuropathy, dysarthria and ophthalmoparesis (SANDO), SPINO CEREBELLAR ATAXIA and epilepsy (SCAE) or ALPERS SYNDROME",SPINO CEREBELLAR ATAXIA,ALPERS SYNDROME
502832732,7/13/2014 19:14:13,,1322060281,7/13/2014 19:13:15,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,na,276,323,298,338,1,RO-has_manifestation,906151-FS1,"ANT1, TWINKLE and POLG genes affect mtDNA stability and are involved in autosomal dominant PEO, while mutations in POLG are responsible for numerous clinical presentations, including autosomal recessive PEO, sensory ataxic neuropathy, dysarthria and ophthalmoparesis (SANDO), SPINO CEREBELLAR ATAXIA and epilepsy (SCAE) or ALPERS SYNDROME",SPINO CEREBELLAR ATAXIA,ALPERS SYNDROME
502832732,7/13/2014 19:14:46,,1322060507,7/13/2014 19:13:49,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[NONE],[NONE],N/A,No clear relationship.,276,323,298,338,1,RO-has_manifestation,906151-FS1,"ANT1, TWINKLE and POLG genes affect mtDNA stability and are involved in autosomal dominant PEO, while mutations in POLG are responsible for numerous clinical presentations, including autosomal recessive PEO, sensory ataxic neuropathy, dysarthria and ophthalmoparesis (SANDO), SPINO CEREBELLAR ATAXIA and epilepsy (SCAE) or ALPERS SYNDROME",SPINO CEREBELLAR ATAXIA,ALPERS SYNDROME
502832732,7/13/2014 19:22:24,,1322063445,7/13/2014 19:21:35,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],"numerous clinical presentations,",N/A,276,323,298,338,1,RO-has_manifestation,906151-FS1,"ANT1, TWINKLE and POLG genes affect mtDNA stability and are involved in autosomal dominant PEO, while mutations in POLG are responsible for numerous clinical presentations, including autosomal recessive PEO, sensory ataxic neuropathy, dysarthria and ophthalmoparesis (SANDO), SPINO CEREBELLAR ATAXIA and epilepsy (SCAE) or ALPERS SYNDROME",SPINO CEREBELLAR ATAXIA,ALPERS SYNDROME
502832732,7/13/2014 19:22:34,,1322063535,7/13/2014 19:21:36,instagc,1.0,19686223,CAN,BC,Surrey,154.20.155.106,[CAUSES],[CAUSES],"mutations in POLG are responsible for clinical presentations, including autosomal recessive PEO, sensory ataxic neuropathy, dysarthria and ophthalmoparesis",N/A,276,323,298,338,1,RO-has_manifestation,906151-FS1,"ANT1, TWINKLE and POLG genes affect mtDNA stability and are involved in autosomal dominant PEO, while mutations in POLG are responsible for numerous clinical presentations, including autosomal recessive PEO, sensory ataxic neuropathy, dysarthria and ophthalmoparesis (SANDO), SPINO CEREBELLAR ATAXIA and epilepsy (SCAE) or ALPERS SYNDROME",SPINO CEREBELLAR ATAXIA,ALPERS SYNDROME
502832732,7/13/2014 19:30:19,,1322066401,7/13/2014 19:29:21,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[MANIFESTATION] [ASSOCIATED_WITH],"[MANIFESTATION]
[ASSOCIATED_WITH]",are responsible for,[MANIFESTATION] [ASSOCIATED_WITH],276,323,298,338,1,RO-has_manifestation,906151-FS1,"ANT1, TWINKLE and POLG genes affect mtDNA stability and are involved in autosomal dominant PEO, while mutations in POLG are responsible for numerous clinical presentations, including autosomal recessive PEO, sensory ataxic neuropathy, dysarthria and ophthalmoparesis (SANDO), SPINO CEREBELLAR ATAXIA and epilepsy (SCAE) or ALPERS SYNDROME",SPINO CEREBELLAR ATAXIA,ALPERS SYNDROME
502832732,7/13/2014 19:39:19,,1322069610,7/13/2014 19:38:44,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and or,N/A,276,323,298,338,1,RO-has_manifestation,906151-FS1,"ANT1, TWINKLE and POLG genes affect mtDNA stability and are involved in autosomal dominant PEO, while mutations in POLG are responsible for numerous clinical presentations, including autosomal recessive PEO, sensory ataxic neuropathy, dysarthria and ophthalmoparesis (SANDO), SPINO CEREBELLAR ATAXIA and epilepsy (SCAE) or ALPERS SYNDROME",SPINO CEREBELLAR ATAXIA,ALPERS SYNDROME
502832732,7/13/2014 20:01:09,,1322088735,7/13/2014 20:00:30,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"mutations numerous clinical presentations,",n/a,276,323,298,338,1,RO-has_manifestation,906151-FS1,"ANT1, TWINKLE and POLG genes affect mtDNA stability and are involved in autosomal dominant PEO, while mutations in POLG are responsible for numerous clinical presentations, including autosomal recessive PEO, sensory ataxic neuropathy, dysarthria and ophthalmoparesis (SANDO), SPINO CEREBELLAR ATAXIA and epilepsy (SCAE) or ALPERS SYNDROME",SPINO CEREBELLAR ATAXIA,ALPERS SYNDROME
502832732,7/13/2014 20:03:07,,1322090769,7/13/2014 20:02:17,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SPINO CEREBELLAR ATAXIA ALPERS SYNDROME,n/a,276,323,298,338,1,RO-has_manifestation,906151-FS1,"ANT1, TWINKLE and POLG genes affect mtDNA stability and are involved in autosomal dominant PEO, while mutations in POLG are responsible for numerous clinical presentations, including autosomal recessive PEO, sensory ataxic neuropathy, dysarthria and ophthalmoparesis (SANDO), SPINO CEREBELLAR ATAXIA and epilepsy (SCAE) or ALPERS SYNDROME",SPINO CEREBELLAR ATAXIA,ALPERS SYNDROME
502832732,7/13/2014 20:04:39,,1322092248,7/13/2014 20:04:18,elite,1.0,28503042,USA,OK,Oakwood,64.250.220.169,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and epilepsy (SCAE) or,N/A,276,323,298,338,1,RO-has_manifestation,906151-FS1,"ANT1, TWINKLE and POLG genes affect mtDNA stability and are involved in autosomal dominant PEO, while mutations in POLG are responsible for numerous clinical presentations, including autosomal recessive PEO, sensory ataxic neuropathy, dysarthria and ophthalmoparesis (SANDO), SPINO CEREBELLAR ATAXIA and epilepsy (SCAE) or ALPERS SYNDROME",SPINO CEREBELLAR ATAXIA,ALPERS SYNDROME
502832732,7/13/2014 20:14:02,,1322100874,7/13/2014 20:12:57,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[IS_A],[IS_A],or,N/A,276,323,298,338,1,RO-has_manifestation,906151-FS1,"ANT1, TWINKLE and POLG genes affect mtDNA stability and are involved in autosomal dominant PEO, while mutations in POLG are responsible for numerous clinical presentations, including autosomal recessive PEO, sensory ataxic neuropathy, dysarthria and ophthalmoparesis (SANDO), SPINO CEREBELLAR ATAXIA and epilepsy (SCAE) or ALPERS SYNDROME",SPINO CEREBELLAR ATAXIA,ALPERS SYNDROME
502832732,7/13/2014 20:16:52,,1322103371,7/13/2014 20:16:31,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],including,Na,276,323,298,338,1,RO-has_manifestation,906151-FS1,"ANT1, TWINKLE and POLG genes affect mtDNA stability and are involved in autosomal dominant PEO, while mutations in POLG are responsible for numerous clinical presentations, including autosomal recessive PEO, sensory ataxic neuropathy, dysarthria and ophthalmoparesis (SANDO), SPINO CEREBELLAR ATAXIA and epilepsy (SCAE) or ALPERS SYNDROME",SPINO CEREBELLAR ATAXIA,ALPERS SYNDROME
502832732,7/13/2014 21:07:55,,1322147089,7/13/2014 21:07:23,clixsense,1.0,26649250,GBR,B7,Bristol,79.71.125.97,[SYMPTOM],[SYMPTOM],and,n/a,276,323,298,338,1,RO-has_manifestation,906151-FS1,"ANT1, TWINKLE and POLG genes affect mtDNA stability and are involved in autosomal dominant PEO, while mutations in POLG are responsible for numerous clinical presentations, including autosomal recessive PEO, sensory ataxic neuropathy, dysarthria and ophthalmoparesis (SANDO), SPINO CEREBELLAR ATAXIA and epilepsy (SCAE) or ALPERS SYNDROME",SPINO CEREBELLAR ATAXIA,ALPERS SYNDROME
502832733,7/13/2014 18:46:08,,1322047613,7/13/2014 18:45:47,clixsense,1.0,19803139,NLD,11,Leiden,82.139.76.131,[TREATS],[TREATS],with,N/A,69,0,82,9,1,RO-may_treat,908057-FS1,PIROXICAM in 211 patients with rheumatoid arthritis (RA) (n = 95) or OSTEOARTHRITIS (OA) (n = 116.,OSTEOARTHRITIS,PIROXICAM
502832733,7/13/2014 19:01:54,,1322054938,7/13/2014 18:59:37,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,N/A,69,0,82,9,1,RO-may_treat,908057-FS1,PIROXICAM in 211 patients with rheumatoid arthritis (RA) (n = 95) or OSTEOARTHRITIS (OA) (n = 116.,OSTEOARTHRITIS,PIROXICAM
502832733,7/13/2014 19:02:58,,1322055407,7/13/2014 19:02:05,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[MANIFESTATION],[MANIFESTATION],in patients with rheumatoid arthritis or,N/A,69,0,82,9,1,RO-may_treat,908057-FS1,PIROXICAM in 211 patients with rheumatoid arthritis (RA) (n = 95) or OSTEOARTHRITIS (OA) (n = 116.,OSTEOARTHRITIS,PIROXICAM
502832733,7/13/2014 19:03:00,,1322055437,7/13/2014 19:02:51,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[SIDE_EFFECT],[SIDE_EFFECT],OSTEOARTHRITIS,da,69,0,82,9,1,RO-may_treat,908057-FS1,PIROXICAM in 211 patients with rheumatoid arthritis (RA) (n = 95) or OSTEOARTHRITIS (OA) (n = 116.,OSTEOARTHRITIS,PIROXICAM
502832733,7/13/2014 19:06:55,,1322057144,7/13/2014 19:06:18,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,69,0,82,9,1,RO-may_treat,908057-FS1,PIROXICAM in 211 patients with rheumatoid arthritis (RA) (n = 95) or OSTEOARTHRITIS (OA) (n = 116.,OSTEOARTHRITIS,PIROXICAM
502832733,7/13/2014 19:07:22,,1322057403,7/13/2014 19:06:29,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],in patients with,N/A,69,0,82,9,1,RO-may_treat,908057-FS1,PIROXICAM in 211 patients with rheumatoid arthritis (RA) (n = 95) or OSTEOARTHRITIS (OA) (n = 116.,OSTEOARTHRITIS,PIROXICAM
502832733,7/13/2014 19:09:06,,1322058142,7/13/2014 19:08:51,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],OSTEOARTHRITIS,N/A,69,0,82,9,1,RO-may_treat,908057-FS1,PIROXICAM in 211 patients with rheumatoid arthritis (RA) (n = 95) or OSTEOARTHRITIS (OA) (n = 116.,OSTEOARTHRITIS,PIROXICAM
502832733,7/13/2014 19:17:23,,1322061570,7/13/2014 19:15:43,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[TREATS],[TREATS],in 211 patients,na,69,0,82,9,1,RO-may_treat,908057-FS1,PIROXICAM in 211 patients with rheumatoid arthritis (RA) (n = 95) or OSTEOARTHRITIS (OA) (n = 116.,OSTEOARTHRITIS,PIROXICAM
502832733,7/13/2014 19:55:16,,1322081996,7/13/2014 19:54:44,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[TREATS],[TREATS],in,n/a,69,0,82,9,1,RO-may_treat,908057-FS1,PIROXICAM in 211 patients with rheumatoid arthritis (RA) (n = 95) or OSTEOARTHRITIS (OA) (n = 116.,OSTEOARTHRITIS,PIROXICAM
502832733,7/13/2014 20:01:25,,1322089014,7/13/2014 20:00:53,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PIROXICAM OSTEOARTHRITIS,n/a,69,0,82,9,1,RO-may_treat,908057-FS1,PIROXICAM in 211 patients with rheumatoid arthritis (RA) (n = 95) or OSTEOARTHRITIS (OA) (n = 116.,OSTEOARTHRITIS,PIROXICAM
502832733,7/13/2014 20:08:22,,1322096070,7/13/2014 20:07:46,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[IS_A],[IS_A],or,N/A,69,0,82,9,1,RO-may_treat,908057-FS1,PIROXICAM in 211 patients with rheumatoid arthritis (RA) (n = 95) or OSTEOARTHRITIS (OA) (n = 116.,OSTEOARTHRITIS,PIROXICAM
502832733,7/13/2014 20:17:39,,1322104071,7/13/2014 20:17:09,elite,1.0,28503042,USA,OK,Oakwood,64.250.220.169,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PIROXICAM in 211 with rheumatoid arthritis or OSTEOARTHRITIS,N/A,69,0,82,9,1,RO-may_treat,908057-FS1,PIROXICAM in 211 patients with rheumatoid arthritis (RA) (n = 95) or OSTEOARTHRITIS (OA) (n = 116.,OSTEOARTHRITIS,PIROXICAM
502832733,7/13/2014 20:21:17,,1322107286,7/13/2014 20:20:58,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],in,Na,69,0,82,9,1,RO-may_treat,908057-FS1,PIROXICAM in 211 patients with rheumatoid arthritis (RA) (n = 95) or OSTEOARTHRITIS (OA) (n = 116.,OSTEOARTHRITIS,PIROXICAM
502832733,7/13/2014 20:51:30,,1322132887,7/13/2014 20:51:14,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],in 211 patients,n/a,69,0,82,9,1,RO-may_treat,908057-FS1,PIROXICAM in 211 patients with rheumatoid arthritis (RA) (n = 95) or OSTEOARTHRITIS (OA) (n = 116.,OSTEOARTHRITIS,PIROXICAM
502832733,7/13/2014 21:13:01,,1322151380,7/13/2014 21:12:29,clixsense,1.0,26649250,GBR,B7,Bristol,79.71.125.97,[ASSOCIATED_WITH],[ASSOCIATED_WITH],patients with,n/a,69,0,82,9,1,RO-may_treat,908057-FS1,PIROXICAM in 211 patients with rheumatoid arthritis (RA) (n = 95) or OSTEOARTHRITIS (OA) (n = 116.,OSTEOARTHRITIS,PIROXICAM
502832734,7/13/2014 18:47:30,,1322048302,7/13/2014 18:47:03,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[SYMPTOM],[SYMPTOM],characterized by,N/A,78,0,126,12,1,RO-disease_has_primary_anatomic_site,902194-FS1,"MASTOCYTOSIS is a heterogeneous group of disorders characterized by mast cell HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH nodes, gastrointestinal tract, and skin.",HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH,MASTOCYTOSIS
502832734,7/13/2014 18:50:11,,1322049452,7/13/2014 18:49:41,clixsense,1.0,19803139,NLD,11,Leiden,82.139.76.131,[CAUSES],[CAUSES],characterized,N/A,78,0,126,12,1,RO-disease_has_primary_anatomic_site,902194-FS1,"MASTOCYTOSIS is a heterogeneous group of disorders characterized by mast cell HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH nodes, gastrointestinal tract, and skin.",HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH,MASTOCYTOSIS
502832734,7/13/2014 19:03:46,,1322055776,7/13/2014 19:03:34,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[PART_OF],[PART_OF],is,N/A,78,0,126,12,1,RO-disease_has_primary_anatomic_site,902194-FS1,"MASTOCYTOSIS is a heterogeneous group of disorders characterized by mast cell HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH nodes, gastrointestinal tract, and skin.",HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH,MASTOCYTOSIS
502832734,7/13/2014 19:25:24,,1322064579,7/13/2014 19:24:56,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[ASSOCIATED_WITH],[ASSOCIATED_WITH],characterized,n/a,78,0,126,12,1,RO-disease_has_primary_anatomic_site,902194-FS1,"MASTOCYTOSIS is a heterogeneous group of disorders characterized by mast cell HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH nodes, gastrointestinal tract, and skin.",HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH,MASTOCYTOSIS
502832734,7/13/2014 19:44:11,,1322072505,7/13/2014 19:43:53,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],characterized by,n/a,78,0,126,12,1,RO-disease_has_primary_anatomic_site,902194-FS1,"MASTOCYTOSIS is a heterogeneous group of disorders characterized by mast cell HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH nodes, gastrointestinal tract, and skin.",HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH,MASTOCYTOSIS
502832734,7/13/2014 19:57:11,,1322083915,7/13/2014 19:56:34,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[CAUSES],[CAUSES],MASTOCYTOSIS HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH,n/a,78,0,126,12,1,RO-disease_has_primary_anatomic_site,902194-FS1,"MASTOCYTOSIS is a heterogeneous group of disorders characterized by mast cell HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH nodes, gastrointestinal tract, and skin.",HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH,MASTOCYTOSIS
502832734,7/13/2014 20:10:11,,1322097571,7/13/2014 20:08:23,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[SYMPTOM],[SYMPTOM],characterized by,n/a,78,0,126,12,1,RO-disease_has_primary_anatomic_site,902194-FS1,"MASTOCYTOSIS is a heterogeneous group of disorders characterized by mast cell HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH nodes, gastrointestinal tract, and skin.",HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH,MASTOCYTOSIS
502832734,7/13/2014 20:15:26,,1322102283,7/13/2014 20:15:07,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],characterized,Na,78,0,126,12,1,RO-disease_has_primary_anatomic_site,902194-FS1,"MASTOCYTOSIS is a heterogeneous group of disorders characterized by mast cell HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH nodes, gastrointestinal tract, and skin.",HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH,MASTOCYTOSIS
502832734,7/13/2014 20:32:59,,1322117317,7/13/2014 20:31:11,elite,1.0,28397222,GBR,"","",31.49.231.211,[SYMPTOM],[SYMPTOM],characterized by,N/A,78,0,126,12,1,RO-disease_has_primary_anatomic_site,902194-FS1,"MASTOCYTOSIS is a heterogeneous group of disorders characterized by mast cell HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH nodes, gastrointestinal tract, and skin.",HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH,MASTOCYTOSIS
502832734,7/13/2014 20:43:06,,1322125495,7/13/2014 20:42:45,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[MANIFESTATION],[MANIFESTATION],characterized by,n/a,78,0,126,12,1,RO-disease_has_primary_anatomic_site,902194-FS1,"MASTOCYTOSIS is a heterogeneous group of disorders characterized by mast cell HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH nodes, gastrointestinal tract, and skin.",HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH,MASTOCYTOSIS
502832734,7/13/2014 21:03:19,,1322143104,7/13/2014 21:02:46,clixsense,1.0,26649250,GBR,B7,Bristol,79.71.125.97,[SYMPTOM],[SYMPTOM],characterized by,n/a,78,0,126,12,1,RO-disease_has_primary_anatomic_site,902194-FS1,"MASTOCYTOSIS is a heterogeneous group of disorders characterized by mast cell HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH nodes, gastrointestinal tract, and skin.",HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH,MASTOCYTOSIS
502832734,7/13/2014 21:40:29,,1322172784,7/13/2014 21:39:48,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[PART_OF],[PART_OF],is heterogeneous group of disorders characterized by mast cell,N/A,78,0,126,12,1,RO-disease_has_primary_anatomic_site,902194-FS1,"MASTOCYTOSIS is a heterogeneous group of disorders characterized by mast cell HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH nodes, gastrointestinal tract, and skin.",HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH,MASTOCYTOSIS
502832734,7/13/2014 21:44:54,,1322176046,7/13/2014 21:44:36,instagc,1.0,28301350,GBR,K4,Plymouth,89.242.63.62,[SYMPTOM],[SYMPTOM],characterized by,N/A,78,0,126,12,1,RO-disease_has_primary_anatomic_site,902194-FS1,"MASTOCYTOSIS is a heterogeneous group of disorders characterized by mast cell HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH nodes, gastrointestinal tract, and skin.",HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH,MASTOCYTOSIS
502832734,7/13/2014 22:50:23,,1322232252,7/13/2014 22:48:37,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[MANIFESTATION],[MANIFESTATION],characterized,n/a,78,0,126,12,1,RO-disease_has_primary_anatomic_site,902194-FS1,"MASTOCYTOSIS is a heterogeneous group of disorders characterized by mast cell HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH nodes, gastrointestinal tract, and skin.",HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH,MASTOCYTOSIS
502832734,7/13/2014 23:08:48,,1322248883,7/13/2014 23:08:06,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[ASSOCIATED_WITH],[ASSOCIATED_WITH],characterized by,N/A,78,0,126,12,1,RO-disease_has_primary_anatomic_site,902194-FS1,"MASTOCYTOSIS is a heterogeneous group of disorders characterized by mast cell HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH nodes, gastrointestinal tract, and skin.",HYPERPLASIA IN THE BONE MARROW LIVER SPLEEN LYMPH,MASTOCYTOSIS
502832735,7/13/2014 18:42:22,,1322045628,7/13/2014 18:41:53,clixsense,1.0,19803139,NLD,11,Leiden,82.139.76.131,[TREATS],[TREATS],preparation was used,N/A,20,71,39,107,1,RO-may_treat,908179-FS1,In 38 patients with PARKINSON'S SYNDROME Madopar preparation was used (L DOPA WITH PERIPHERAL DECARBOXYLASE inhibitor) in 33 cases as the main drug and in 5 cases as an addition to L dopa.,PARKINSON'S SYNDROME,L DOPA WITH PERIPHERAL DECARBOXYLASE
502832735,7/13/2014 18:46:38,,1322047855,7/13/2014 18:46:22,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[PREVENTS],[PREVENTS],used,N/A,20,71,39,107,1,RO-may_treat,908179-FS1,In 38 patients with PARKINSON'S SYNDROME Madopar preparation was used (L DOPA WITH PERIPHERAL DECARBOXYLASE inhibitor) in 33 cases as the main drug and in 5 cases as an addition to L dopa.,PARKINSON'S SYNDROME,L DOPA WITH PERIPHERAL DECARBOXYLASE
502832735,7/13/2014 18:50:32,,1322049617,7/13/2014 18:50:14,neodev,1.0,18517457,GBR,"","",86.29.147.112,[TREATS],[TREATS],as the main drug,N/a,20,71,39,107,1,RO-may_treat,908179-FS1,In 38 patients with PARKINSON'S SYNDROME Madopar preparation was used (L DOPA WITH PERIPHERAL DECARBOXYLASE inhibitor) in 33 cases as the main drug and in 5 cases as an addition to L dopa.,PARKINSON'S SYNDROME,L DOPA WITH PERIPHERAL DECARBOXYLASE
502832735,7/13/2014 19:04:58,,1322056292,7/13/2014 19:04:52,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[CONTRAINDICATES],[CONTRAINDICATES],PERIPHERAL,da,20,71,39,107,1,RO-may_treat,908179-FS1,In 38 patients with PARKINSON'S SYNDROME Madopar preparation was used (L DOPA WITH PERIPHERAL DECARBOXYLASE inhibitor) in 33 cases as the main drug and in 5 cases as an addition to L dopa.,PARKINSON'S SYNDROME,L DOPA WITH PERIPHERAL DECARBOXYLASE
502832735,7/13/2014 19:16:44,,1322061293,7/13/2014 19:15:41,instagc,1.0,19686223,CAN,BC,Surrey,154.20.155.106,[TREATS],[TREATS],In 38 patients with PARKINSON'S SYNDROME Madopar preparation was used (L DOPA WITH PERIPHERAL DECARBOXYLASE inhibitor) in 33 cases as the main drug and in 5 cases as an addition to L dopa.,N/A,20,71,39,107,1,RO-may_treat,908179-FS1,In 38 patients with PARKINSON'S SYNDROME Madopar preparation was used (L DOPA WITH PERIPHERAL DECARBOXYLASE inhibitor) in 33 cases as the main drug and in 5 cases as an addition to L dopa.,PARKINSON'S SYNDROME,L DOPA WITH PERIPHERAL DECARBOXYLASE
502832735,7/13/2014 19:17:47,,1322061705,7/13/2014 19:17:27,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],was used,N/A,20,71,39,107,1,RO-may_treat,908179-FS1,In 38 patients with PARKINSON'S SYNDROME Madopar preparation was used (L DOPA WITH PERIPHERAL DECARBOXYLASE inhibitor) in 33 cases as the main drug and in 5 cases as an addition to L dopa.,PARKINSON'S SYNDROME,L DOPA WITH PERIPHERAL DECARBOXYLASE
502832735,7/13/2014 19:23:59,,1322064010,7/13/2014 19:23:43,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[TREATS],[TREATS],used,n/a,20,71,39,107,1,RO-may_treat,908179-FS1,In 38 patients with PARKINSON'S SYNDROME Madopar preparation was used (L DOPA WITH PERIPHERAL DECARBOXYLASE inhibitor) in 33 cases as the main drug and in 5 cases as an addition to L dopa.,PARKINSON'S SYNDROME,L DOPA WITH PERIPHERAL DECARBOXYLASE
502832735,7/13/2014 19:24:46,,1322064322,7/13/2014 19:22:45,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DECARBOXYLASE inhibitor),na,20,71,39,107,1,RO-may_treat,908179-FS1,In 38 patients with PARKINSON'S SYNDROME Madopar preparation was used (L DOPA WITH PERIPHERAL DECARBOXYLASE inhibitor) in 33 cases as the main drug and in 5 cases as an addition to L dopa.,PARKINSON'S SYNDROME,L DOPA WITH PERIPHERAL DECARBOXYLASE
502832735,7/13/2014 19:45:20,,1322073370,7/13/2014 19:44:56,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],preparation was used,N/A,20,71,39,107,1,RO-may_treat,908179-FS1,In 38 patients with PARKINSON'S SYNDROME Madopar preparation was used (L DOPA WITH PERIPHERAL DECARBOXYLASE inhibitor) in 33 cases as the main drug and in 5 cases as an addition to L dopa.,PARKINSON'S SYNDROME,L DOPA WITH PERIPHERAL DECARBOXYLASE
502832735,7/13/2014 19:50:57,,1322077881,7/13/2014 19:50:07,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[OTHER],[OTHER],main drug,is treated by,20,71,39,107,1,RO-may_treat,908179-FS1,In 38 patients with PARKINSON'S SYNDROME Madopar preparation was used (L DOPA WITH PERIPHERAL DECARBOXYLASE inhibitor) in 33 cases as the main drug and in 5 cases as an addition to L dopa.,PARKINSON'S SYNDROME,L DOPA WITH PERIPHERAL DECARBOXYLASE
502832735,7/13/2014 20:04:59,,1322092590,7/13/2014 20:04:27,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[OTHER],[OTHER],(L inhibitor),N/A,20,71,39,107,1,RO-may_treat,908179-FS1,In 38 patients with PARKINSON'S SYNDROME Madopar preparation was used (L DOPA WITH PERIPHERAL DECARBOXYLASE inhibitor) in 33 cases as the main drug and in 5 cases as an addition to L dopa.,PARKINSON'S SYNDROME,L DOPA WITH PERIPHERAL DECARBOXYLASE
502832735,7/13/2014 20:06:31,,1322094253,7/13/2014 20:05:54,elite,1.0,28503042,USA,OK,Oakwood,64.250.220.169,[TREATS],[TREATS],was used,N/A,20,71,39,107,1,RO-may_treat,908179-FS1,In 38 patients with PARKINSON'S SYNDROME Madopar preparation was used (L DOPA WITH PERIPHERAL DECARBOXYLASE inhibitor) in 33 cases as the main drug and in 5 cases as an addition to L dopa.,PARKINSON'S SYNDROME,L DOPA WITH PERIPHERAL DECARBOXYLASE
502832735,7/13/2014 20:49:50,,1322131462,7/13/2014 20:49:23,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],preparation was used as the main drug,n/a,20,71,39,107,1,RO-may_treat,908179-FS1,In 38 patients with PARKINSON'S SYNDROME Madopar preparation was used (L DOPA WITH PERIPHERAL DECARBOXYLASE inhibitor) in 33 cases as the main drug and in 5 cases as an addition to L dopa.,PARKINSON'S SYNDROME,L DOPA WITH PERIPHERAL DECARBOXYLASE
502832735,7/13/2014 21:05:24,,1322144890,7/13/2014 21:04:55,clixsense,1.0,26649250,GBR,B7,Bristol,79.71.125.97,[TREATS],[TREATS],was used,n/a,20,71,39,107,1,RO-may_treat,908179-FS1,In 38 patients with PARKINSON'S SYNDROME Madopar preparation was used (L DOPA WITH PERIPHERAL DECARBOXYLASE inhibitor) in 33 cases as the main drug and in 5 cases as an addition to L dopa.,PARKINSON'S SYNDROME,L DOPA WITH PERIPHERAL DECARBOXYLASE
502832735,7/13/2014 21:42:09,,1322174123,7/13/2014 21:41:49,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],Madopar preparation was used,N/A,20,71,39,107,1,RO-may_treat,908179-FS1,In 38 patients with PARKINSON'S SYNDROME Madopar preparation was used (L DOPA WITH PERIPHERAL DECARBOXYLASE inhibitor) in 33 cases as the main drug and in 5 cases as an addition to L dopa.,PARKINSON'S SYNDROME,L DOPA WITH PERIPHERAL DECARBOXYLASE
502832736,7/13/2014 18:51:48,,1322050234,7/13/2014 18:50:16,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],an,N/A,112,128,123,137,1,RO-may_prevent,907365-FS1,"After an outbreak of hepatitis in Washington, D.C. in 1970 among a group of persons taking isoniazid to prevent TUBERCULOSIS an ISONIAZID surveillance study was conducted among 13,838 persons in 21 participating health departments.",TUBERCULOSIS,ISONIAZID
502832736,7/13/2014 19:04:15,,1322055995,7/13/2014 19:04:06,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[LOCATION],[LOCATION],"Washington,",da,112,128,123,137,1,RO-may_prevent,907365-FS1,"After an outbreak of hepatitis in Washington, D.C. in 1970 among a group of persons taking isoniazid to prevent TUBERCULOSIS an ISONIAZID surveillance study was conducted among 13,838 persons in 21 participating health departments.",TUBERCULOSIS,ISONIAZID
502832736,7/13/2014 19:06:01,,1322056717,7/13/2014 19:05:53,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],participating,N/A,112,128,123,137,1,RO-may_prevent,907365-FS1,"After an outbreak of hepatitis in Washington, D.C. in 1970 among a group of persons taking isoniazid to prevent TUBERCULOSIS an ISONIAZID surveillance study was conducted among 13,838 persons in 21 participating health departments.",TUBERCULOSIS,ISONIAZID
502832736,7/13/2014 19:09:59,,1322058596,7/13/2014 19:09:19,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[PREVENTS],[PREVENTS],isoniazid to prevent,na,112,128,123,137,1,RO-may_prevent,907365-FS1,"After an outbreak of hepatitis in Washington, D.C. in 1970 among a group of persons taking isoniazid to prevent TUBERCULOSIS an ISONIAZID surveillance study was conducted among 13,838 persons in 21 participating health departments.",TUBERCULOSIS,ISONIAZID
502832736,7/13/2014 19:12:32,,1322059660,7/13/2014 19:11:54,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was conducted,[DIAGNOSE_BY_TEST_OR_DRUG],112,128,123,137,1,RO-may_prevent,907365-FS1,"After an outbreak of hepatitis in Washington, D.C. in 1970 among a group of persons taking isoniazid to prevent TUBERCULOSIS an ISONIAZID surveillance study was conducted among 13,838 persons in 21 participating health departments.",TUBERCULOSIS,ISONIAZID
502832736,7/13/2014 19:14:40,,1322060466,7/13/2014 19:13:51,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[PREVENTS],[PREVENTS],taking to prevent,N/A,112,128,123,137,1,RO-may_prevent,907365-FS1,"After an outbreak of hepatitis in Washington, D.C. in 1970 among a group of persons taking isoniazid to prevent TUBERCULOSIS an ISONIAZID surveillance study was conducted among 13,838 persons in 21 participating health departments.",TUBERCULOSIS,ISONIAZID
502832736,7/13/2014 19:15:52,,1322060905,7/13/2014 19:15:13,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[PREVENTS],[PREVENTS],to prevent,N/A,112,128,123,137,1,RO-may_prevent,907365-FS1,"After an outbreak of hepatitis in Washington, D.C. in 1970 among a group of persons taking isoniazid to prevent TUBERCULOSIS an ISONIAZID surveillance study was conducted among 13,838 persons in 21 participating health departments.",TUBERCULOSIS,ISONIAZID
502832736,7/13/2014 19:27:30,,1322065369,7/13/2014 19:27:19,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[PREVENTS],[PREVENTS],prevent,n/a,112,128,123,137,1,RO-may_prevent,907365-FS1,"After an outbreak of hepatitis in Washington, D.C. in 1970 among a group of persons taking isoniazid to prevent TUBERCULOSIS an ISONIAZID surveillance study was conducted among 13,838 persons in 21 participating health departments.",TUBERCULOSIS,ISONIAZID
502832736,7/13/2014 19:32:24,,1322067056,7/13/2014 19:30:40,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[TREATS],[TREATS],to prevent TUBERCULOSIS an ISONIAZID surveillance study,n/a,112,128,123,137,1,RO-may_prevent,907365-FS1,"After an outbreak of hepatitis in Washington, D.C. in 1970 among a group of persons taking isoniazid to prevent TUBERCULOSIS an ISONIAZID surveillance study was conducted among 13,838 persons in 21 participating health departments.",TUBERCULOSIS,ISONIAZID
502832736,7/13/2014 19:51:43,,1322078527,7/13/2014 19:50:58,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[OTHER],[OTHER],taking isoniazid,is treated by,112,128,123,137,1,RO-may_prevent,907365-FS1,"After an outbreak of hepatitis in Washington, D.C. in 1970 among a group of persons taking isoniazid to prevent TUBERCULOSIS an ISONIAZID surveillance study was conducted among 13,838 persons in 21 participating health departments.",TUBERCULOSIS,ISONIAZID
502832736,7/13/2014 19:57:48,,1322084561,7/13/2014 19:57:17,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TUBERCULOSIS ISONIAZID,n/a,112,128,123,137,1,RO-may_prevent,907365-FS1,"After an outbreak of hepatitis in Washington, D.C. in 1970 among a group of persons taking isoniazid to prevent TUBERCULOSIS an ISONIAZID surveillance study was conducted among 13,838 persons in 21 participating health departments.",TUBERCULOSIS,ISONIAZID
502832736,7/13/2014 20:06:01,,1322093766,7/13/2014 20:05:28,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[NONE],[NONE],N/A,No relation,112,128,123,137,1,RO-may_prevent,907365-FS1,"After an outbreak of hepatitis in Washington, D.C. in 1970 among a group of persons taking isoniazid to prevent TUBERCULOSIS an ISONIAZID surveillance study was conducted among 13,838 persons in 21 participating health departments.",TUBERCULOSIS,ISONIAZID
502832736,7/13/2014 20:11:14,,1322098478,7/13/2014 20:10:55,elite,1.0,28503042,USA,OK,Oakwood,64.250.220.169,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TUBERCULOSIS an ISONIAZID,N/A,112,128,123,137,1,RO-may_prevent,907365-FS1,"After an outbreak of hepatitis in Washington, D.C. in 1970 among a group of persons taking isoniazid to prevent TUBERCULOSIS an ISONIAZID surveillance study was conducted among 13,838 persons in 21 participating health departments.",TUBERCULOSIS,ISONIAZID
502832736,7/13/2014 20:19:53,,1322106102,7/13/2014 20:19:36,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],prevent,Na,112,128,123,137,1,RO-may_prevent,907365-FS1,"After an outbreak of hepatitis in Washington, D.C. in 1970 among a group of persons taking isoniazid to prevent TUBERCULOSIS an ISONIAZID surveillance study was conducted among 13,838 persons in 21 participating health departments.",TUBERCULOSIS,ISONIAZID
502832736,7/13/2014 20:31:11,,1322115645,7/13/2014 20:29:33,elite,1.0,28397222,GBR,"","",31.49.231.211,[PREVENTS],[PREVENTS],to prevent,N/A,112,128,123,137,1,RO-may_prevent,907365-FS1,"After an outbreak of hepatitis in Washington, D.C. in 1970 among a group of persons taking isoniazid to prevent TUBERCULOSIS an ISONIAZID surveillance study was conducted among 13,838 persons in 21 participating health departments.",TUBERCULOSIS,ISONIAZID
502832737,7/13/2014 19:01:40,,1322054803,7/13/2014 19:01:34,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[PREVENTS],[PREVENTS],DIAGNOSIS,da,98,26,102,57,1,RO-has_finding_site,905265-FS1,The standard radiological DIAGNOSIS OF ADVANCED SCOLIOSIS consists of roentgenograms of the total SPINE in anterior posterior and lateral views.,SPINE,DIAGNOSIS OF ADVANCED SCOLIOSIS
502832737,7/13/2014 19:05:26,,1322056471,7/13/2014 19:04:42,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[LOCATION],[LOCATION],roentgenograms of the,N/A,98,26,102,57,1,RO-has_finding_site,905265-FS1,The standard radiological DIAGNOSIS OF ADVANCED SCOLIOSIS consists of roentgenograms of the total SPINE in anterior posterior and lateral views.,SPINE,DIAGNOSIS OF ADVANCED SCOLIOSIS
502832737,7/13/2014 19:17:15,,1322061502,7/13/2014 19:16:45,instagc,1.0,19686223,CAN,BC,Surrey,154.20.155.106,[DIAGNOSE_BY_TEST_OR_DRUG] [LOCATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]",standard radiological DIAGNOSIS OF ADVANCED SCOLIOSIS consists of roentgenograms of the total SPINE in anterior posterior and lateral views.,N/A,98,26,102,57,1,RO-has_finding_site,905265-FS1,The standard radiological DIAGNOSIS OF ADVANCED SCOLIOSIS consists of roentgenograms of the total SPINE in anterior posterior and lateral views.,SPINE,DIAGNOSIS OF ADVANCED SCOLIOSIS
502832737,7/13/2014 19:36:58,,1322068682,7/13/2014 19:36:02,instagc,1.0,13763729,USA,"","",75.182.89.225,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],DIAGNOSIS OF,N/A,98,26,102,57,1,RO-has_finding_site,905265-FS1,The standard radiological DIAGNOSIS OF ADVANCED SCOLIOSIS consists of roentgenograms of the total SPINE in anterior posterior and lateral views.,SPINE,DIAGNOSIS OF ADVANCED SCOLIOSIS
502832737,7/13/2014 19:55:05,,1322081803,7/13/2014 19:54:32,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],DIAGNOSIS OF ADVANCED SCOLIOSIS SPINE,n/a,98,26,102,57,1,RO-has_finding_site,905265-FS1,The standard radiological DIAGNOSIS OF ADVANCED SCOLIOSIS consists of roentgenograms of the total SPINE in anterior posterior and lateral views.,SPINE,DIAGNOSIS OF ADVANCED SCOLIOSIS
502832737,7/13/2014 20:23:12,,1322108939,7/13/2014 20:23:02,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],SCOLIOSIS SPINE,N/A,98,26,102,57,1,RO-has_finding_site,905265-FS1,The standard radiological DIAGNOSIS OF ADVANCED SCOLIOSIS consists of roentgenograms of the total SPINE in anterior posterior and lateral views.,SPINE,DIAGNOSIS OF ADVANCED SCOLIOSIS
502832737,7/13/2014 21:18:31,,1322156172,7/13/2014 21:17:45,clixsense,1.0,26649250,GBR,B7,Bristol,79.71.125.97,[ASSOCIATED_WITH],[ASSOCIATED_WITH],consists of roentgenograms of,n/a,98,26,102,57,1,RO-has_finding_site,905265-FS1,The standard radiological DIAGNOSIS OF ADVANCED SCOLIOSIS consists of roentgenograms of the total SPINE in anterior posterior and lateral views.,SPINE,DIAGNOSIS OF ADVANCED SCOLIOSIS
502832737,7/13/2014 21:19:33,,1322157034,7/13/2014 21:17:57,elite,1.0,28397222,GBR,"","",31.49.231.211,[LOCATION],[LOCATION],roentgenograms of,N/A,98,26,102,57,1,RO-has_finding_site,905265-FS1,The standard radiological DIAGNOSIS OF ADVANCED SCOLIOSIS consists of roentgenograms of the total SPINE in anterior posterior and lateral views.,SPINE,DIAGNOSIS OF ADVANCED SCOLIOSIS
502832737,7/13/2014 21:40:54,,1322173064,7/13/2014 21:40:37,instagc,1.0,28301350,GBR,K4,Plymouth,89.242.63.62,[LOCATION],[LOCATION],of the,N/A,98,26,102,57,1,RO-has_finding_site,905265-FS1,The standard radiological DIAGNOSIS OF ADVANCED SCOLIOSIS consists of roentgenograms of the total SPINE in anterior posterior and lateral views.,SPINE,DIAGNOSIS OF ADVANCED SCOLIOSIS
502832737,7/13/2014 21:46:25,,1322177346,7/13/2014 21:45:39,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[NONE],[NONE],N/A,There is no link between those two words. Spine is a body part and DIAGNOSIS OF ADVANCED SCOLIOSIS is a diagnosis of a disease.,98,26,102,57,1,RO-has_finding_site,905265-FS1,The standard radiological DIAGNOSIS OF ADVANCED SCOLIOSIS consists of roentgenograms of the total SPINE in anterior posterior and lateral views.,SPINE,DIAGNOSIS OF ADVANCED SCOLIOSIS
502832737,7/13/2014 22:52:48,,1322234465,7/13/2014 22:52:09,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[PART_OF],[PART_OF],of the,n/a,98,26,102,57,1,RO-has_finding_site,905265-FS1,The standard radiological DIAGNOSIS OF ADVANCED SCOLIOSIS consists of roentgenograms of the total SPINE in anterior posterior and lateral views.,SPINE,DIAGNOSIS OF ADVANCED SCOLIOSIS
502832737,7/13/2014 23:08:04,,1322248353,7/13/2014 23:07:00,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],radiological DIAGNOSIS,N/A,98,26,102,57,1,RO-has_finding_site,905265-FS1,The standard radiological DIAGNOSIS OF ADVANCED SCOLIOSIS consists of roentgenograms of the total SPINE in anterior posterior and lateral views.,SPINE,DIAGNOSIS OF ADVANCED SCOLIOSIS
502832737,7/13/2014 23:10:14,,1322250151,7/13/2014 23:08:43,clixsense,1.0,6365250,CAN,BC,Burnaby,70.79.16.165,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],standard radiological DIAGNOSIS ADVANCED SCOLIOSIS roentgenograms total SPINE,diagnosed by test or drug,98,26,102,57,1,RO-has_finding_site,905265-FS1,The standard radiological DIAGNOSIS OF ADVANCED SCOLIOSIS consists of roentgenograms of the total SPINE in anterior posterior and lateral views.,SPINE,DIAGNOSIS OF ADVANCED SCOLIOSIS
502832737,7/13/2014 23:39:18,,1322272503,7/13/2014 23:38:42,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],DIAGNOSIS OF ADVANCED SCOLIOSIS consists of the total SPINE,N/A,98,26,102,57,1,RO-has_finding_site,905265-FS1,The standard radiological DIAGNOSIS OF ADVANCED SCOLIOSIS consists of roentgenograms of the total SPINE in anterior posterior and lateral views.,SPINE,DIAGNOSIS OF ADVANCED SCOLIOSIS
502832737,7/13/2014 23:47:30,,1322278438,7/13/2014 23:46:46,instagc,1,19378092,USA,PA,Reading,174.55.181.238,[LOCATION],[LOCATION],total,na,98,26,102,57,1,RO-has_finding_site,905265-FS1,The standard radiological DIAGNOSIS OF ADVANCED SCOLIOSIS consists of roentgenograms of the total SPINE in anterior posterior and lateral views.,SPINE,DIAGNOSIS OF ADVANCED SCOLIOSIS
502832738,7/13/2014 18:43:17,,1322046176,7/13/2014 18:43:01,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[CONTRAINDICATES] [ASSOCIATED_WITH],"[CONTRAINDICATES]
[ASSOCIATED_WITH]",compared,Na,146,198,170,228,1,RO-may_treat,908259-FS1,"Tobramycin 0.3%/dexamethasone 0.1% significantly decreased clinical signs of ocular inflammation (ie, blepharitis, discharge, conjunctivitis) and TOTAL OCULAR INFLAMMATION scores when compared with TOBRAMYCIN 03%/LOTEPREDNOL 05% in patients with moderate to severe blepharo keratoconjunctivitis.",TOTAL OCULAR INFLAMMATION,TOBRAMYCIN 03%/LOTEPREDNOL 05%
502832738,7/13/2014 18:51:04,,1322049879,7/13/2014 18:50:44,clixsense,1.0,19803139,NLD,11,Leiden,82.139.76.131,[IS_A],[IS_A],compared with,N/A,146,198,170,228,1,RO-may_treat,908259-FS1,"Tobramycin 0.3%/dexamethasone 0.1% significantly decreased clinical signs of ocular inflammation (ie, blepharitis, discharge, conjunctivitis) and TOTAL OCULAR INFLAMMATION scores when compared with TOBRAMYCIN 03%/LOTEPREDNOL 05% in patients with moderate to severe blepharo keratoconjunctivitis.",TOTAL OCULAR INFLAMMATION,TOBRAMYCIN 03%/LOTEPREDNOL 05%
502832738,7/13/2014 18:52:18,,1322050491,7/13/2014 18:51:46,neodev,1.0,18517457,GBR,"","",86.29.147.112,[TREATS],[TREATS],decreased clinical signs,N/a,146,198,170,228,1,RO-may_treat,908259-FS1,"Tobramycin 0.3%/dexamethasone 0.1% significantly decreased clinical signs of ocular inflammation (ie, blepharitis, discharge, conjunctivitis) and TOTAL OCULAR INFLAMMATION scores when compared with TOBRAMYCIN 03%/LOTEPREDNOL 05% in patients with moderate to severe blepharo keratoconjunctivitis.",TOTAL OCULAR INFLAMMATION,TOBRAMYCIN 03%/LOTEPREDNOL 05%
502832738,7/13/2014 18:53:22,,1322051040,7/13/2014 18:52:57,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[OTHER],[OTHER],compared,comparsion,146,198,170,228,1,RO-may_treat,908259-FS1,"Tobramycin 0.3%/dexamethasone 0.1% significantly decreased clinical signs of ocular inflammation (ie, blepharitis, discharge, conjunctivitis) and TOTAL OCULAR INFLAMMATION scores when compared with TOBRAMYCIN 03%/LOTEPREDNOL 05% in patients with moderate to severe blepharo keratoconjunctivitis.",TOTAL OCULAR INFLAMMATION,TOBRAMYCIN 03%/LOTEPREDNOL 05%
502832738,7/13/2014 19:08:16,,1322057810,7/13/2014 19:07:43,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PREVENTS],[PREVENTS],compared with,N/A,146,198,170,228,1,RO-may_treat,908259-FS1,"Tobramycin 0.3%/dexamethasone 0.1% significantly decreased clinical signs of ocular inflammation (ie, blepharitis, discharge, conjunctivitis) and TOTAL OCULAR INFLAMMATION scores when compared with TOBRAMYCIN 03%/LOTEPREDNOL 05% in patients with moderate to severe blepharo keratoconjunctivitis.",TOTAL OCULAR INFLAMMATION,TOBRAMYCIN 03%/LOTEPREDNOL 05%
502832738,7/13/2014 19:08:40,,1322057980,7/13/2014 19:08:27,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],03%/LOTEPREDNOL,N/A,146,198,170,228,1,RO-may_treat,908259-FS1,"Tobramycin 0.3%/dexamethasone 0.1% significantly decreased clinical signs of ocular inflammation (ie, blepharitis, discharge, conjunctivitis) and TOTAL OCULAR INFLAMMATION scores when compared with TOBRAMYCIN 03%/LOTEPREDNOL 05% in patients with moderate to severe blepharo keratoconjunctivitis.",TOTAL OCULAR INFLAMMATION,TOBRAMYCIN 03%/LOTEPREDNOL 05%
502832738,7/13/2014 19:15:40,,1322060815,7/13/2014 19:15:01,instagc,1.0,19686223,CAN,BC,Surrey,154.20.155.106,[NONE],[NONE],N/A,I cannot find any relations.,146,198,170,228,1,RO-may_treat,908259-FS1,"Tobramycin 0.3%/dexamethasone 0.1% significantly decreased clinical signs of ocular inflammation (ie, blepharitis, discharge, conjunctivitis) and TOTAL OCULAR INFLAMMATION scores when compared with TOBRAMYCIN 03%/LOTEPREDNOL 05% in patients with moderate to severe blepharo keratoconjunctivitis.",TOTAL OCULAR INFLAMMATION,TOBRAMYCIN 03%/LOTEPREDNOL 05%
502832738,7/13/2014 19:30:40,,1322066504,7/13/2014 19:29:49,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[TREATS],[TREATS],significantly decreased clinical signs of ocular inflammation and TOTAL OCULAR INFLAMMATION TOBRAMYCIN 03%/LOTEPREDNOL 05%,n/a,146,198,170,228,1,RO-may_treat,908259-FS1,"Tobramycin 0.3%/dexamethasone 0.1% significantly decreased clinical signs of ocular inflammation (ie, blepharitis, discharge, conjunctivitis) and TOTAL OCULAR INFLAMMATION scores when compared with TOBRAMYCIN 03%/LOTEPREDNOL 05% in patients with moderate to severe blepharo keratoconjunctivitis.",TOTAL OCULAR INFLAMMATION,TOBRAMYCIN 03%/LOTEPREDNOL 05%
502832738,7/13/2014 19:31:10,,1322066631,7/13/2014 19:30:06,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[PREVENTS] [ASSOCIATED_WITH],"[PREVENTS]
[ASSOCIATED_WITH]",with,n/a,146,198,170,228,1,RO-may_treat,908259-FS1,"Tobramycin 0.3%/dexamethasone 0.1% significantly decreased clinical signs of ocular inflammation (ie, blepharitis, discharge, conjunctivitis) and TOTAL OCULAR INFLAMMATION scores when compared with TOBRAMYCIN 03%/LOTEPREDNOL 05% in patients with moderate to severe blepharo keratoconjunctivitis.",TOTAL OCULAR INFLAMMATION,TOBRAMYCIN 03%/LOTEPREDNOL 05%
502832738,7/13/2014 19:45:57,,1322073793,7/13/2014 19:45:08,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[CONTRAINDICATES],[CONTRAINDICATES],TOTAL OCULAR INFLAMMATION TOBRAMYCIN 03%/LOTEPREDNOL 05%,n/a,146,198,170,228,1,RO-may_treat,908259-FS1,"Tobramycin 0.3%/dexamethasone 0.1% significantly decreased clinical signs of ocular inflammation (ie, blepharitis, discharge, conjunctivitis) and TOTAL OCULAR INFLAMMATION scores when compared with TOBRAMYCIN 03%/LOTEPREDNOL 05% in patients with moderate to severe blepharo keratoconjunctivitis.",TOTAL OCULAR INFLAMMATION,TOBRAMYCIN 03%/LOTEPREDNOL 05%
502832738,7/13/2014 20:15:22,,1322102205,7/13/2014 20:14:52,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[OTHER],[OTHER],compared,N/A,146,198,170,228,1,RO-may_treat,908259-FS1,"Tobramycin 0.3%/dexamethasone 0.1% significantly decreased clinical signs of ocular inflammation (ie, blepharitis, discharge, conjunctivitis) and TOTAL OCULAR INFLAMMATION scores when compared with TOBRAMYCIN 03%/LOTEPREDNOL 05% in patients with moderate to severe blepharo keratoconjunctivitis.",TOTAL OCULAR INFLAMMATION,TOBRAMYCIN 03%/LOTEPREDNOL 05%
502832738,7/13/2014 20:53:34,,1322134476,7/13/2014 20:53:09,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],significantly decreased,n/a,146,198,170,228,1,RO-may_treat,908259-FS1,"Tobramycin 0.3%/dexamethasone 0.1% significantly decreased clinical signs of ocular inflammation (ie, blepharitis, discharge, conjunctivitis) and TOTAL OCULAR INFLAMMATION scores when compared with TOBRAMYCIN 03%/LOTEPREDNOL 05% in patients with moderate to severe blepharo keratoconjunctivitis.",TOTAL OCULAR INFLAMMATION,TOBRAMYCIN 03%/LOTEPREDNOL 05%
502832738,7/13/2014 21:14:26,,1322152562,7/13/2014 21:13:34,clixsense,1.0,26649250,GBR,B7,Bristol,79.71.125.97,[ASSOCIATED_WITH],[ASSOCIATED_WITH],compared with,n/a,146,198,170,228,1,RO-may_treat,908259-FS1,"Tobramycin 0.3%/dexamethasone 0.1% significantly decreased clinical signs of ocular inflammation (ie, blepharitis, discharge, conjunctivitis) and TOTAL OCULAR INFLAMMATION scores when compared with TOBRAMYCIN 03%/LOTEPREDNOL 05% in patients with moderate to severe blepharo keratoconjunctivitis.",TOTAL OCULAR INFLAMMATION,TOBRAMYCIN 03%/LOTEPREDNOL 05%
502832738,7/13/2014 21:36:28,,1322169811,7/13/2014 21:35:06,elite,1.0,28397222,GBR,"","",31.49.231.211,[TREATS],[TREATS],decreased clinical signs,N/A,146,198,170,228,1,RO-may_treat,908259-FS1,"Tobramycin 0.3%/dexamethasone 0.1% significantly decreased clinical signs of ocular inflammation (ie, blepharitis, discharge, conjunctivitis) and TOTAL OCULAR INFLAMMATION scores when compared with TOBRAMYCIN 03%/LOTEPREDNOL 05% in patients with moderate to severe blepharo keratoconjunctivitis.",TOTAL OCULAR INFLAMMATION,TOBRAMYCIN 03%/LOTEPREDNOL 05%
502832738,7/13/2014 21:39:33,,1322172222,7/13/2014 21:39:00,instagc,1.0,28301350,GBR,K4,Plymouth,89.242.63.62,[TREATS],[TREATS],compared with,N/A,146,198,170,228,1,RO-may_treat,908259-FS1,"Tobramycin 0.3%/dexamethasone 0.1% significantly decreased clinical signs of ocular inflammation (ie, blepharitis, discharge, conjunctivitis) and TOTAL OCULAR INFLAMMATION scores when compared with TOBRAMYCIN 03%/LOTEPREDNOL 05% in patients with moderate to severe blepharo keratoconjunctivitis.",TOTAL OCULAR INFLAMMATION,TOBRAMYCIN 03%/LOTEPREDNOL 05%
502832739,7/13/2014 18:44:55,,1322046985,7/13/2014 18:44:28,clixsense,1.0,19803139,NLD,11,Leiden,82.139.76.131,[SYMPTOM],[SYMPTOM],found to have,N/A,51,83,58,96,1,RO-disease_may_have_finding,902994-FS1,We present a rare case of an adult patient without SEIZURES who is found to have a GANGLIOGLIOMA occurring in the cerebellopontine angle.,SEIZURES,GANGLIOGLIOMA
502832739,7/13/2014 18:59:07,,1322053725,7/13/2014 18:58:11,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],is found,N/A,51,83,58,96,1,RO-disease_may_have_finding,902994-FS1,We present a rare case of an adult patient without SEIZURES who is found to have a GANGLIOGLIOMA occurring in the cerebellopontine angle.,SEIZURES,GANGLIOGLIOMA
502832739,7/13/2014 19:13:49,,1322060127,7/13/2014 19:13:04,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],without,N/A,51,83,58,96,1,RO-disease_may_have_finding,902994-FS1,We present a rare case of an adult patient without SEIZURES who is found to have a GANGLIOGLIOMA occurring in the cerebellopontine angle.,SEIZURES,GANGLIOGLIOMA
502832739,7/13/2014 19:14:33,,1322060385,7/13/2014 19:13:47,instagc,1.0,19686223,CAN,BC,Surrey,154.20.155.106,[LOCATION],[LOCATION],GANGLIOGLIOMA occurring in the cerebellopontine angle.,N/A,51,83,58,96,1,RO-disease_may_have_finding,902994-FS1,We present a rare case of an adult patient without SEIZURES who is found to have a GANGLIOGLIOMA occurring in the cerebellopontine angle.,SEIZURES,GANGLIOGLIOMA
502832739,7/13/2014 19:15:39,,1322060822,7/13/2014 19:14:16,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],found to have,na,51,83,58,96,1,RO-disease_may_have_finding,902994-FS1,We present a rare case of an adult patient without SEIZURES who is found to have a GANGLIOGLIOMA occurring in the cerebellopontine angle.,SEIZURES,GANGLIOGLIOMA
502832739,7/13/2014 19:26:35,,1322065008,7/13/2014 19:26:02,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[LOCATION],[LOCATION],who is found,[LOCATION],51,83,58,96,1,RO-disease_may_have_finding,902994-FS1,We present a rare case of an adult patient without SEIZURES who is found to have a GANGLIOGLIOMA occurring in the cerebellopontine angle.,SEIZURES,GANGLIOGLIOMA
502832739,7/13/2014 19:30:38,,1322066485,7/13/2014 19:29:41,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],rare case without SEIZURES found to have,N/A,51,83,58,96,1,RO-disease_may_have_finding,902994-FS1,We present a rare case of an adult patient without SEIZURES who is found to have a GANGLIOGLIOMA occurring in the cerebellopontine angle.,SEIZURES,GANGLIOGLIOMA
502832739,7/13/2014 19:58:26,,1322085497,7/13/2014 19:57:53,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",SEIZURES GANGLIOGLIOMA,n/a,51,83,58,96,1,RO-disease_may_have_finding,902994-FS1,We present a rare case of an adult patient without SEIZURES who is found to have a GANGLIOGLIOMA occurring in the cerebellopontine angle.,SEIZURES,GANGLIOGLIOMA
502832739,7/13/2014 20:05:14,,1322092903,7/13/2014 20:04:41,elite,1.0,28503042,USA,OK,Oakwood,64.250.220.169,[OTHER],[OTHER],who is found to have a,N/A,51,83,58,96,1,RO-disease_may_have_finding,902994-FS1,We present a rare case of an adult patient without SEIZURES who is found to have a GANGLIOGLIOMA occurring in the cerebellopontine angle.,SEIZURES,GANGLIOGLIOMA
502832739,7/13/2014 20:23:30,,1322109254,7/13/2014 20:23:13,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[SYMPTOM],[SYMPTOM],SEIZURES have a,N/A,51,83,58,96,1,RO-disease_may_have_finding,902994-FS1,We present a rare case of an adult patient without SEIZURES who is found to have a GANGLIOGLIOMA occurring in the cerebellopontine angle.,SEIZURES,GANGLIOGLIOMA
502832739,7/13/2014 20:52:33,,1322133628,7/13/2014 20:52:11,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[SYMPTOM],[SYMPTOM],rare case of an adult patient without,n/a,51,83,58,96,1,RO-disease_may_have_finding,902994-FS1,We present a rare case of an adult patient without SEIZURES who is found to have a GANGLIOGLIOMA occurring in the cerebellopontine angle.,SEIZURES,GANGLIOGLIOMA
502832739,7/13/2014 21:12:27,,1322151054,7/13/2014 21:11:48,clixsense,1.0,26649250,GBR,B7,Bristol,79.71.125.97,[ASSOCIATED_WITH],[ASSOCIATED_WITH],patient without,n/a,51,83,58,96,1,RO-disease_may_have_finding,902994-FS1,We present a rare case of an adult patient without SEIZURES who is found to have a GANGLIOGLIOMA occurring in the cerebellopontine angle.,SEIZURES,GANGLIOGLIOMA
502832739,7/13/2014 21:39:58,,1322172479,7/13/2014 21:39:34,instagc,1.0,28301350,GBR,K4,Plymouth,89.242.63.62,[SYMPTOM],[SYMPTOM],to have a,N/A,51,83,58,96,1,RO-disease_may_have_finding,902994-FS1,We present a rare case of an adult patient without SEIZURES who is found to have a GANGLIOGLIOMA occurring in the cerebellopontine angle.,SEIZURES,GANGLIOGLIOMA
502832739,7/13/2014 21:42:57,,1322174726,7/13/2014 21:42:32,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[MANIFESTATION],[MANIFESTATION],who is found to have a,N/A,51,83,58,96,1,RO-disease_may_have_finding,902994-FS1,We present a rare case of an adult patient without SEIZURES who is found to have a GANGLIOGLIOMA occurring in the cerebellopontine angle.,SEIZURES,GANGLIOGLIOMA
502832739,7/13/2014 21:48:04,,1322178650,7/13/2014 21:47:01,elite,1.0,28397222,GBR,"","",31.49.231.211,[MANIFESTATION],[MANIFESTATION],found to have,N/A,51,83,58,96,1,RO-disease_may_have_finding,902994-FS1,We present a rare case of an adult patient without SEIZURES who is found to have a GANGLIOGLIOMA occurring in the cerebellopontine angle.,SEIZURES,GANGLIOGLIOMA
502832740,7/13/2014 18:48:04,,1322048541,7/13/2014 18:47:41,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[CAUSES],[CAUSES],rather than initiating,N/A,232,78,255,112,-1,RO-has_definitional_manifestation,904736-FS1,"There is some evidence for a role of ET 1 in blood pressure elevation in some EXPERIMENTAL FORMS OF HYPERTENSION particularly severe, sodium sensitive hypertension, in which it may play a role in accentuating rather than initiating BLOOD PRESSURE ELEVATION.",BLOOD PRESSURE ELEVATION,EXPERIMENTAL FORMS OF HYPERTENSION
502832740,7/13/2014 18:53:27,,1322051067,7/13/2014 18:53:00,neodev,1.0,18517457,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],accentuating rather than initiating,N/a,232,78,255,112,-1,RO-has_definitional_manifestation,904736-FS1,"There is some evidence for a role of ET 1 in blood pressure elevation in some EXPERIMENTAL FORMS OF HYPERTENSION particularly severe, sodium sensitive hypertension, in which it may play a role in accentuating rather than initiating BLOOD PRESSURE ELEVATION.",BLOOD PRESSURE ELEVATION,EXPERIMENTAL FORMS OF HYPERTENSION
502832740,7/13/2014 18:57:41,,1322053054,7/13/2014 18:55:20,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],in accentuating,N/A,232,78,255,112,-1,RO-has_definitional_manifestation,904736-FS1,"There is some evidence for a role of ET 1 in blood pressure elevation in some EXPERIMENTAL FORMS OF HYPERTENSION particularly severe, sodium sensitive hypertension, in which it may play a role in accentuating rather than initiating BLOOD PRESSURE ELEVATION.",BLOOD PRESSURE ELEVATION,EXPERIMENTAL FORMS OF HYPERTENSION
502832740,7/13/2014 19:01:32,,1322054772,7/13/2014 19:01:25,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[TREATS],[TREATS],which,da,232,78,255,112,-1,RO-has_definitional_manifestation,904736-FS1,"There is some evidence for a role of ET 1 in blood pressure elevation in some EXPERIMENTAL FORMS OF HYPERTENSION particularly severe, sodium sensitive hypertension, in which it may play a role in accentuating rather than initiating BLOOD PRESSURE ELEVATION.",BLOOD PRESSURE ELEVATION,EXPERIMENTAL FORMS OF HYPERTENSION
502832740,7/13/2014 19:05:08,,1322056347,7/13/2014 19:05:00,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],EXPERIMENTAL,N/A,232,78,255,112,-1,RO-has_definitional_manifestation,904736-FS1,"There is some evidence for a role of ET 1 in blood pressure elevation in some EXPERIMENTAL FORMS OF HYPERTENSION particularly severe, sodium sensitive hypertension, in which it may play a role in accentuating rather than initiating BLOOD PRESSURE ELEVATION.",BLOOD PRESSURE ELEVATION,EXPERIMENTAL FORMS OF HYPERTENSION
502832740,7/13/2014 19:17:26,,1322061600,7/13/2014 19:16:38,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],in some,N/A,232,78,255,112,-1,RO-has_definitional_manifestation,904736-FS1,"There is some evidence for a role of ET 1 in blood pressure elevation in some EXPERIMENTAL FORMS OF HYPERTENSION particularly severe, sodium sensitive hypertension, in which it may play a role in accentuating rather than initiating BLOOD PRESSURE ELEVATION.",BLOOD PRESSURE ELEVATION,EXPERIMENTAL FORMS OF HYPERTENSION
502832740,7/13/2014 19:19:17,,1322062326,7/13/2014 19:18:00,instagc,1.0,19686223,CAN,BC,Surrey,154.20.155.106,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]","There is some evidence for a role of ET 1 in blood pressure elevation in some EXPERIMENTAL FORMS OF HYPERTENSION particularly severe, sodium sensitive hypertension, in which it may play a role in accentuating rather than initiating BLOOD PRESSURE ELEVATION.",N/A,232,78,255,112,-1,RO-has_definitional_manifestation,904736-FS1,"There is some evidence for a role of ET 1 in blood pressure elevation in some EXPERIMENTAL FORMS OF HYPERTENSION particularly severe, sodium sensitive hypertension, in which it may play a role in accentuating rather than initiating BLOOD PRESSURE ELEVATION.",BLOOD PRESSURE ELEVATION,EXPERIMENTAL FORMS OF HYPERTENSION
502832740,7/13/2014 19:26:37,,1322065014,7/13/2014 19:26:12,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[ASSOCIATED_WITH],[ASSOCIATED_WITH],accentuating,n/a,232,78,255,112,-1,RO-has_definitional_manifestation,904736-FS1,"There is some evidence for a role of ET 1 in blood pressure elevation in some EXPERIMENTAL FORMS OF HYPERTENSION particularly severe, sodium sensitive hypertension, in which it may play a role in accentuating rather than initiating BLOOD PRESSURE ELEVATION.",BLOOD PRESSURE ELEVATION,EXPERIMENTAL FORMS OF HYPERTENSION
502832740,7/13/2014 19:41:37,,1322070743,7/13/2014 19:40:50,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[CAUSES],[CAUSES],EXPERIMENTAL FORMS OF HYPERTENSION BLOOD PRESSURE ELEVATION.,n/a,232,78,255,112,-1,RO-has_definitional_manifestation,904736-FS1,"There is some evidence for a role of ET 1 in blood pressure elevation in some EXPERIMENTAL FORMS OF HYPERTENSION particularly severe, sodium sensitive hypertension, in which it may play a role in accentuating rather than initiating BLOOD PRESSURE ELEVATION.",BLOOD PRESSURE ELEVATION,EXPERIMENTAL FORMS OF HYPERTENSION
502832740,7/13/2014 20:11:10,,1322098417,7/13/2014 20:10:37,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[SYMPTOM],[SYMPTOM],role in accentuating,n/a,232,78,255,112,-1,RO-has_definitional_manifestation,904736-FS1,"There is some evidence for a role of ET 1 in blood pressure elevation in some EXPERIMENTAL FORMS OF HYPERTENSION particularly severe, sodium sensitive hypertension, in which it may play a role in accentuating rather than initiating BLOOD PRESSURE ELEVATION.",BLOOD PRESSURE ELEVATION,EXPERIMENTAL FORMS OF HYPERTENSION
502832740,7/13/2014 20:20:57,,1322106987,7/13/2014 20:20:32,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],role,Na,232,78,255,112,-1,RO-has_definitional_manifestation,904736-FS1,"There is some evidence for a role of ET 1 in blood pressure elevation in some EXPERIMENTAL FORMS OF HYPERTENSION particularly severe, sodium sensitive hypertension, in which it may play a role in accentuating rather than initiating BLOOD PRESSURE ELEVATION.",BLOOD PRESSURE ELEVATION,EXPERIMENTAL FORMS OF HYPERTENSION
502832740,7/13/2014 20:38:02,,1322121419,7/13/2014 20:37:36,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],EXPERIMENTAL FORMS OF HYPERTENSION BLOOD PRESSURE ELEVATION.,n/a,232,78,255,112,-1,RO-has_definitional_manifestation,904736-FS1,"There is some evidence for a role of ET 1 in blood pressure elevation in some EXPERIMENTAL FORMS OF HYPERTENSION particularly severe, sodium sensitive hypertension, in which it may play a role in accentuating rather than initiating BLOOD PRESSURE ELEVATION.",BLOOD PRESSURE ELEVATION,EXPERIMENTAL FORMS OF HYPERTENSION
502832740,7/13/2014 20:54:11,,1322135093,7/13/2014 20:53:35,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[CAUSES],[CAUSES],may play a role in accentuating,n/a,232,78,255,112,-1,RO-has_definitional_manifestation,904736-FS1,"There is some evidence for a role of ET 1 in blood pressure elevation in some EXPERIMENTAL FORMS OF HYPERTENSION particularly severe, sodium sensitive hypertension, in which it may play a role in accentuating rather than initiating BLOOD PRESSURE ELEVATION.",BLOOD PRESSURE ELEVATION,EXPERIMENTAL FORMS OF HYPERTENSION
502832740,7/13/2014 21:11:35,,1322150290,7/13/2014 21:09:18,elite,1.0,28397222,GBR,"","",31.49.231.211,[SYMPTOM],[SYMPTOM],play a role in accentuating,N/A,232,78,255,112,-1,RO-has_definitional_manifestation,904736-FS1,"There is some evidence for a role of ET 1 in blood pressure elevation in some EXPERIMENTAL FORMS OF HYPERTENSION particularly severe, sodium sensitive hypertension, in which it may play a role in accentuating rather than initiating BLOOD PRESSURE ELEVATION.",BLOOD PRESSURE ELEVATION,EXPERIMENTAL FORMS OF HYPERTENSION
502832740,7/13/2014 21:46:19,,1322177273,7/13/2014 21:45:29,instagc,1.0,28301350,GBR,K4,Plymouth,89.242.63.62,[SYMPTOM],[SYMPTOM],in some,N/A,232,78,255,112,-1,RO-has_definitional_manifestation,904736-FS1,"There is some evidence for a role of ET 1 in blood pressure elevation in some EXPERIMENTAL FORMS OF HYPERTENSION particularly severe, sodium sensitive hypertension, in which it may play a role in accentuating rather than initiating BLOOD PRESSURE ELEVATION.",BLOOD PRESSURE ELEVATION,EXPERIMENTAL FORMS OF HYPERTENSION
502832741,7/13/2014 18:52:32,,1322050671,7/13/2014 18:52:17,prodege,1,2143114,CAN,BC,Vancouver,24.84.160.12,[SYMPTOM],[SYMPTOM],are suggestive,N/A,168,141,181,149,1,RO-may_prevent,907372-FS1,The screening usually consists of measuring thyroxin in dried blood spot specimens followed by measurement of thyrotropin if the results for THYROXIN are suggestive of HYPOTHYROIDISM,HYPOTHYROIDISM,THYROXIN
502832741,7/13/2014 18:52:35,,1322050696,7/13/2014 18:51:55,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],suggestive of,N/A,168,141,181,149,1,RO-may_prevent,907372-FS1,The screening usually consists of measuring thyroxin in dried blood spot specimens followed by measurement of thyrotropin if the results for THYROXIN are suggestive of HYPOTHYROIDISM,HYPOTHYROIDISM,THYROXIN
502832741,7/13/2014 18:53:52,,1322051226,7/13/2014 18:53:28,neodev,1.0,18517457,GBR,"","",86.29.147.112,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],if the results for THYROXIN are,N/a,168,141,181,149,1,RO-may_prevent,907372-FS1,The screening usually consists of measuring thyroxin in dried blood spot specimens followed by measurement of thyrotropin if the results for THYROXIN are suggestive of HYPOTHYROIDISM,HYPOTHYROIDISM,THYROXIN
502832741,7/13/2014 19:04:09,,1322055958,7/13/2014 19:03:58,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],specimens,N/A,168,141,181,149,1,RO-may_prevent,907372-FS1,The screening usually consists of measuring thyroxin in dried blood spot specimens followed by measurement of thyrotropin if the results for THYROXIN are suggestive of HYPOTHYROIDISM,HYPOTHYROIDISM,THYROXIN
502832741,7/13/2014 19:05:13,,1322056380,7/13/2014 19:05:07,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[PREVENTS],[PREVENTS],thyroxin,da,168,141,181,149,1,RO-may_prevent,907372-FS1,The screening usually consists of measuring thyroxin in dried blood spot specimens followed by measurement of thyrotropin if the results for THYROXIN are suggestive of HYPOTHYROIDISM,HYPOTHYROIDISM,THYROXIN
502832741,7/13/2014 19:11:12,,1322059034,7/13/2014 19:10:18,vivatic,1,25451531,GBR,"","",83.67.28.193,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],The screening consists of,N/A,168,141,181,149,1,RO-may_prevent,907372-FS1,The screening usually consists of measuring thyroxin in dried blood spot specimens followed by measurement of thyrotropin if the results for THYROXIN are suggestive of HYPOTHYROIDISM,HYPOTHYROIDISM,THYROXIN
502832741,7/13/2014 19:21:36,,1322063151,7/13/2014 19:20:38,elite,1,28276268,USA,CA,San Diego,76.88.95.100,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",measuring thyroxin in dried blood spot specimens,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],168,141,181,149,1,RO-may_prevent,907372-FS1,The screening usually consists of measuring thyroxin in dried blood spot specimens followed by measurement of thyrotropin if the results for THYROXIN are suggestive of HYPOTHYROIDISM,HYPOTHYROIDISM,THYROXIN
502832741,7/13/2014 19:29:48,,1322066232,7/13/2014 19:29:08,prodege,1,9378607,GBR,H9,London,90.201.89.10,[MANIFESTATION],[MANIFESTATION],THYROXIN are suggestive of HYPOTHYROIDISM,n/a,168,141,181,149,1,RO-may_prevent,907372-FS1,The screening usually consists of measuring thyroxin in dried blood spot specimens followed by measurement of thyrotropin if the results for THYROXIN are suggestive of HYPOTHYROIDISM,HYPOTHYROIDISM,THYROXIN
502832741,7/13/2014 19:37:24,,1322068899,7/13/2014 19:37:00,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],are suggestive of,N/A,168,141,181,149,1,RO-may_prevent,907372-FS1,The screening usually consists of measuring thyroxin in dried blood spot specimens followed by measurement of thyrotropin if the results for THYROXIN are suggestive of HYPOTHYROIDISM,HYPOTHYROIDISM,THYROXIN
502832741,7/13/2014 19:55:50,,1322082598,7/13/2014 19:55:12,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[TREATS],[TREATS],THYROXIN HYPOTHYROIDISM,n/a,168,141,181,149,1,RO-may_prevent,907372-FS1,The screening usually consists of measuring thyroxin in dried blood spot specimens followed by measurement of thyrotropin if the results for THYROXIN are suggestive of HYPOTHYROIDISM,HYPOTHYROIDISM,THYROXIN
502832741,7/13/2014 20:06:18,,1322094075,7/13/2014 20:05:35,prodege,1,19192508,USA,OK,Broken Arrow,70.177.111.89,[CAUSES],[CAUSES],results are suggestive,n/a,168,141,181,149,1,RO-may_prevent,907372-FS1,The screening usually consists of measuring thyroxin in dried blood spot specimens followed by measurement of thyrotropin if the results for THYROXIN are suggestive of HYPOTHYROIDISM,HYPOTHYROIDISM,THYROXIN
502832741,7/13/2014 20:10:10,,1322097582,7/13/2014 20:09:12,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[TREATS],[TREATS],are suggestive of,N/A,168,141,181,149,1,RO-may_prevent,907372-FS1,The screening usually consists of measuring thyroxin in dried blood spot specimens followed by measurement of thyrotropin if the results for THYROXIN are suggestive of HYPOTHYROIDISM,HYPOTHYROIDISM,THYROXIN
502832741,7/13/2014 20:18:10,,1322104512,7/13/2014 20:17:40,elite,1.0,28503042,USA,OK,Oakwood,64.250.220.169,[MANIFESTATION],[MANIFESTATION],THYROXIN are suggestive of HYPOTHYROIDISM,N/A,168,141,181,149,1,RO-may_prevent,907372-FS1,The screening usually consists of measuring thyroxin in dried blood spot specimens followed by measurement of thyrotropin if the results for THYROXIN are suggestive of HYPOTHYROIDISM,HYPOTHYROIDISM,THYROXIN
502832741,7/13/2014 20:29:32,,1322114459,7/13/2014 20:26:47,elite,1,28397222,GBR,"","",31.49.231.211,[ASSOCIATED_WITH],[ASSOCIATED_WITH],suggestive of,N/A,168,141,181,149,1,RO-may_prevent,907372-FS1,The screening usually consists of measuring thyroxin in dried blood spot specimens followed by measurement of thyrotropin if the results for THYROXIN are suggestive of HYPOTHYROIDISM,HYPOTHYROIDISM,THYROXIN
502832741,7/13/2014 20:47:59,,1322129575,7/13/2014 20:47:38,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],are suggestive of,n/a,168,141,181,149,1,RO-may_prevent,907372-FS1,The screening usually consists of measuring thyroxin in dried blood spot specimens followed by measurement of thyrotropin if the results for THYROXIN are suggestive of HYPOTHYROIDISM,HYPOTHYROIDISM,THYROXIN
502832742,7/13/2014 18:46:55,,1322047999,7/13/2014 18:46:31,neodev,1.0,18517457,GBR,"","",86.29.147.112,[TREATS],[TREATS],is superior to in the treatment,N/a,84,279,107,290,1,RO-may_treat,907970-FS1,"The study demonstrated that vasopressin is similar to epinephrine for OOH CA due to VENTRICULAR FIBRILLATION or pulseless electrical activity, and superior to epinephrine for the initial treatment of asystolic arrest; it also demonstrated that the combination of vasopressin and EPINEPHRINE is superior to epinephrine alone in the treatment of refractory, out of hospital cardiac arrest.",VENTRICULAR FIBRILLATION,EPINEPHRINE
502832742,7/13/2014 18:56:28,,1322052474,7/13/2014 18:55:52,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[TREATS],[TREATS],in the treatment,na,84,279,107,290,1,RO-may_treat,907970-FS1,"The study demonstrated that vasopressin is similar to epinephrine for OOH CA due to VENTRICULAR FIBRILLATION or pulseless electrical activity, and superior to epinephrine for the initial treatment of asystolic arrest; it also demonstrated that the combination of vasopressin and EPINEPHRINE is superior to epinephrine alone in the treatment of refractory, out of hospital cardiac arrest.",VENTRICULAR FIBRILLATION,EPINEPHRINE
502832742,7/13/2014 19:03:22,,1322055616,7/13/2014 19:03:04,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],epinephrine,N/A,84,279,107,290,1,RO-may_treat,907970-FS1,"The study demonstrated that vasopressin is similar to epinephrine for OOH CA due to VENTRICULAR FIBRILLATION or pulseless electrical activity, and superior to epinephrine for the initial treatment of asystolic arrest; it also demonstrated that the combination of vasopressin and EPINEPHRINE is superior to epinephrine alone in the treatment of refractory, out of hospital cardiac arrest.",VENTRICULAR FIBRILLATION,EPINEPHRINE
502832742,7/13/2014 19:04:23,,1322056065,7/13/2014 19:04:16,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[PREVENTS],[PREVENTS],similar,da,84,279,107,290,1,RO-may_treat,907970-FS1,"The study demonstrated that vasopressin is similar to epinephrine for OOH CA due to VENTRICULAR FIBRILLATION or pulseless electrical activity, and superior to epinephrine for the initial treatment of asystolic arrest; it also demonstrated that the combination of vasopressin and EPINEPHRINE is superior to epinephrine alone in the treatment of refractory, out of hospital cardiac arrest.",VENTRICULAR FIBRILLATION,EPINEPHRINE
502832742,7/13/2014 19:15:55,,1322060922,7/13/2014 19:15:21,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],treatment,N/A,84,279,107,290,1,RO-may_treat,907970-FS1,"The study demonstrated that vasopressin is similar to epinephrine for OOH CA due to VENTRICULAR FIBRILLATION or pulseless electrical activity, and superior to epinephrine for the initial treatment of asystolic arrest; it also demonstrated that the combination of vasopressin and EPINEPHRINE is superior to epinephrine alone in the treatment of refractory, out of hospital cardiac arrest.",VENTRICULAR FIBRILLATION,EPINEPHRINE
502832742,7/13/2014 19:18:45,,1322062081,7/13/2014 19:17:57,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[ASSOCIATED_WITH],[ASSOCIATED_WITH],VENTRICULAR FIBRILLATION superior to EPINEPHRINE,n/a,84,279,107,290,1,RO-may_treat,907970-FS1,"The study demonstrated that vasopressin is similar to epinephrine for OOH CA due to VENTRICULAR FIBRILLATION or pulseless electrical activity, and superior to epinephrine for the initial treatment of asystolic arrest; it also demonstrated that the combination of vasopressin and EPINEPHRINE is superior to epinephrine alone in the treatment of refractory, out of hospital cardiac arrest.",VENTRICULAR FIBRILLATION,EPINEPHRINE
502832742,7/13/2014 19:20:14,,1322062707,7/13/2014 19:19:09,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],initial treatment of,N/A,84,279,107,290,1,RO-may_treat,907970-FS1,"The study demonstrated that vasopressin is similar to epinephrine for OOH CA due to VENTRICULAR FIBRILLATION or pulseless electrical activity, and superior to epinephrine for the initial treatment of asystolic arrest; it also demonstrated that the combination of vasopressin and EPINEPHRINE is superior to epinephrine alone in the treatment of refractory, out of hospital cardiac arrest.",VENTRICULAR FIBRILLATION,EPINEPHRINE
502832742,7/13/2014 19:35:11,,1322068021,7/13/2014 19:34:04,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],in the treatment,N/A,84,279,107,290,1,RO-may_treat,907970-FS1,"The study demonstrated that vasopressin is similar to epinephrine for OOH CA due to VENTRICULAR FIBRILLATION or pulseless electrical activity, and superior to epinephrine for the initial treatment of asystolic arrest; it also demonstrated that the combination of vasopressin and EPINEPHRINE is superior to epinephrine alone in the treatment of refractory, out of hospital cardiac arrest.",VENTRICULAR FIBRILLATION,EPINEPHRINE
502832742,7/13/2014 19:58:10,,1322085159,7/13/2014 19:56:49,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],vasopressin similar epinephrine OOH CA due VENTRICULAR FIBRILLATION EPINEPHRINE,treats,84,279,107,290,1,RO-may_treat,907970-FS1,"The study demonstrated that vasopressin is similar to epinephrine for OOH CA due to VENTRICULAR FIBRILLATION or pulseless electrical activity, and superior to epinephrine for the initial treatment of asystolic arrest; it also demonstrated that the combination of vasopressin and EPINEPHRINE is superior to epinephrine alone in the treatment of refractory, out of hospital cardiac arrest.",VENTRICULAR FIBRILLATION,EPINEPHRINE
502832742,7/13/2014 20:04:29,,1322092047,7/13/2014 20:03:55,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[TREATS],[TREATS],VENTRICULAR FIBRILLATION EPINEPHRINE,n/a,84,279,107,290,1,RO-may_treat,907970-FS1,"The study demonstrated that vasopressin is similar to epinephrine for OOH CA due to VENTRICULAR FIBRILLATION or pulseless electrical activity, and superior to epinephrine for the initial treatment of asystolic arrest; it also demonstrated that the combination of vasopressin and EPINEPHRINE is superior to epinephrine alone in the treatment of refractory, out of hospital cardiac arrest.",VENTRICULAR FIBRILLATION,EPINEPHRINE
502832742,7/13/2014 20:20:01,,1322106218,7/13/2014 20:18:16,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],similar,N/A,84,279,107,290,1,RO-may_treat,907970-FS1,"The study demonstrated that vasopressin is similar to epinephrine for OOH CA due to VENTRICULAR FIBRILLATION or pulseless electrical activity, and superior to epinephrine for the initial treatment of asystolic arrest; it also demonstrated that the combination of vasopressin and EPINEPHRINE is superior to epinephrine alone in the treatment of refractory, out of hospital cardiac arrest.",VENTRICULAR FIBRILLATION,EPINEPHRINE
502832742,7/13/2014 20:21:32,,1322107520,7/13/2014 20:20:47,elite,1.0,28503042,USA,OK,Oakwood,64.250.220.169,[OTHER],[OTHER],combination of vasopressin and EPINEPHRINE,N/A,84,279,107,290,1,RO-may_treat,907970-FS1,"The study demonstrated that vasopressin is similar to epinephrine for OOH CA due to VENTRICULAR FIBRILLATION or pulseless electrical activity, and superior to epinephrine for the initial treatment of asystolic arrest; it also demonstrated that the combination of vasopressin and EPINEPHRINE is superior to epinephrine alone in the treatment of refractory, out of hospital cardiac arrest.",VENTRICULAR FIBRILLATION,EPINEPHRINE
502832742,7/13/2014 20:22:16,,1322108131,7/13/2014 20:21:59,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],combination,Na,84,279,107,290,1,RO-may_treat,907970-FS1,"The study demonstrated that vasopressin is similar to epinephrine for OOH CA due to VENTRICULAR FIBRILLATION or pulseless electrical activity, and superior to epinephrine for the initial treatment of asystolic arrest; it also demonstrated that the combination of vasopressin and EPINEPHRINE is superior to epinephrine alone in the treatment of refractory, out of hospital cardiac arrest.",VENTRICULAR FIBRILLATION,EPINEPHRINE
502832742,7/13/2014 20:48:32,,1322130198,7/13/2014 20:48:00,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],epinephrine for OOH CA due to,n/a,84,279,107,290,1,RO-may_treat,907970-FS1,"The study demonstrated that vasopressin is similar to epinephrine for OOH CA due to VENTRICULAR FIBRILLATION or pulseless electrical activity, and superior to epinephrine for the initial treatment of asystolic arrest; it also demonstrated that the combination of vasopressin and EPINEPHRINE is superior to epinephrine alone in the treatment of refractory, out of hospital cardiac arrest.",VENTRICULAR FIBRILLATION,EPINEPHRINE
502832742,7/13/2014 21:01:29,,1322141652,7/13/2014 21:00:13,clixsense,1,26649250,GBR,B7,Bristol,79.71.125.97,[TREATS],[TREATS],is superior to epinephrine alone in the treatment,n/a,84,279,107,290,1,RO-may_treat,907970-FS1,"The study demonstrated that vasopressin is similar to epinephrine for OOH CA due to VENTRICULAR FIBRILLATION or pulseless electrical activity, and superior to epinephrine for the initial treatment of asystolic arrest; it also demonstrated that the combination of vasopressin and EPINEPHRINE is superior to epinephrine alone in the treatment of refractory, out of hospital cardiac arrest.",VENTRICULAR FIBRILLATION,EPINEPHRINE
502832743,7/13/2014 18:45:25,,1322047272,7/13/2014 18:44:56,clixsense,1.0,19803139,NLD,11,Leiden,82.139.76.131,[PART_OF],[PART_OF],instead reflect a,N/A,110,153,129,203,1,RO-may_prevent,907453-FS1,The results suggest that the low serum vitamin A levels in primary biliary cirrhosis are not a consequence of VITAMIN A DEFICIENCY but instead reflect a DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER.,VITAMIN A DEFICIENCY,DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER
502832743,7/13/2014 18:48:35,,1322048808,7/13/2014 18:48:05,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[SIDE_EFFECT],[SIDE_EFFECT],but instead reflect a,N/A,110,153,129,203,1,RO-may_prevent,907453-FS1,The results suggest that the low serum vitamin A levels in primary biliary cirrhosis are not a consequence of VITAMIN A DEFICIENCY but instead reflect a DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER.,VITAMIN A DEFICIENCY,DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER
502832743,7/13/2014 18:49:52,,1322049296,7/13/2014 18:49:23,neodev,1.0,18517457,GBR,"","",86.29.147.112,[CONTRAINDICATES],[CONTRAINDICATES],but instead reflect a,N/a,110,153,129,203,1,RO-may_prevent,907453-FS1,The results suggest that the low serum vitamin A levels in primary biliary cirrhosis are not a consequence of VITAMIN A DEFICIENCY but instead reflect a DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER.,VITAMIN A DEFICIENCY,DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER
502832743,7/13/2014 19:00:03,,1322054169,7/13/2014 18:59:08,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],results,N/A,110,153,129,203,1,RO-may_prevent,907453-FS1,The results suggest that the low serum vitamin A levels in primary biliary cirrhosis are not a consequence of VITAMIN A DEFICIENCY but instead reflect a DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER.,VITAMIN A DEFICIENCY,DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER
502832743,7/13/2014 19:04:59,,1322056296,7/13/2014 19:04:49,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],VITAMIN,N/A,110,153,129,203,1,RO-may_prevent,907453-FS1,The results suggest that the low serum vitamin A levels in primary biliary cirrhosis are not a consequence of VITAMIN A DEFICIENCY but instead reflect a DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER.,VITAMIN A DEFICIENCY,DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER
502832743,7/13/2014 19:08:24,,1322057879,7/13/2014 19:07:32,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[NONE],[NONE],N/A,"One is proven to be a symptom, the other is not.",110,153,129,203,1,RO-may_prevent,907453-FS1,The results suggest that the low serum vitamin A levels in primary biliary cirrhosis are not a consequence of VITAMIN A DEFICIENCY but instead reflect a DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER.,VITAMIN A DEFICIENCY,DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER
502832743,7/13/2014 19:10:06,,1322058656,7/13/2014 19:09:20,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],instead reflect a,n/a,110,153,129,203,1,RO-may_prevent,907453-FS1,The results suggest that the low serum vitamin A levels in primary biliary cirrhosis are not a consequence of VITAMIN A DEFICIENCY but instead reflect a DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER.,VITAMIN A DEFICIENCY,DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER
502832743,7/13/2014 19:11:03,,1322058969,7/13/2014 19:10:19,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[PART_OF],[PART_OF],reflect,[PART_OF],110,153,129,203,1,RO-may_prevent,907453-FS1,The results suggest that the low serum vitamin A levels in primary biliary cirrhosis are not a consequence of VITAMIN A DEFICIENCY but instead reflect a DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER.,VITAMIN A DEFICIENCY,DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER
502832743,7/13/2014 19:20:29,,1322062772,7/13/2014 19:19:54,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[NONE],[NONE],N/A,No clear relationship.,110,153,129,203,1,RO-may_prevent,907453-FS1,The results suggest that the low serum vitamin A levels in primary biliary cirrhosis are not a consequence of VITAMIN A DEFICIENCY but instead reflect a DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER.,VITAMIN A DEFICIENCY,DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER
502832743,7/13/2014 19:27:23,,1322065343,7/13/2014 19:26:25,instagc,1.0,19686223,CAN,BC,Surrey,154.20.155.106,[CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]",The results suggest that the low serum vitamin A levels in primary biliary cirrhosis are not a consequence of VITAMIN A DEFICIENCY but instead reflect a DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER.,N/A,110,153,129,203,1,RO-may_prevent,907453-FS1,The results suggest that the low serum vitamin A levels in primary biliary cirrhosis are not a consequence of VITAMIN A DEFICIENCY but instead reflect a DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER.,VITAMIN A DEFICIENCY,DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER
502832743,7/13/2014 19:36:02,,1322068341,7/13/2014 19:35:13,instagc,1.0,13763729,USA,"","",75.182.89.225,[CAUSES],[CAUSES],a consequence of,N/A,110,153,129,203,1,RO-may_prevent,907453-FS1,The results suggest that the low serum vitamin A levels in primary biliary cirrhosis are not a consequence of VITAMIN A DEFICIENCY but instead reflect a DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER.,VITAMIN A DEFICIENCY,DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER
502832743,7/13/2014 19:53:43,,1322080473,7/13/2014 19:52:02,clixsense,1.0,6365250,CAN,BC,Burnaby,70.79.16.165,[NONE],[NONE],none,not related - two different deficiencies,110,153,129,203,1,RO-may_prevent,907453-FS1,The results suggest that the low serum vitamin A levels in primary biliary cirrhosis are not a consequence of VITAMIN A DEFICIENCY but instead reflect a DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER.,VITAMIN A DEFICIENCY,DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER
502832743,7/13/2014 20:03:50,,1322091441,7/13/2014 20:03:13,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],VITAMIN DEFICIENCY DEFECTIVE MOBILIZATION OF VITAMIN FROM THE LIVER.,n/a,110,153,129,203,1,RO-may_prevent,907453-FS1,The results suggest that the low serum vitamin A levels in primary biliary cirrhosis are not a consequence of VITAMIN A DEFICIENCY but instead reflect a DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER.,VITAMIN A DEFICIENCY,DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER
502832743,7/13/2014 20:06:57,,1322094757,7/13/2014 20:06:32,elite,1.0,28503042,USA,OK,Oakwood,64.250.220.169,[OTHER],[OTHER],but instead reflect a,N/A,110,153,129,203,1,RO-may_prevent,907453-FS1,The results suggest that the low serum vitamin A levels in primary biliary cirrhosis are not a consequence of VITAMIN A DEFICIENCY but instead reflect a DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER.,VITAMIN A DEFICIENCY,DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER
502832743,7/13/2014 20:16:58,,1322103462,7/13/2014 20:16:30,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[OTHER],[OTHER],VITAMIN A DEFICIENCY DEFECTIVE MOBILIZATION VITAMIN A,N/A,110,153,129,203,1,RO-may_prevent,907453-FS1,The results suggest that the low serum vitamin A levels in primary biliary cirrhosis are not a consequence of VITAMIN A DEFICIENCY but instead reflect a DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER.,VITAMIN A DEFICIENCY,DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER
502832744,7/13/2014 18:44:24,,1322046789,7/13/2014 18:44:03,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],followed,not sure,154,81,165,117,1,RO-may_treat,907653-FS1,"Nevertheless, immunosuppressive therapy (pulse IV methylprednisolone followed by ORAL PREDNISONE AND CYCLOPHOSPHAMIDE) can be given to attempt to control INFLAMMATION in patients who develop severe renal disease.",INFLAMMATION,ORAL PREDNISONE AND CYCLOPHOSPHAMIDE
502832744,7/13/2014 19:00:45,,1322054451,7/13/2014 18:59:48,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[TREATS],[TREATS],to attempt to control,na,154,81,165,117,1,RO-may_treat,907653-FS1,"Nevertheless, immunosuppressive therapy (pulse IV methylprednisolone followed by ORAL PREDNISONE AND CYCLOPHOSPHAMIDE) can be given to attempt to control INFLAMMATION in patients who develop severe renal disease.",INFLAMMATION,ORAL PREDNISONE AND CYCLOPHOSPHAMIDE
502832744,7/13/2014 19:03:56,,1322055859,7/13/2014 19:03:49,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[SIDE_EFFECT],[SIDE_EFFECT],CYCLOPHOSPHAMIDE),da,154,81,165,117,1,RO-may_treat,907653-FS1,"Nevertheless, immunosuppressive therapy (pulse IV methylprednisolone followed by ORAL PREDNISONE AND CYCLOPHOSPHAMIDE) can be given to attempt to control INFLAMMATION in patients who develop severe renal disease.",INFLAMMATION,ORAL PREDNISONE AND CYCLOPHOSPHAMIDE
502832744,7/13/2014 19:05:23,,1322056434,7/13/2014 19:05:10,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],IV,N/A,154,81,165,117,1,RO-may_treat,907653-FS1,"Nevertheless, immunosuppressive therapy (pulse IV methylprednisolone followed by ORAL PREDNISONE AND CYCLOPHOSPHAMIDE) can be given to attempt to control INFLAMMATION in patients who develop severe renal disease.",INFLAMMATION,ORAL PREDNISONE AND CYCLOPHOSPHAMIDE
502832744,7/13/2014 19:10:16,,1322058702,7/13/2014 19:09:36,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],can be given,N/A,154,81,165,117,1,RO-may_treat,907653-FS1,"Nevertheless, immunosuppressive therapy (pulse IV methylprednisolone followed by ORAL PREDNISONE AND CYCLOPHOSPHAMIDE) can be given to attempt to control INFLAMMATION in patients who develop severe renal disease.",INFLAMMATION,ORAL PREDNISONE AND CYCLOPHOSPHAMIDE
502832744,7/13/2014 19:18:01,,1322061841,7/13/2014 19:17:08,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[CAUSES],[CAUSES],followed by,N/A,154,81,165,117,1,RO-may_treat,907653-FS1,"Nevertheless, immunosuppressive therapy (pulse IV methylprednisolone followed by ORAL PREDNISONE AND CYCLOPHOSPHAMIDE) can be given to attempt to control INFLAMMATION in patients who develop severe renal disease.",INFLAMMATION,ORAL PREDNISONE AND CYCLOPHOSPHAMIDE
502832744,7/13/2014 19:22:44,,1322063591,7/13/2014 19:22:09,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[CAUSES] [SYMPTOM],"[CAUSES]
[SYMPTOM]",can be given to attempt,[CAUSES] [SYMPTOM],154,81,165,117,1,RO-may_treat,907653-FS1,"Nevertheless, immunosuppressive therapy (pulse IV methylprednisolone followed by ORAL PREDNISONE AND CYCLOPHOSPHAMIDE) can be given to attempt to control INFLAMMATION in patients who develop severe renal disease.",INFLAMMATION,ORAL PREDNISONE AND CYCLOPHOSPHAMIDE
502832744,7/13/2014 19:41:24,,1322070549,7/13/2014 19:41:01,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],to attempt to control,N/A,154,81,165,117,1,RO-may_treat,907653-FS1,"Nevertheless, immunosuppressive therapy (pulse IV methylprednisolone followed by ORAL PREDNISONE AND CYCLOPHOSPHAMIDE) can be given to attempt to control INFLAMMATION in patients who develop severe renal disease.",INFLAMMATION,ORAL PREDNISONE AND CYCLOPHOSPHAMIDE
502832744,7/13/2014 20:20:31,,1322106662,7/13/2014 20:20:12,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],attempt to control,Na,154,81,165,117,1,RO-may_treat,907653-FS1,"Nevertheless, immunosuppressive therapy (pulse IV methylprednisolone followed by ORAL PREDNISONE AND CYCLOPHOSPHAMIDE) can be given to attempt to control INFLAMMATION in patients who develop severe renal disease.",INFLAMMATION,ORAL PREDNISONE AND CYCLOPHOSPHAMIDE
502832744,7/13/2014 20:44:51,,1322127040,7/13/2014 20:44:29,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],attempt to control,n/a,154,81,165,117,1,RO-may_treat,907653-FS1,"Nevertheless, immunosuppressive therapy (pulse IV methylprednisolone followed by ORAL PREDNISONE AND CYCLOPHOSPHAMIDE) can be given to attempt to control INFLAMMATION in patients who develop severe renal disease.",INFLAMMATION,ORAL PREDNISONE AND CYCLOPHOSPHAMIDE
502832744,7/13/2014 21:43:42,,1322175260,7/13/2014 21:43:28,tremorgames,1,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],can be given to attempt to control,N/A,154,81,165,117,1,RO-may_treat,907653-FS1,"Nevertheless, immunosuppressive therapy (pulse IV methylprednisolone followed by ORAL PREDNISONE AND CYCLOPHOSPHAMIDE) can be given to attempt to control INFLAMMATION in patients who develop severe renal disease.",INFLAMMATION,ORAL PREDNISONE AND CYCLOPHOSPHAMIDE
502832744,7/13/2014 21:45:38,,1322176732,7/13/2014 21:42:42,elite,1.0,28397222,GBR,"","",31.49.231.211,[OTHER],[OTHER],attempt to control,ORAL PREDNISONE AND CYCLOPHOSPHAMIDE can be used as part of the treatment of inflammation,154,81,165,117,1,RO-may_treat,907653-FS1,"Nevertheless, immunosuppressive therapy (pulse IV methylprednisolone followed by ORAL PREDNISONE AND CYCLOPHOSPHAMIDE) can be given to attempt to control INFLAMMATION in patients who develop severe renal disease.",INFLAMMATION,ORAL PREDNISONE AND CYCLOPHOSPHAMIDE
502832744,7/13/2014 22:02:49,,1322191752,7/13/2014 22:02:23,instagc,1,28301350,GBR,K4,Plymouth,89.242.63.62,[TREATS],[TREATS],can be given,N/A,154,81,165,117,1,RO-may_treat,907653-FS1,"Nevertheless, immunosuppressive therapy (pulse IV methylprednisolone followed by ORAL PREDNISONE AND CYCLOPHOSPHAMIDE) can be given to attempt to control INFLAMMATION in patients who develop severe renal disease.",INFLAMMATION,ORAL PREDNISONE AND CYCLOPHOSPHAMIDE
502832744,7/13/2014 22:48:35,,1322230850,7/13/2014 22:47:53,prodege,1,15439740,AUS,02,Jannali,27.96.208.89,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",attempt to control,n/a,154,81,165,117,1,RO-may_treat,907653-FS1,"Nevertheless, immunosuppressive therapy (pulse IV methylprednisolone followed by ORAL PREDNISONE AND CYCLOPHOSPHAMIDE) can be given to attempt to control INFLAMMATION in patients who develop severe renal disease.",INFLAMMATION,ORAL PREDNISONE AND CYCLOPHOSPHAMIDE
502832744,7/13/2014 23:09:39,,1322249576,7/13/2014 23:08:50,clixsense,1,10428985,GBR,N7,Weybridge,81.132.17.135,[PREVENTS],[PREVENTS],attempt to control,N/A,154,81,165,117,1,RO-may_treat,907653-FS1,"Nevertheless, immunosuppressive therapy (pulse IV methylprednisolone followed by ORAL PREDNISONE AND CYCLOPHOSPHAMIDE) can be given to attempt to control INFLAMMATION in patients who develop severe renal disease.",INFLAMMATION,ORAL PREDNISONE AND CYCLOPHOSPHAMIDE
502832745,7/13/2014 18:44:27,,1322046782,7/13/2014 18:44:03,clixsense,1.0,19803139,NLD,11,Leiden,82.139.76.131,[LOCATION],[LOCATION],from,N/A,71,101,75,112,1,RO-disease_has_primary_anatomic_site,902120-FS1,Quantitative counts of ferruginous bodies were performed on digests of LUNGS from 100 control and 30 LUNG CANCER patients.,LUNGS,LUNG CANCER
502832745,7/13/2014 18:47:47,,1322048428,7/13/2014 18:47:33,neodev,1.0,18517457,GBR,"","",86.29.147.112,[LOCATION],[LOCATION],of,N/a,71,101,75,112,1,RO-disease_has_primary_anatomic_site,902120-FS1,Quantitative counts of ferruginous bodies were performed on digests of LUNGS from 100 control and 30 LUNG CANCER patients.,LUNGS,LUNG CANCER
502832745,7/13/2014 18:55:40,,1322052050,7/13/2014 18:54:32,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[LOCATION],[LOCATION],performed on digests of LUNGS LUNG CANCER patients.,N/A,71,101,75,112,1,RO-disease_has_primary_anatomic_site,902120-FS1,Quantitative counts of ferruginous bodies were performed on digests of LUNGS from 100 control and 30 LUNG CANCER patients.,LUNGS,LUNG CANCER
502832745,7/13/2014 19:03:26,,1322055644,7/13/2014 19:03:18,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[MANIFESTATION],[MANIFESTATION],bodies,da,71,101,75,112,1,RO-disease_has_primary_anatomic_site,902120-FS1,Quantitative counts of ferruginous bodies were performed on digests of LUNGS from 100 control and 30 LUNG CANCER patients.,LUNGS,LUNG CANCER
502832745,7/13/2014 19:03:33,,1322055694,7/13/2014 19:01:55,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,71,101,75,112,1,RO-disease_has_primary_anatomic_site,902120-FS1,Quantitative counts of ferruginous bodies were performed on digests of LUNGS from 100 control and 30 LUNG CANCER patients.,LUNGS,LUNG CANCER
502832745,7/13/2014 19:08:26,,1322057886,7/13/2014 19:08:12,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],digests,N/A,71,101,75,112,1,RO-disease_has_primary_anatomic_site,902120-FS1,Quantitative counts of ferruginous bodies were performed on digests of LUNGS from 100 control and 30 LUNG CANCER patients.,LUNGS,LUNG CANCER
502832745,7/13/2014 19:11:46,,1322059287,7/13/2014 19:10:50,instagc,1.0,19686223,CAN,BC,Surrey,154.20.155.106,[NONE],[NONE],N/A,I cannot find any relations.,71,101,75,112,1,RO-disease_has_primary_anatomic_site,902120-FS1,Quantitative counts of ferruginous bodies were performed on digests of LUNGS from 100 control and 30 LUNG CANCER patients.,LUNGS,LUNG CANCER
502832745,7/13/2014 19:20:33,,1322062803,7/13/2014 19:19:52,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],were performed,[DIAGNOSE_BY_TEST_OR_DRUG],71,101,75,112,1,RO-disease_has_primary_anatomic_site,902120-FS1,Quantitative counts of ferruginous bodies were performed on digests of LUNGS from 100 control and 30 LUNG CANCER patients.,LUNGS,LUNG CANCER
502832745,7/13/2014 19:22:28,,1322063480,7/13/2014 19:22:07,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[LOCATION],[LOCATION],from,n/a,71,101,75,112,1,RO-disease_has_primary_anatomic_site,902120-FS1,Quantitative counts of ferruginous bodies were performed on digests of LUNGS from 100 control and 30 LUNG CANCER patients.,LUNGS,LUNG CANCER
502832745,7/13/2014 19:31:54,,1322066912,7/13/2014 19:31:29,instagc,1.0,13763729,USA,"","",75.182.89.225,[LOCATION],[LOCATION],of LUNGS LUNG CANCER patients.,N/A,71,101,75,112,1,RO-disease_has_primary_anatomic_site,902120-FS1,Quantitative counts of ferruginous bodies were performed on digests of LUNGS from 100 control and 30 LUNG CANCER patients.,LUNGS,LUNG CANCER
502832745,7/13/2014 19:44:20,,1322072602,7/13/2014 19:43:44,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],LUNGS LUNG CANCER,n/a,71,101,75,112,1,RO-disease_has_primary_anatomic_site,902120-FS1,Quantitative counts of ferruginous bodies were performed on digests of LUNGS from 100 control and 30 LUNG CANCER patients.,LUNGS,LUNG CANCER
502832745,7/13/2014 19:54:43,,1322081313,7/13/2014 19:54:15,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[LOCATION],[LOCATION],performed on digests,n/a,71,101,75,112,1,RO-disease_has_primary_anatomic_site,902120-FS1,Quantitative counts of ferruginous bodies were performed on digests of LUNGS from 100 control and 30 LUNG CANCER patients.,LUNGS,LUNG CANCER
502832745,7/13/2014 20:04:17,,1322091853,7/13/2014 20:03:43,elite,1.0,28503042,USA,OK,Oakwood,64.250.220.169,[OTHER],[OTHER],from 100 control and,N/A,71,101,75,112,1,RO-disease_has_primary_anatomic_site,902120-FS1,Quantitative counts of ferruginous bodies were performed on digests of LUNGS from 100 control and 30 LUNG CANCER patients.,LUNGS,LUNG CANCER
502832745,7/13/2014 21:02:00,,1322142031,7/13/2014 21:01:31,clixsense,1.0,26649250,GBR,B7,Bristol,79.71.125.97,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,71,101,75,112,1,RO-disease_has_primary_anatomic_site,902120-FS1,Quantitative counts of ferruginous bodies were performed on digests of LUNGS from 100 control and 30 LUNG CANCER patients.,LUNGS,LUNG CANCER
502832745,7/13/2014 21:44:26,,1322175706,7/13/2014 21:44:10,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],LUNGS LUNG CANCER,N/A,71,101,75,112,1,RO-disease_has_primary_anatomic_site,902120-FS1,Quantitative counts of ferruginous bodies were performed on digests of LUNGS from 100 control and 30 LUNG CANCER patients.,LUNGS,LUNG CANCER
502832746,7/13/2014 18:45:55,,1322047517,7/13/2014 18:45:34,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],between,N/A,39,31,42,53,-1,RO-has_causative_agent,903694-FS1,"The elderly are predisposed to ADVERSE DRUG REACTIONS because of age related physiologic changes, interaction of one drug with another, and interaction between a DRUG and a coexisting medical condition.",DRUG,ADVERSE DRUG REACTIONS
502832746,7/13/2014 18:51:24,,1322050060,7/13/2014 18:51:05,neodev,1.0,18517457,GBR,"","",86.29.147.112,[CAUSES],[CAUSES],interaction between a,N/a,39,31,42,53,-1,RO-has_causative_agent,903694-FS1,"The elderly are predisposed to ADVERSE DRUG REACTIONS because of age related physiologic changes, interaction of one drug with another, and interaction between a DRUG and a coexisting medical condition.",DRUG,ADVERSE DRUG REACTIONS
502832746,7/13/2014 18:51:35,,1322050144,7/13/2014 18:51:05,clixsense,1.0,19803139,NLD,11,Leiden,82.139.76.131,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],interaction of one drug,N/A,39,31,42,53,-1,RO-has_causative_agent,903694-FS1,"The elderly are predisposed to ADVERSE DRUG REACTIONS because of age related physiologic changes, interaction of one drug with another, and interaction between a DRUG and a coexisting medical condition.",DRUG,ADVERSE DRUG REACTIONS
502832746,7/13/2014 19:13:13,,1322059888,7/13/2014 19:12:28,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],interaction,na,39,31,42,53,-1,RO-has_causative_agent,903694-FS1,"The elderly are predisposed to ADVERSE DRUG REACTIONS because of age related physiologic changes, interaction of one drug with another, and interaction between a DRUG and a coexisting medical condition.",DRUG,ADVERSE DRUG REACTIONS
502832746,7/13/2014 19:16:15,,1322061088,7/13/2014 19:15:09,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[CAUSES],[CAUSES],"because of age related physiologic changes,",[CAUSES],39,31,42,53,-1,RO-has_causative_agent,903694-FS1,"The elderly are predisposed to ADVERSE DRUG REACTIONS because of age related physiologic changes, interaction of one drug with another, and interaction between a DRUG and a coexisting medical condition.",DRUG,ADVERSE DRUG REACTIONS
502832746,7/13/2014 19:17:07,,1322061455,7/13/2014 19:15:56,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],are related,N/A,39,31,42,53,-1,RO-has_causative_agent,903694-FS1,"The elderly are predisposed to ADVERSE DRUG REACTIONS because of age related physiologic changes, interaction of one drug with another, and interaction between a DRUG and a coexisting medical condition.",DRUG,ADVERSE DRUG REACTIONS
502832746,7/13/2014 19:22:48,,1322063616,7/13/2014 19:22:29,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[ASSOCIATED_WITH],[ASSOCIATED_WITH],interaction,n/a,39,31,42,53,-1,RO-has_causative_agent,903694-FS1,"The elderly are predisposed to ADVERSE DRUG REACTIONS because of age related physiologic changes, interaction of one drug with another, and interaction between a DRUG and a coexisting medical condition.",DRUG,ADVERSE DRUG REACTIONS
502832746,7/13/2014 19:42:20,,1322071135,7/13/2014 19:41:25,instagc,1.0,13763729,USA,"","",75.182.89.225,[SIDE_EFFECT],[SIDE_EFFECT],ADVERSE DRUG REACTIONS interaction between DRUG,N/A,39,31,42,53,-1,RO-has_causative_agent,903694-FS1,"The elderly are predisposed to ADVERSE DRUG REACTIONS because of age related physiologic changes, interaction of one drug with another, and interaction between a DRUG and a coexisting medical condition.",DRUG,ADVERSE DRUG REACTIONS
502832746,7/13/2014 19:54:14,,1322080869,7/13/2014 19:53:36,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[CAUSES],[CAUSES],interaction between coexisting medical condition.,n/a,39,31,42,53,-1,RO-has_causative_agent,903694-FS1,"The elderly are predisposed to ADVERSE DRUG REACTIONS because of age related physiologic changes, interaction of one drug with another, and interaction between a DRUG and a coexisting medical condition.",DRUG,ADVERSE DRUG REACTIONS
502832746,7/13/2014 20:18:53,,1322105211,7/13/2014 20:18:12,elite,1.0,28503042,USA,OK,Oakwood,64.250.220.169,[CAUSES],[CAUSES],interaction between a DRUG and coexisting medical condition.,N/A,39,31,42,53,-1,RO-has_causative_agent,903694-FS1,"The elderly are predisposed to ADVERSE DRUG REACTIONS because of age related physiologic changes, interaction of one drug with another, and interaction between a DRUG and a coexisting medical condition.",DRUG,ADVERSE DRUG REACTIONS
502832746,7/13/2014 20:39:07,,1322122451,7/13/2014 20:38:03,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",ADVERSE DRUG REACTIONS DRUG,n/a,39,31,42,53,-1,RO-has_causative_agent,903694-FS1,"The elderly are predisposed to ADVERSE DRUG REACTIONS because of age related physiologic changes, interaction of one drug with another, and interaction between a DRUG and a coexisting medical condition.",DRUG,ADVERSE DRUG REACTIONS
502832746,7/13/2014 21:07:21,,1322146453,7/13/2014 21:06:26,clixsense,1.0,26649250,GBR,B7,Bristol,79.71.125.97,[ASSOCIATED_WITH],[ASSOCIATED_WITH],interaction of one,n/a,39,31,42,53,-1,RO-has_causative_agent,903694-FS1,"The elderly are predisposed to ADVERSE DRUG REACTIONS because of age related physiologic changes, interaction of one drug with another, and interaction between a DRUG and a coexisting medical condition.",DRUG,ADVERSE DRUG REACTIONS
502832746,7/13/2014 21:17:55,,1322155581,7/13/2014 21:16:44,elite,1.0,28397222,GBR,"","",31.49.231.211,[CAUSES],[CAUSES],because of,N/A,39,31,42,53,-1,RO-has_causative_agent,903694-FS1,"The elderly are predisposed to ADVERSE DRUG REACTIONS because of age related physiologic changes, interaction of one drug with another, and interaction between a DRUG and a coexisting medical condition.",DRUG,ADVERSE DRUG REACTIONS
502832746,7/13/2014 21:39:47,,1322172369,7/13/2014 21:39:22,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and interaction between a,N/A,39,31,42,53,-1,RO-has_causative_agent,903694-FS1,"The elderly are predisposed to ADVERSE DRUG REACTIONS because of age related physiologic changes, interaction of one drug with another, and interaction between a DRUG and a coexisting medical condition.",DRUG,ADVERSE DRUG REACTIONS
502832746,7/13/2014 21:40:17,,1322172681,7/13/2014 21:39:59,instagc,1.0,28301350,GBR,K4,Plymouth,89.242.63.62,[PART_OF],[PART_OF],DRUG DRUG,N/A,39,31,42,53,-1,RO-has_causative_agent,903694-FS1,"The elderly are predisposed to ADVERSE DRUG REACTIONS because of age related physiologic changes, interaction of one drug with another, and interaction between a DRUG and a coexisting medical condition.",DRUG,ADVERSE DRUG REACTIONS
502832747,7/13/2014 18:46:21,,1322047713,7/13/2014 18:45:57,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],as well as,N/A,169,210,190,259,-1,RO-cause_of,900341-FS1,"This should definitely establish the value of this diagnostic test, particularly in instances where other in vitro or in vivo diagnostic tests are not reliable, such as FOOD OR DRUG ALLERGIES as well as in non IGE MEDIATED IMMEDIATE HYPERSENSITIVITY REACTIONS.",FOOD OR DRUG ALLERGIES,IGE MEDIATED IMMEDIATE HYPERSENSITIVITY REACTIONS
502832747,7/13/2014 18:48:16,,1322048621,7/13/2014 18:47:49,neodev,1.0,18517457,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],as well as,N/a,169,210,190,259,-1,RO-cause_of,900341-FS1,"This should definitely establish the value of this diagnostic test, particularly in instances where other in vitro or in vivo diagnostic tests are not reliable, such as FOOD OR DRUG ALLERGIES as well as in non IGE MEDIATED IMMEDIATE HYPERSENSITIVITY REACTIONS.",FOOD OR DRUG ALLERGIES,IGE MEDIATED IMMEDIATE HYPERSENSITIVITY REACTIONS
502832747,7/13/2014 18:48:26,,1322048703,7/13/2014 18:47:50,clixsense,1.0,19803139,NLD,11,Leiden,82.139.76.131,[OTHER],[OTHER],as well as,N/A,169,210,190,259,-1,RO-cause_of,900341-FS1,"This should definitely establish the value of this diagnostic test, particularly in instances where other in vitro or in vivo diagnostic tests are not reliable, such as FOOD OR DRUG ALLERGIES as well as in non IGE MEDIATED IMMEDIATE HYPERSENSITIVITY REACTIONS.",FOOD OR DRUG ALLERGIES,IGE MEDIATED IMMEDIATE HYPERSENSITIVITY REACTIONS
502832747,7/13/2014 18:48:42,,1322048840,7/13/2014 18:48:24,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],as,Na,169,210,190,259,-1,RO-cause_of,900341-FS1,"This should definitely establish the value of this diagnostic test, particularly in instances where other in vitro or in vivo diagnostic tests are not reliable, such as FOOD OR DRUG ALLERGIES as well as in non IGE MEDIATED IMMEDIATE HYPERSENSITIVITY REACTIONS.",FOOD OR DRUG ALLERGIES,IGE MEDIATED IMMEDIATE HYPERSENSITIVITY REACTIONS
502832747,7/13/2014 19:02:18,,1322055096,7/13/2014 19:02:11,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[TREATS],[TREATS],this,da,169,210,190,259,-1,RO-cause_of,900341-FS1,"This should definitely establish the value of this diagnostic test, particularly in instances where other in vitro or in vivo diagnostic tests are not reliable, such as FOOD OR DRUG ALLERGIES as well as in non IGE MEDIATED IMMEDIATE HYPERSENSITIVITY REACTIONS.",FOOD OR DRUG ALLERGIES,IGE MEDIATED IMMEDIATE HYPERSENSITIVITY REACTIONS
502832747,7/13/2014 19:09:16,,1322058239,7/13/2014 19:09:07,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],IMMEDIATE,N/A,169,210,190,259,-1,RO-cause_of,900341-FS1,"This should definitely establish the value of this diagnostic test, particularly in instances where other in vitro or in vivo diagnostic tests are not reliable, such as FOOD OR DRUG ALLERGIES as well as in non IGE MEDIATED IMMEDIATE HYPERSENSITIVITY REACTIONS.",FOOD OR DRUG ALLERGIES,IGE MEDIATED IMMEDIATE HYPERSENSITIVITY REACTIONS
502832747,7/13/2014 19:12:26,,1322059603,7/13/2014 19:11:58,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"diagnostic test,",N/A,169,210,190,259,-1,RO-cause_of,900341-FS1,"This should definitely establish the value of this diagnostic test, particularly in instances where other in vitro or in vivo diagnostic tests are not reliable, such as FOOD OR DRUG ALLERGIES as well as in non IGE MEDIATED IMMEDIATE HYPERSENSITIVITY REACTIONS.",FOOD OR DRUG ALLERGIES,IGE MEDIATED IMMEDIATE HYPERSENSITIVITY REACTIONS
502832747,7/13/2014 19:18:21,,1322061961,7/13/2014 19:17:35,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],such as as well as in,N/A,169,210,190,259,-1,RO-cause_of,900341-FS1,"This should definitely establish the value of this diagnostic test, particularly in instances where other in vitro or in vivo diagnostic tests are not reliable, such as FOOD OR DRUG ALLERGIES as well as in non IGE MEDIATED IMMEDIATE HYPERSENSITIVITY REACTIONS.",FOOD OR DRUG ALLERGIES,IGE MEDIATED IMMEDIATE HYPERSENSITIVITY REACTIONS
502832747,7/13/2014 19:21:20,,1322063044,7/13/2014 19:20:30,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[OTHER],[OTHER],HYPERSENSITIVITY REACTIONS.,N/A,169,210,190,259,-1,RO-cause_of,900341-FS1,"This should definitely establish the value of this diagnostic test, particularly in instances where other in vitro or in vivo diagnostic tests are not reliable, such as FOOD OR DRUG ALLERGIES as well as in non IGE MEDIATED IMMEDIATE HYPERSENSITIVITY REACTIONS.",FOOD OR DRUG ALLERGIES,IGE MEDIATED IMMEDIATE HYPERSENSITIVITY REACTIONS
502832747,7/13/2014 19:26:11,,1322064854,7/13/2014 19:25:45,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[ASSOCIATED_WITH],[ASSOCIATED_WITH],as well as,n/a,169,210,190,259,-1,RO-cause_of,900341-FS1,"This should definitely establish the value of this diagnostic test, particularly in instances where other in vitro or in vivo diagnostic tests are not reliable, such as FOOD OR DRUG ALLERGIES as well as in non IGE MEDIATED IMMEDIATE HYPERSENSITIVITY REACTIONS.",FOOD OR DRUG ALLERGIES,IGE MEDIATED IMMEDIATE HYPERSENSITIVITY REACTIONS
502832747,7/13/2014 19:31:30,,1322066747,7/13/2014 19:30:38,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],as well as in,na,169,210,190,259,-1,RO-cause_of,900341-FS1,"This should definitely establish the value of this diagnostic test, particularly in instances where other in vitro or in vivo diagnostic tests are not reliable, such as FOOD OR DRUG ALLERGIES as well as in non IGE MEDIATED IMMEDIATE HYPERSENSITIVITY REACTIONS.",FOOD OR DRUG ALLERGIES,IGE MEDIATED IMMEDIATE HYPERSENSITIVITY REACTIONS
502832747,7/13/2014 19:49:28,,1322076531,7/13/2014 19:48:54,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],FOOD OR DRUG ALLERGIES IGE MEDIATED IMMEDIATE HYPERSENSITIVITY REACTIONS.,n/a,169,210,190,259,-1,RO-cause_of,900341-FS1,"This should definitely establish the value of this diagnostic test, particularly in instances where other in vitro or in vivo diagnostic tests are not reliable, such as FOOD OR DRUG ALLERGIES as well as in non IGE MEDIATED IMMEDIATE HYPERSENSITIVITY REACTIONS.",FOOD OR DRUG ALLERGIES,IGE MEDIATED IMMEDIATE HYPERSENSITIVITY REACTIONS
502832747,7/13/2014 19:59:15,,1322086500,7/13/2014 19:58:11,clixsense,1.0,6365250,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],FOOD DRUG ALLERGIES well non IGE MEDIATED IMMEDIATE HYPERSENSITIVITY REACTIONS.,associated with,169,210,190,259,-1,RO-cause_of,900341-FS1,"This should definitely establish the value of this diagnostic test, particularly in instances where other in vitro or in vivo diagnostic tests are not reliable, such as FOOD OR DRUG ALLERGIES as well as in non IGE MEDIATED IMMEDIATE HYPERSENSITIVITY REACTIONS.",FOOD OR DRUG ALLERGIES,IGE MEDIATED IMMEDIATE HYPERSENSITIVITY REACTIONS
502832747,7/13/2014 20:14:08,,1322100978,7/13/2014 20:13:33,elite,1.0,28503042,USA,OK,Oakwood,64.250.220.169,[NONE],[NONE],N/A,"Comparing two separate, unrelated examples",169,210,190,259,-1,RO-cause_of,900341-FS1,"This should definitely establish the value of this diagnostic test, particularly in instances where other in vitro or in vivo diagnostic tests are not reliable, such as FOOD OR DRUG ALLERGIES as well as in non IGE MEDIATED IMMEDIATE HYPERSENSITIVITY REACTIONS.",FOOD OR DRUG ALLERGIES,IGE MEDIATED IMMEDIATE HYPERSENSITIVITY REACTIONS
502832747,7/13/2014 20:34:55,,1322118860,7/13/2014 20:33:28,neodev,1,14861092,GBR,I2,Manchester,90.194.137.76,[NONE],[NONE],N/A,Separate terms,169,210,190,259,-1,RO-cause_of,900341-FS1,"This should definitely establish the value of this diagnostic test, particularly in instances where other in vitro or in vivo diagnostic tests are not reliable, such as FOOD OR DRUG ALLERGIES as well as in non IGE MEDIATED IMMEDIATE HYPERSENSITIVITY REACTIONS.",FOOD OR DRUG ALLERGIES,IGE MEDIATED IMMEDIATE HYPERSENSITIVITY REACTIONS
502832748,7/13/2014 18:50:43,,1322049716,7/13/2014 18:50:12,clixsense,1.0,19803139,NLD,11,Leiden,82.139.76.131,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnostic test,N/A,164,75,180,88,1,RO-may_diagnose,906688-FS1,"Head up tilt table testing, either alone or with a graded dose infusion of ISOPROTERENOL is a useful diagnostic test for identifying persons who are susceptible to VASOVAGAL SYNCOPE",VASOVAGAL SYNCOPE,ISOPROTERENOL
502832748,7/13/2014 18:55:19,,1322051879,7/13/2014 18:54:54,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnostic test,N/A,164,75,180,88,1,RO-may_diagnose,906688-FS1,"Head up tilt table testing, either alone or with a graded dose infusion of ISOPROTERENOL is a useful diagnostic test for identifying persons who are susceptible to VASOVAGAL SYNCOPE",VASOVAGAL SYNCOPE,ISOPROTERENOL
502832748,7/13/2014 19:03:36,,1322055708,7/13/2014 19:03:28,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[MANIFESTATION],[MANIFESTATION],graded,da,164,75,180,88,1,RO-may_diagnose,906688-FS1,"Head up tilt table testing, either alone or with a graded dose infusion of ISOPROTERENOL is a useful diagnostic test for identifying persons who are susceptible to VASOVAGAL SYNCOPE",VASOVAGAL SYNCOPE,ISOPROTERENOL
502832748,7/13/2014 19:21:32,,1322063102,7/13/2014 19:20:53,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ISOPROTERENOL is a useful diagnostic test for VASOVAGAL SYNCOPE,n/a,164,75,180,88,1,RO-may_diagnose,906688-FS1,"Head up tilt table testing, either alone or with a graded dose infusion of ISOPROTERENOL is a useful diagnostic test for identifying persons who are susceptible to VASOVAGAL SYNCOPE",VASOVAGAL SYNCOPE,ISOPROTERENOL
502832748,7/13/2014 19:25:56,,1322064753,7/13/2014 19:25:12,instagc,1.0,19686223,CAN,BC,Surrey,154.20.155.106,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"Head up tilt table testing, either alone or with a graded dose infusion of ISOPROTERENOL is a useful diagnostic test for identifying persons who are susceptible to VASOVAGAL SYNCOPE",N/A,164,75,180,88,1,RO-may_diagnose,906688-FS1,"Head up tilt table testing, either alone or with a graded dose infusion of ISOPROTERENOL is a useful diagnostic test for identifying persons who are susceptible to VASOVAGAL SYNCOPE",VASOVAGAL SYNCOPE,ISOPROTERENOL
502832748,7/13/2014 19:26:52,,1322065138,7/13/2014 19:24:49,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnostic test,na,164,75,180,88,1,RO-may_diagnose,906688-FS1,"Head up tilt table testing, either alone or with a graded dose infusion of ISOPROTERENOL is a useful diagnostic test for identifying persons who are susceptible to VASOVAGAL SYNCOPE",VASOVAGAL SYNCOPE,ISOPROTERENOL
502832748,7/13/2014 19:29:40,,1322066191,7/13/2014 19:28:19,instagc,1.0,13763729,USA,"","",75.182.89.225,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnostic test for identifying,N/A,164,75,180,88,1,RO-may_diagnose,906688-FS1,"Head up tilt table testing, either alone or with a graded dose infusion of ISOPROTERENOL is a useful diagnostic test for identifying persons who are susceptible to VASOVAGAL SYNCOPE",VASOVAGAL SYNCOPE,ISOPROTERENOL
502832748,7/13/2014 19:31:48,,1322066869,7/13/2014 19:31:12,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnostic test,n/a,164,75,180,88,1,RO-may_diagnose,906688-FS1,"Head up tilt table testing, either alone or with a graded dose infusion of ISOPROTERENOL is a useful diagnostic test for identifying persons who are susceptible to VASOVAGAL SYNCOPE",VASOVAGAL SYNCOPE,ISOPROTERENOL
502832748,7/13/2014 19:34:01,,1322067562,7/13/2014 19:32:12,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[TREATS] [PREVENTS] [CONTRAINDICATES],"[TREATS]
[PREVENTS]
[CONTRAINDICATES]",is a useful diagnostic test,[TREATS] [PREVENTS] [CONTRAINDICATES],164,75,180,88,1,RO-may_diagnose,906688-FS1,"Head up tilt table testing, either alone or with a graded dose infusion of ISOPROTERENOL is a useful diagnostic test for identifying persons who are susceptible to VASOVAGAL SYNCOPE",VASOVAGAL SYNCOPE,ISOPROTERENOL
502832748,7/13/2014 19:55:22,,1322082064,7/13/2014 19:54:18,clixsense,1.0,6365250,CAN,BC,Burnaby,70.79.16.165,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ISOPROTERENOL is useful diagnostic test identifying persons susceptible VASOVAGAL SYNCOPE,diagnosed by test or drug,164,75,180,88,1,RO-may_diagnose,906688-FS1,"Head up tilt table testing, either alone or with a graded dose infusion of ISOPROTERENOL is a useful diagnostic test for identifying persons who are susceptible to VASOVAGAL SYNCOPE",VASOVAGAL SYNCOPE,ISOPROTERENOL
502832748,7/13/2014 20:05:35,,1322093303,7/13/2014 20:05:10,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],useful diagnostic test,n/a,164,75,180,88,1,RO-may_diagnose,906688-FS1,"Head up tilt table testing, either alone or with a graded dose infusion of ISOPROTERENOL is a useful diagnostic test for identifying persons who are susceptible to VASOVAGAL SYNCOPE",VASOVAGAL SYNCOPE,ISOPROTERENOL
502832748,7/13/2014 20:07:39,,1322095432,7/13/2014 20:06:58,elite,1.0,28503042,USA,OK,Oakwood,64.250.220.169,[SYMPTOM],[SYMPTOM],is a useful diagnostic test for identifying persons who are susceptible to,N/A,164,75,180,88,1,RO-may_diagnose,906688-FS1,"Head up tilt table testing, either alone or with a graded dose infusion of ISOPROTERENOL is a useful diagnostic test for identifying persons who are susceptible to VASOVAGAL SYNCOPE",VASOVAGAL SYNCOPE,ISOPROTERENOL
502832748,7/13/2014 20:12:22,,1322099511,7/13/2014 20:12:04,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnostic test,N/A,164,75,180,88,1,RO-may_diagnose,906688-FS1,"Head up tilt table testing, either alone or with a graded dose infusion of ISOPROTERENOL is a useful diagnostic test for identifying persons who are susceptible to VASOVAGAL SYNCOPE",VASOVAGAL SYNCOPE,ISOPROTERENOL
502832748,7/13/2014 20:18:26,,1322104725,7/13/2014 20:17:58,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",dose infusion diagnostic test,Na,164,75,180,88,1,RO-may_diagnose,906688-FS1,"Head up tilt table testing, either alone or with a graded dose infusion of ISOPROTERENOL is a useful diagnostic test for identifying persons who are susceptible to VASOVAGAL SYNCOPE",VASOVAGAL SYNCOPE,ISOPROTERENOL
502832748,7/13/2014 20:53:31,,1322134381,7/13/2014 20:52:50,elite,1.0,28397222,GBR,"","",31.49.231.211,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnostic test for,N/A,164,75,180,88,1,RO-may_diagnose,906688-FS1,"Head up tilt table testing, either alone or with a graded dose infusion of ISOPROTERENOL is a useful diagnostic test for identifying persons who are susceptible to VASOVAGAL SYNCOPE",VASOVAGAL SYNCOPE,ISOPROTERENOL
502832749,7/13/2014 18:49:59,,1322049350,7/13/2014 18:49:46,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],treatment,N/A,75,45,86,54,1,RO-may_treat,907976-FS1,Atropine and pralidoxime are the most useful ANTIDOTES in the treatment of OP POISONING,OP POISONING,ANTIDOTES
502832749,7/13/2014 18:54:44,,1322051624,7/13/2014 18:54:27,clixsense,1.0,19803139,NLD,11,Leiden,82.139.76.131,[TREATS],[TREATS],treatment,N/A,75,45,86,54,1,RO-may_treat,907976-FS1,Atropine and pralidoxime are the most useful ANTIDOTES in the treatment of OP POISONING,OP POISONING,ANTIDOTES
502832749,7/13/2014 19:03:56,,1322055861,7/13/2014 19:03:34,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],treatment,N/A,75,45,86,54,1,RO-may_treat,907976-FS1,Atropine and pralidoxime are the most useful ANTIDOTES in the treatment of OP POISONING,OP POISONING,ANTIDOTES
502832749,7/13/2014 19:04:10,,1322055983,7/13/2014 19:03:09,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[TREATS],[TREATS],ANTIDOTES,na,75,45,86,54,1,RO-may_treat,907976-FS1,Atropine and pralidoxime are the most useful ANTIDOTES in the treatment of OP POISONING,OP POISONING,ANTIDOTES
502832749,7/13/2014 19:04:50,,1322056240,7/13/2014 19:04:44,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[TREATS],[TREATS],Atropine,da,75,45,86,54,1,RO-may_treat,907976-FS1,Atropine and pralidoxime are the most useful ANTIDOTES in the treatment of OP POISONING,OP POISONING,ANTIDOTES
502832749,7/13/2014 19:08:13,,1322057807,7/13/2014 19:07:54,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],in the treatment of,N/A,75,45,86,54,1,RO-may_treat,907976-FS1,Atropine and pralidoxime are the most useful ANTIDOTES in the treatment of OP POISONING,OP POISONING,ANTIDOTES
502832749,7/13/2014 19:23:07,,1322063694,7/13/2014 19:22:35,instagc,1.0,19686223,CAN,BC,Surrey,154.20.155.106,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",Atropine and pralidoxime are the most useful ANTIDOTES in the treatment of OP POISONING,N/A,75,45,86,54,1,RO-may_treat,907976-FS1,Atropine and pralidoxime are the most useful ANTIDOTES in the treatment of OP POISONING,OP POISONING,ANTIDOTES
502832749,7/13/2014 19:27:20,,1322065294,7/13/2014 19:26:57,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[TREATS],[TREATS],ANTIDOTES in the treatment of OP POISONING,n/a,75,45,86,54,1,RO-may_treat,907976-FS1,Atropine and pralidoxime are the most useful ANTIDOTES in the treatment of OP POISONING,OP POISONING,ANTIDOTES
502832749,7/13/2014 19:30:04,,1322066315,7/13/2014 19:29:52,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[TREATS],[TREATS],treatment,n/a,75,45,86,54,1,RO-may_treat,907976-FS1,Atropine and pralidoxime are the most useful ANTIDOTES in the treatment of OP POISONING,OP POISONING,ANTIDOTES
502832749,7/13/2014 20:08:23,,1322096072,7/13/2014 20:07:39,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[OTHER],[OTHER],ANTIDOTES treatment OP POISONING,is treated by,75,45,86,54,1,RO-may_treat,907976-FS1,Atropine and pralidoxime are the most useful ANTIDOTES in the treatment of OP POISONING,OP POISONING,ANTIDOTES
502832749,7/13/2014 20:22:45,,1322108539,7/13/2014 20:21:46,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[TREATS],[TREATS],treatment,N/A,75,45,86,54,1,RO-may_treat,907976-FS1,Atropine and pralidoxime are the most useful ANTIDOTES in the treatment of OP POISONING,OP POISONING,ANTIDOTES
502832749,7/13/2014 20:43:23,,1322125816,7/13/2014 20:43:07,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],treatment,n/a,75,45,86,54,1,RO-may_treat,907976-FS1,Atropine and pralidoxime are the most useful ANTIDOTES in the treatment of OP POISONING,OP POISONING,ANTIDOTES
502832749,7/13/2014 21:05:49,,1322145192,7/13/2014 21:05:25,clixsense,1.0,26649250,GBR,B7,Bristol,79.71.125.97,[TREATS],[TREATS],in the treatment of,n/a,75,45,86,54,1,RO-may_treat,907976-FS1,Atropine and pralidoxime are the most useful ANTIDOTES in the treatment of OP POISONING,OP POISONING,ANTIDOTES
502832749,7/13/2014 21:42:30,,1322174337,7/13/2014 21:42:17,instagc,1.0,28301350,GBR,K4,Plymouth,89.242.63.62,[TREATS],[TREATS],treatment,N/A,75,45,86,54,1,RO-may_treat,907976-FS1,Atropine and pralidoxime are the most useful ANTIDOTES in the treatment of OP POISONING,OP POISONING,ANTIDOTES
502832749,7/13/2014 21:43:10,,1322174888,7/13/2014 21:42:57,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],in the treatment of,N/A,75,45,86,54,1,RO-may_treat,907976-FS1,Atropine and pralidoxime are the most useful ANTIDOTES in the treatment of OP POISONING,OP POISONING,ANTIDOTES
502832750,7/13/2014 18:50:13,,1322049472,7/13/2014 18:49:53,neodev,1.0,18517457,GBR,"","",86.29.147.112,[SYMPTOM],[SYMPTOM],diagnosis,N/a,17,76,30,93,1,RO-cause_of,900023-FS1,The diagnosis of GYRATE ATROPHY was confirmed biochemically and clinically; HYPERORNITHINEMIA and a deficiency of ornithine ketoacid transaminase were confirmed biochemically.,GYRATE ATROPHY,HYPERORNITHINEMIA
502832750,7/13/2014 18:57:10,,1322052798,7/13/2014 18:55:40,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[NONE],[NONE],n/a,They aren't conditions related to each other - the sentence is talking about ways to diagnose something and these are two examples of different ways to disgnose,17,76,30,93,1,RO-cause_of,900023-FS1,The diagnosis of GYRATE ATROPHY was confirmed biochemically and clinically; HYPERORNITHINEMIA and a deficiency of ornithine ketoacid transaminase were confirmed biochemically.,GYRATE ATROPHY,HYPERORNITHINEMIA
502832750,7/13/2014 19:02:34,,1322055240,7/13/2014 19:02:27,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[PREVENTS],[PREVENTS],ATROPHY,da,17,76,30,93,1,RO-cause_of,900023-FS1,The diagnosis of GYRATE ATROPHY was confirmed biochemically and clinically; HYPERORNITHINEMIA and a deficiency of ornithine ketoacid transaminase were confirmed biochemically.,GYRATE ATROPHY,HYPERORNITHINEMIA
502832750,7/13/2014 19:03:58,,1322055873,7/13/2014 19:03:47,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],confirmed,N/A,17,76,30,93,1,RO-cause_of,900023-FS1,The diagnosis of GYRATE ATROPHY was confirmed biochemically and clinically; HYPERORNITHINEMIA and a deficiency of ornithine ketoacid transaminase were confirmed biochemically.,GYRATE ATROPHY,HYPERORNITHINEMIA
502832750,7/13/2014 19:06:29,,1322056980,7/13/2014 19:06:21,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],clinically;,N/A,17,76,30,93,1,RO-cause_of,900023-FS1,The diagnosis of GYRATE ATROPHY was confirmed biochemically and clinically; HYPERORNITHINEMIA and a deficiency of ornithine ketoacid transaminase were confirmed biochemically.,GYRATE ATROPHY,HYPERORNITHINEMIA
502832750,7/13/2014 19:08:48,,1322058052,7/13/2014 19:08:15,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[NONE],[NONE],N/A,No clear relationship.,17,76,30,93,1,RO-cause_of,900023-FS1,The diagnosis of GYRATE ATROPHY was confirmed biochemically and clinically; HYPERORNITHINEMIA and a deficiency of ornithine ketoacid transaminase were confirmed biochemically.,GYRATE ATROPHY,HYPERORNITHINEMIA
502832750,7/13/2014 19:15:01,,1322060587,7/13/2014 19:14:34,instagc,1.0,19686223,CAN,BC,Surrey,154.20.155.106,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis of GYRATE ATROPHY was confirmed biochemically and clinically;,N/A,17,76,30,93,1,RO-cause_of,900023-FS1,The diagnosis of GYRATE ATROPHY was confirmed biochemically and clinically; HYPERORNITHINEMIA and a deficiency of ornithine ketoacid transaminase were confirmed biochemically.,GYRATE ATROPHY,HYPERORNITHINEMIA
502832750,7/13/2014 19:19:13,,1322062308,7/13/2014 19:18:39,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was confirmed biochemically and clinically;,[DIAGNOSE_BY_TEST_OR_DRUG],17,76,30,93,1,RO-cause_of,900023-FS1,The diagnosis of GYRATE ATROPHY was confirmed biochemically and clinically; HYPERORNITHINEMIA and a deficiency of ornithine ketoacid transaminase were confirmed biochemically.,GYRATE ATROPHY,HYPERORNITHINEMIA
502832750,7/13/2014 19:20:46,,1322062875,7/13/2014 19:20:15,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],confirmed biochemically and clinically;,N/A,17,76,30,93,1,RO-cause_of,900023-FS1,The diagnosis of GYRATE ATROPHY was confirmed biochemically and clinically; HYPERORNITHINEMIA and a deficiency of ornithine ketoacid transaminase were confirmed biochemically.,GYRATE ATROPHY,HYPERORNITHINEMIA
502832750,7/13/2014 20:05:09,,1322092842,7/13/2014 20:04:14,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[NONE],[NONE],n/a,both were tests to confirm something,17,76,30,93,1,RO-cause_of,900023-FS1,The diagnosis of GYRATE ATROPHY was confirmed biochemically and clinically; HYPERORNITHINEMIA and a deficiency of ornithine ketoacid transaminase were confirmed biochemically.,GYRATE ATROPHY,HYPERORNITHINEMIA
502832750,7/13/2014 20:26:46,,1322112067,7/13/2014 20:23:58,elite,1.0,28397222,GBR,"","",31.49.231.211,[NONE],[NONE],N/A,"The two statements are independent diagnoses, as indicated by the semi-colon. There is not necessarily a connection between them.",17,76,30,93,1,RO-cause_of,900023-FS1,The diagnosis of GYRATE ATROPHY was confirmed biochemically and clinically; HYPERORNITHINEMIA and a deficiency of ornithine ketoacid transaminase were confirmed biochemically.,GYRATE ATROPHY,HYPERORNITHINEMIA
502832750,7/13/2014 20:32:06,,1322116441,7/13/2014 20:31:34,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[NONE],[NONE],N/A,Separate conditions.,17,76,30,93,1,RO-cause_of,900023-FS1,The diagnosis of GYRATE ATROPHY was confirmed biochemically and clinically; HYPERORNITHINEMIA and a deficiency of ornithine ketoacid transaminase were confirmed biochemically.,GYRATE ATROPHY,HYPERORNITHINEMIA
502832750,7/13/2014 20:50:55,,1322132349,7/13/2014 20:50:14,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[OTHER],[OTHER],clinically;,n/a,17,76,30,93,1,RO-cause_of,900023-FS1,The diagnosis of GYRATE ATROPHY was confirmed biochemically and clinically; HYPERORNITHINEMIA and a deficiency of ornithine ketoacid transaminase were confirmed biochemically.,GYRATE ATROPHY,HYPERORNITHINEMIA
502832750,7/13/2014 21:16:08,,1322153970,7/13/2014 21:15:26,clixsense,1.0,26649250,GBR,B7,Bristol,79.71.125.97,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],The diagnosis of,n/a,17,76,30,93,1,RO-cause_of,900023-FS1,The diagnosis of GYRATE ATROPHY was confirmed biochemically and clinically; HYPERORNITHINEMIA and a deficiency of ornithine ketoacid transaminase were confirmed biochemically.,GYRATE ATROPHY,HYPERORNITHINEMIA
502832750,7/13/2014 21:41:23,,1322173409,7/13/2014 21:41:01,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[NONE],[NONE],N/A,Two different terms.,17,76,30,93,1,RO-cause_of,900023-FS1,The diagnosis of GYRATE ATROPHY was confirmed biochemically and clinically; HYPERORNITHINEMIA and a deficiency of ornithine ketoacid transaminase were confirmed biochemically.,GYRATE ATROPHY,HYPERORNITHINEMIA
502832751,7/13/2014 18:49:40,,1322049228,7/13/2014 18:49:18,clixsense,1.0,19803139,NLD,11,Leiden,82.139.76.131,[IS_A],[IS_A],presents,N/A,112,17,125,29,1,RO-disease_may_have_finding,902763-FS1,In comparison to WILMS' TUMOR renal cell carcinoma in childhood and adolescence usually presents with a smaller ABDOMINAL MASS which is frequently not palpable or visible on plain abdominal radiographs.,ABDOMINAL MASS,WILMS' TUMOR
502832751,7/13/2014 19:04:03,,1322055927,7/13/2014 19:03:57,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[PREVENTS],[PREVENTS],smaller,da,112,17,125,29,1,RO-disease_may_have_finding,902763-FS1,In comparison to WILMS' TUMOR renal cell carcinoma in childhood and adolescence usually presents with a smaller ABDOMINAL MASS which is frequently not palpable or visible on plain abdominal radiographs.,ABDOMINAL MASS,WILMS' TUMOR
502832751,7/13/2014 19:19:06,,1322062220,7/13/2014 19:17:48,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],presents with,N/A,112,17,125,29,1,RO-disease_may_have_finding,902763-FS1,In comparison to WILMS' TUMOR renal cell carcinoma in childhood and adolescence usually presents with a smaller ABDOMINAL MASS which is frequently not palpable or visible on plain abdominal radiographs.,ABDOMINAL MASS,WILMS' TUMOR
502832751,7/13/2014 19:22:42,,1322063578,7/13/2014 19:22:02,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[ASSOCIATED_WITH],[ASSOCIATED_WITH],WILMS' TUMOR in childhood and adolescence usually presents with a smaller ABDOMINAL MASS,n/a,112,17,125,29,1,RO-disease_may_have_finding,902763-FS1,In comparison to WILMS' TUMOR renal cell carcinoma in childhood and adolescence usually presents with a smaller ABDOMINAL MASS which is frequently not palpable or visible on plain abdominal radiographs.,ABDOMINAL MASS,WILMS' TUMOR
502832751,7/13/2014 19:24:55,,1322064390,7/13/2014 19:24:38,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,n/a,112,17,125,29,1,RO-disease_may_have_finding,902763-FS1,In comparison to WILMS' TUMOR renal cell carcinoma in childhood and adolescence usually presents with a smaller ABDOMINAL MASS which is frequently not palpable or visible on plain abdominal radiographs.,ABDOMINAL MASS,WILMS' TUMOR
502832751,7/13/2014 19:28:59,,1322065898,7/13/2014 19:26:54,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[SYMPTOM],[SYMPTOM],presents with,na,112,17,125,29,1,RO-disease_may_have_finding,902763-FS1,In comparison to WILMS' TUMOR renal cell carcinoma in childhood and adolescence usually presents with a smaller ABDOMINAL MASS which is frequently not palpable or visible on plain abdominal radiographs.,ABDOMINAL MASS,WILMS' TUMOR
502832751,7/13/2014 19:29:12,,1322066004,7/13/2014 19:28:15,instagc,1.0,19686223,CAN,BC,Surrey,154.20.155.106,[IS_A] [LOCATION],"[LOCATION]
[IS_A]",renal cell carcinoma in childhood and adolescence usually presents with a smaller ABDOMINAL MASS which is frequently not palpable or visible on plain abdominal radiographs.,N/A,112,17,125,29,1,RO-disease_may_have_finding,902763-FS1,In comparison to WILMS' TUMOR renal cell carcinoma in childhood and adolescence usually presents with a smaller ABDOMINAL MASS which is frequently not palpable or visible on plain abdominal radiographs.,ABDOMINAL MASS,WILMS' TUMOR
502832751,7/13/2014 20:10:37,,1322098004,7/13/2014 20:10:12,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[SYMPTOM],[SYMPTOM],usually presents with,n/a,112,17,125,29,1,RO-disease_may_have_finding,902763-FS1,In comparison to WILMS' TUMOR renal cell carcinoma in childhood and adolescence usually presents with a smaller ABDOMINAL MASS which is frequently not palpable or visible on plain abdominal radiographs.,ABDOMINAL MASS,WILMS' TUMOR
502832751,7/13/2014 20:12:03,,1322099114,7/13/2014 20:11:14,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TUMOR ABDOMINAL MASS,N/A,112,17,125,29,1,RO-disease_may_have_finding,902763-FS1,In comparison to WILMS' TUMOR renal cell carcinoma in childhood and adolescence usually presents with a smaller ABDOMINAL MASS which is frequently not palpable or visible on plain abdominal radiographs.,ABDOMINAL MASS,WILMS' TUMOR
502832751,7/13/2014 20:16:11,,1322102815,7/13/2014 20:15:50,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],presents,Na,112,17,125,29,1,RO-disease_may_have_finding,902763-FS1,In comparison to WILMS' TUMOR renal cell carcinoma in childhood and adolescence usually presents with a smaller ABDOMINAL MASS which is frequently not palpable or visible on plain abdominal radiographs.,ABDOMINAL MASS,WILMS' TUMOR
502832751,7/13/2014 20:20:21,,1322106501,7/13/2014 20:19:59,elite,1.0,28503042,USA,OK,Oakwood,64.250.220.169,[SYMPTOM],[SYMPTOM],WILMS' TUMOR usually presents ABDOMINAL MASS,N/A,112,17,125,29,1,RO-disease_may_have_finding,902763-FS1,In comparison to WILMS' TUMOR renal cell carcinoma in childhood and adolescence usually presents with a smaller ABDOMINAL MASS which is frequently not palpable or visible on plain abdominal radiographs.,ABDOMINAL MASS,WILMS' TUMOR
502832751,7/13/2014 20:48:58,,1322130538,7/13/2014 20:48:34,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[MANIFESTATION],[MANIFESTATION],usually presents with,n/a,112,17,125,29,1,RO-disease_may_have_finding,902763-FS1,In comparison to WILMS' TUMOR renal cell carcinoma in childhood and adolescence usually presents with a smaller ABDOMINAL MASS which is frequently not palpable or visible on plain abdominal radiographs.,ABDOMINAL MASS,WILMS' TUMOR
502832751,7/13/2014 21:14:53,,1322152946,7/13/2014 21:14:28,clixsense,1.0,26649250,GBR,B7,Bristol,79.71.125.97,[SYMPTOM],[SYMPTOM],presents with,n/a,112,17,125,29,1,RO-disease_may_have_finding,902763-FS1,In comparison to WILMS' TUMOR renal cell carcinoma in childhood and adolescence usually presents with a smaller ABDOMINAL MASS which is frequently not palpable or visible on plain abdominal radiographs.,ABDOMINAL MASS,WILMS' TUMOR
502832751,7/13/2014 21:42:40,,1322174492,7/13/2014 21:41:52,elite,1.0,28397222,GBR,"","",31.49.231.211,[MANIFESTATION],[MANIFESTATION],presents with,N/A,112,17,125,29,1,RO-disease_may_have_finding,902763-FS1,In comparison to WILMS' TUMOR renal cell carcinoma in childhood and adolescence usually presents with a smaller ABDOMINAL MASS which is frequently not palpable or visible on plain abdominal radiographs.,ABDOMINAL MASS,WILMS' TUMOR
502832751,7/13/2014 21:44:17,,1322175603,7/13/2014 21:44:00,instagc,1.0,28301350,GBR,K4,Plymouth,89.242.63.62,[SYMPTOM],[SYMPTOM],usually presents,N/A,112,17,125,29,1,RO-disease_may_have_finding,902763-FS1,In comparison to WILMS' TUMOR renal cell carcinoma in childhood and adolescence usually presents with a smaller ABDOMINAL MASS which is frequently not palpable or visible on plain abdominal radiographs.,ABDOMINAL MASS,WILMS' TUMOR
502832752,7/13/2014 18:42:49,,1322045889,7/13/2014 18:42:23,clixsense,1.0,19803139,NLD,11,Leiden,82.139.76.131,[CAUSES],[CAUSES],of,N/A,100,130,125,188,-1,RO-cause_of,900347-FS1,"The human pathological condition most commonly associated with hyperproduction of IgE is atopy, the FAMILIAL ALLERGIC DISORDER of IMMEDIATE TYPE HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS.",FAMILIAL ALLERGIC DISORDER,IMMEDIATE TYPE HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS
502832752,7/13/2014 18:52:56,,1322050821,7/13/2014 18:52:32,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],of,N/A,100,130,125,188,-1,RO-cause_of,900347-FS1,"The human pathological condition most commonly associated with hyperproduction of IgE is atopy, the FAMILIAL ALLERGIC DISORDER of IMMEDIATE TYPE HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS.",FAMILIAL ALLERGIC DISORDER,IMMEDIATE TYPE HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS
502832752,7/13/2014 19:04:35,,1322056165,7/13/2014 19:04:25,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[IS_A],[IS_A],DISORDER,da,100,130,125,188,-1,RO-cause_of,900347-FS1,"The human pathological condition most commonly associated with hyperproduction of IgE is atopy, the FAMILIAL ALLERGIC DISORDER of IMMEDIATE TYPE HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS.",FAMILIAL ALLERGIC DISORDER,IMMEDIATE TYPE HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS
502832752,7/13/2014 19:11:30,,1322059183,7/13/2014 19:10:55,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],most commonly associated with,na,100,130,125,188,-1,RO-cause_of,900347-FS1,"The human pathological condition most commonly associated with hyperproduction of IgE is atopy, the FAMILIAL ALLERGIC DISORDER of IMMEDIATE TYPE HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS.",FAMILIAL ALLERGIC DISORDER,IMMEDIATE TYPE HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS
502832752,7/13/2014 19:16:04,,1322060993,7/13/2014 19:15:35,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],of,N/A,100,130,125,188,-1,RO-cause_of,900347-FS1,"The human pathological condition most commonly associated with hyperproduction of IgE is atopy, the FAMILIAL ALLERGIC DISORDER of IMMEDIATE TYPE HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS.",FAMILIAL ALLERGIC DISORDER,IMMEDIATE TYPE HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS
502832752,7/13/2014 19:23:12,,1322063734,7/13/2014 19:22:46,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,[ASSOCIATED_WITH],100,130,125,188,-1,RO-cause_of,900347-FS1,"The human pathological condition most commonly associated with hyperproduction of IgE is atopy, the FAMILIAL ALLERGIC DISORDER of IMMEDIATE TYPE HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS.",FAMILIAL ALLERGIC DISORDER,IMMEDIATE TYPE HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS
502832752,7/13/2014 19:29:35,,1322066163,7/13/2014 19:29:21,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,n/a,100,130,125,188,-1,RO-cause_of,900347-FS1,"The human pathological condition most commonly associated with hyperproduction of IgE is atopy, the FAMILIAL ALLERGIC DISORDER of IMMEDIATE TYPE HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS.",FAMILIAL ALLERGIC DISORDER,IMMEDIATE TYPE HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS
502832752,7/13/2014 19:38:44,,1322069396,7/13/2014 19:38:24,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],DISORDER of,N/A,100,130,125,188,-1,RO-cause_of,900347-FS1,"The human pathological condition most commonly associated with hyperproduction of IgE is atopy, the FAMILIAL ALLERGIC DISORDER of IMMEDIATE TYPE HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS.",FAMILIAL ALLERGIC DISORDER,IMMEDIATE TYPE HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS
502832752,7/13/2014 19:41:33,,1322070666,7/13/2014 19:40:52,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],of,N/A,100,130,125,188,-1,RO-cause_of,900347-FS1,"The human pathological condition most commonly associated with hyperproduction of IgE is atopy, the FAMILIAL ALLERGIC DISORDER of IMMEDIATE TYPE HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS.",FAMILIAL ALLERGIC DISORDER,IMMEDIATE TYPE HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS
502832752,7/13/2014 20:16:30,,1322103035,7/13/2014 20:16:12,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,Na,100,130,125,188,-1,RO-cause_of,900347-FS1,"The human pathological condition most commonly associated with hyperproduction of IgE is atopy, the FAMILIAL ALLERGIC DISORDER of IMMEDIATE TYPE HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS.",FAMILIAL ALLERGIC DISORDER,IMMEDIATE TYPE HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS
502832752,7/13/2014 20:36:24,,1322120142,7/13/2014 20:33:58,elite,1.0,28397222,GBR,"","",31.49.231.211,[IS_A],[IS_A],of,N/A,100,130,125,188,-1,RO-cause_of,900347-FS1,"The human pathological condition most commonly associated with hyperproduction of IgE is atopy, the FAMILIAL ALLERGIC DISORDER of IMMEDIATE TYPE HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS.",FAMILIAL ALLERGIC DISORDER,IMMEDIATE TYPE HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS
502832752,7/13/2014 20:46:47,,1322128628,7/13/2014 20:46:22,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[PART_OF],[PART_OF],of,n/a,100,130,125,188,-1,RO-cause_of,900347-FS1,"The human pathological condition most commonly associated with hyperproduction of IgE is atopy, the FAMILIAL ALLERGIC DISORDER of IMMEDIATE TYPE HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS.",FAMILIAL ALLERGIC DISORDER,IMMEDIATE TYPE HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS
502832752,7/13/2014 21:00:12,,1322140640,7/13/2014 20:59:09,clixsense,1.0,26649250,GBR,B7,Bristol,79.71.125.97,[IS_A],[IS_A],of,n/a,100,130,125,188,-1,RO-cause_of,900347-FS1,"The human pathological condition most commonly associated with hyperproduction of IgE is atopy, the FAMILIAL ALLERGIC DISORDER of IMMEDIATE TYPE HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS.",FAMILIAL ALLERGIC DISORDER,IMMEDIATE TYPE HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS
502832752,7/13/2014 21:44:35,,1322175872,7/13/2014 21:44:18,instagc,1.0,28301350,GBR,K4,Plymouth,89.242.63.62,[ASSOCIATED_WITH],[ASSOCIATED_WITH],of,N/A,100,130,125,188,-1,RO-cause_of,900347-FS1,"The human pathological condition most commonly associated with hyperproduction of IgE is atopy, the FAMILIAL ALLERGIC DISORDER of IMMEDIATE TYPE HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS.",FAMILIAL ALLERGIC DISORDER,IMMEDIATE TYPE HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS
502832752,7/13/2014 21:44:56,,1322176081,7/13/2014 21:44:41,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[PART_OF],[PART_OF],of,N/A,100,130,125,188,-1,RO-cause_of,900347-FS1,"The human pathological condition most commonly associated with hyperproduction of IgE is atopy, the FAMILIAL ALLERGIC DISORDER of IMMEDIATE TYPE HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS.",FAMILIAL ALLERGIC DISORDER,IMMEDIATE TYPE HYPERSENSITIVITY TO ENVIRONMENTAL ALLERGENS
502832753,7/13/2014 18:43:14,,1322046135,7/13/2014 18:42:50,clixsense,1.0,19803139,NLD,11,Leiden,82.139.76.131,[CAUSES],[CAUSES],cells of,N/A,71,120,78,124,-1,RO-disease_has_finding,901513-FS1,Xenograft histology following radioimmunotherapy showed large areas of NECROSIS fibrosis and very few residual cells of SCLC origin.,NECROSIS,SCLC
502832753,7/13/2014 18:55:49,,1322052167,7/13/2014 18:54:45,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[SIDE_EFFECT],[SIDE_EFFECT],very few residual cells,na,71,120,78,124,-1,RO-disease_has_finding,901513-FS1,Xenograft histology following radioimmunotherapy showed large areas of NECROSIS fibrosis and very few residual cells of SCLC origin.,NECROSIS,SCLC
502832753,7/13/2014 19:07:02,,1322057204,7/13/2014 19:06:26,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],showed and,N/A,71,120,78,124,-1,RO-disease_has_finding,901513-FS1,Xenograft histology following radioimmunotherapy showed large areas of NECROSIS fibrosis and very few residual cells of SCLC origin.,NECROSIS,SCLC
502832753,7/13/2014 19:08:11,,1322057795,7/13/2014 19:08:01,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],showed,N/A,71,120,78,124,-1,RO-disease_has_finding,901513-FS1,Xenograft histology following radioimmunotherapy showed large areas of NECROSIS fibrosis and very few residual cells of SCLC origin.,NECROSIS,SCLC
502832753,7/13/2014 19:24:39,,1322064285,7/13/2014 19:23:16,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[MANIFESTATION] [SIDE_EFFECT],"[MANIFESTATION]
[SIDE_EFFECT]",showed large areas,[MANIFESTATION] [SIDE_EFFECT],71,120,78,124,-1,RO-disease_has_finding,901513-FS1,Xenograft histology following radioimmunotherapy showed large areas of NECROSIS fibrosis and very few residual cells of SCLC origin.,NECROSIS,SCLC
502832753,7/13/2014 19:28:14,,1322065628,7/13/2014 19:27:24,instagc,1.0,19686223,CAN,BC,Surrey,154.20.155.106,[LOCATION],[LOCATION],Xenograft histology following radioimmunotherapy showed large areas of NECROSIS fibrosis and very few residual cells of SCLC origin.,N/A,71,120,78,124,-1,RO-disease_has_finding,901513-FS1,Xenograft histology following radioimmunotherapy showed large areas of NECROSIS fibrosis and very few residual cells of SCLC origin.,NECROSIS,SCLC
502832753,7/13/2014 20:00:21,,1322087961,7/13/2014 19:59:17,clixsense,1.0,6365250,CAN,BC,Burnaby,70.79.16.165,[LOCATION],[LOCATION],large areas NECROSIS fibrosis very few residual cells SCLC,location,71,120,78,124,-1,RO-disease_has_finding,901513-FS1,Xenograft histology following radioimmunotherapy showed large areas of NECROSIS fibrosis and very few residual cells of SCLC origin.,NECROSIS,SCLC
502832753,7/13/2014 20:02:58,,1322090636,7/13/2014 20:01:40,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[NONE],[NONE],N/A,BOTH THINGS WERE SHOWN ON A RADIOGRAPH BUT ARE NOT RELATED,71,120,78,124,-1,RO-disease_has_finding,901513-FS1,Xenograft histology following radioimmunotherapy showed large areas of NECROSIS fibrosis and very few residual cells of SCLC origin.,NECROSIS,SCLC
502832753,7/13/2014 20:16:29,,1322103020,7/13/2014 20:16:09,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[NONE],[NONE],N/A,No relation,71,120,78,124,-1,RO-disease_has_finding,901513-FS1,Xenograft histology following radioimmunotherapy showed large areas of NECROSIS fibrosis and very few residual cells of SCLC origin.,NECROSIS,SCLC
502832753,7/13/2014 20:20:46,,1322106881,7/13/2014 20:20:22,elite,1.0,28503042,USA,OK,Oakwood,64.250.220.169,[ASSOCIATED_WITH],[ASSOCIATED_WITH],NECROSIS fibrosis and very few residual cells of SCLC origin.,N/A,71,120,78,124,-1,RO-disease_has_finding,901513-FS1,Xenograft histology following radioimmunotherapy showed large areas of NECROSIS fibrosis and very few residual cells of SCLC origin.,NECROSIS,SCLC
502832753,7/13/2014 20:35:32,,1322119388,7/13/2014 20:34:57,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[NONE],[NONE],N/A,Separate terms,71,120,78,124,-1,RO-disease_has_finding,901513-FS1,Xenograft histology following radioimmunotherapy showed large areas of NECROSIS fibrosis and very few residual cells of SCLC origin.,NECROSIS,SCLC
502832753,7/13/2014 20:47:17,,1322128991,7/13/2014 20:46:49,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[OTHER],[OTHER],and,n/a,71,120,78,124,-1,RO-disease_has_finding,901513-FS1,Xenograft histology following radioimmunotherapy showed large areas of NECROSIS fibrosis and very few residual cells of SCLC origin.,NECROSIS,SCLC
502832753,7/13/2014 20:56:10,,1322136659,7/13/2014 20:54:31,prodege,1,1852770,USA,TX,Abilene,76.198.102.54,[NONE],[NONE],n/a,these symptoms od not appear together in this disease.,71,120,78,124,-1,RO-disease_has_finding,901513-FS1,Xenograft histology following radioimmunotherapy showed large areas of NECROSIS fibrosis and very few residual cells of SCLC origin.,NECROSIS,SCLC
502832753,7/13/2014 21:10:54,,1322149773,7/13/2014 21:10:21,clixsense,1.0,26649250,GBR,B7,Bristol,79.71.125.97,[SYMPTOM],[SYMPTOM],showed,n/a,71,120,78,124,-1,RO-disease_has_finding,901513-FS1,Xenograft histology following radioimmunotherapy showed large areas of NECROSIS fibrosis and very few residual cells of SCLC origin.,NECROSIS,SCLC
502832753,7/13/2014 21:35:05,,1322168949,7/13/2014 21:34:13,elite,1.0,28397222,GBR,"","",31.49.231.211,[ASSOCIATED_WITH],[ASSOCIATED_WITH],showed,N/A,71,120,78,124,-1,RO-disease_has_finding,901513-FS1,Xenograft histology following radioimmunotherapy showed large areas of NECROSIS fibrosis and very few residual cells of SCLC origin.,NECROSIS,SCLC
502832754,7/13/2014 18:54:01,,1322051293,7/13/2014 18:53:33,clixsense,1.0,19803139,NLD,11,Leiden,82.139.76.131,[IS_A],[IS_A],compared,N/A,40,69,64,81,1,RO-may_diagnose,906849-FS1,We compared the changes of non specific BRONCHIAL HYPERREACTIVITY to METHACHOLINE UNDW and exercise in 2 groups of patients with mite asthma treated with local immunotherapy (LIT group: 12 patients) and subcutaneous immunotherapy (SIT group: 8 patients) for 1 year.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
502832754,7/13/2014 18:59:36,,1322053928,7/13/2014 18:59:07,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[OTHER],[OTHER],to,comparison,40,69,64,81,1,RO-may_diagnose,906849-FS1,We compared the changes of non specific BRONCHIAL HYPERREACTIVITY to METHACHOLINE UNDW and exercise in 2 groups of patients with mite asthma treated with local immunotherapy (LIT group: 12 patients) and subcutaneous immunotherapy (SIT group: 8 patients) for 1 year.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
502832754,7/13/2014 19:00:57,,1322054552,7/13/2014 18:59:49,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],HYPERREACTIVITY to,N/A,40,69,64,81,1,RO-may_diagnose,906849-FS1,We compared the changes of non specific BRONCHIAL HYPERREACTIVITY to METHACHOLINE UNDW and exercise in 2 groups of patients with mite asthma treated with local immunotherapy (LIT group: 12 patients) and subcutaneous immunotherapy (SIT group: 8 patients) for 1 year.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
502832754,7/13/2014 19:01:12,,1322054648,7/13/2014 19:00:32,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],treated with,N/A,40,69,64,81,1,RO-may_diagnose,906849-FS1,We compared the changes of non specific BRONCHIAL HYPERREACTIVITY to METHACHOLINE UNDW and exercise in 2 groups of patients with mite asthma treated with local immunotherapy (LIT group: 12 patients) and subcutaneous immunotherapy (SIT group: 8 patients) for 1 year.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
502832754,7/13/2014 19:05:30,,1322056494,7/13/2014 19:05:23,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[OTHER],[OTHER],immunotherapy,da,40,69,64,81,1,RO-may_diagnose,906849-FS1,We compared the changes of non specific BRONCHIAL HYPERREACTIVITY to METHACHOLINE UNDW and exercise in 2 groups of patients with mite asthma treated with local immunotherapy (LIT group: 12 patients) and subcutaneous immunotherapy (SIT group: 8 patients) for 1 year.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
502832754,7/13/2014 19:08:44,,1322058016,7/13/2014 19:06:30,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],treated,n/a,40,69,64,81,1,RO-may_diagnose,906849-FS1,We compared the changes of non specific BRONCHIAL HYPERREACTIVITY to METHACHOLINE UNDW and exercise in 2 groups of patients with mite asthma treated with local immunotherapy (LIT group: 12 patients) and subcutaneous immunotherapy (SIT group: 8 patients) for 1 year.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
502832754,7/13/2014 19:09:17,,1322058249,7/13/2014 19:07:59,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],compared the changes,na,40,69,64,81,1,RO-may_diagnose,906849-FS1,We compared the changes of non specific BRONCHIAL HYPERREACTIVITY to METHACHOLINE UNDW and exercise in 2 groups of patients with mite asthma treated with local immunotherapy (LIT group: 12 patients) and subcutaneous immunotherapy (SIT group: 8 patients) for 1 year.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
502832754,7/13/2014 19:14:25,,1322060352,7/13/2014 19:13:13,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],treated with,[DIAGNOSE_BY_TEST_OR_DRUG],40,69,64,81,1,RO-may_diagnose,906849-FS1,We compared the changes of non specific BRONCHIAL HYPERREACTIVITY to METHACHOLINE UNDW and exercise in 2 groups of patients with mite asthma treated with local immunotherapy (LIT group: 12 patients) and subcutaneous immunotherapy (SIT group: 8 patients) for 1 year.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
502832754,7/13/2014 19:21:23,,1322063061,7/13/2014 19:20:54,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[TREATS],[TREATS],changes,n/a,40,69,64,81,1,RO-may_diagnose,906849-FS1,We compared the changes of non specific BRONCHIAL HYPERREACTIVITY to METHACHOLINE UNDW and exercise in 2 groups of patients with mite asthma treated with local immunotherapy (LIT group: 12 patients) and subcutaneous immunotherapy (SIT group: 8 patients) for 1 year.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
502832754,7/13/2014 19:37:56,,1322069105,7/13/2014 19:37:12,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[ASSOCIATED_WITH],[ASSOCIATED_WITH],compared the changes of BRONCHIAL HYPERREACTIVITY to METHACHOLINE UNDW,n/a,40,69,64,81,1,RO-may_diagnose,906849-FS1,We compared the changes of non specific BRONCHIAL HYPERREACTIVITY to METHACHOLINE UNDW and exercise in 2 groups of patients with mite asthma treated with local immunotherapy (LIT group: 12 patients) and subcutaneous immunotherapy (SIT group: 8 patients) for 1 year.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
502832754,7/13/2014 20:07:38,,1322095405,7/13/2014 20:06:39,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[OTHER],[OTHER],changes,is treated by,40,69,64,81,1,RO-may_diagnose,906849-FS1,We compared the changes of non specific BRONCHIAL HYPERREACTIVITY to METHACHOLINE UNDW and exercise in 2 groups of patients with mite asthma treated with local immunotherapy (LIT group: 12 patients) and subcutaneous immunotherapy (SIT group: 8 patients) for 1 year.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
502832754,7/13/2014 20:09:59,,1322097423,7/13/2014 20:09:29,elite,1.0,28503042,USA,OK,Oakwood,64.250.220.169,[CAUSES],[CAUSES],BRONCHIAL HYPERREACTIVITY to METHACHOLINE UNDW,N/A,40,69,64,81,1,RO-may_diagnose,906849-FS1,We compared the changes of non specific BRONCHIAL HYPERREACTIVITY to METHACHOLINE UNDW and exercise in 2 groups of patients with mite asthma treated with local immunotherapy (LIT group: 12 patients) and subcutaneous immunotherapy (SIT group: 8 patients) for 1 year.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
502832754,7/13/2014 20:21:45,,1322107689,7/13/2014 20:20:02,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],compared to,N/A,40,69,64,81,1,RO-may_diagnose,906849-FS1,We compared the changes of non specific BRONCHIAL HYPERREACTIVITY to METHACHOLINE UNDW and exercise in 2 groups of patients with mite asthma treated with local immunotherapy (LIT group: 12 patients) and subcutaneous immunotherapy (SIT group: 8 patients) for 1 year.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
502832754,7/13/2014 21:04:21,,1322144118,7/13/2014 21:03:21,clixsense,1.0,26649250,GBR,B7,Bristol,79.71.125.97,[OTHER],[OTHER],compared to,n/a,40,69,64,81,1,RO-may_diagnose,906849-FS1,We compared the changes of non specific BRONCHIAL HYPERREACTIVITY to METHACHOLINE UNDW and exercise in 2 groups of patients with mite asthma treated with local immunotherapy (LIT group: 12 patients) and subcutaneous immunotherapy (SIT group: 8 patients) for 1 year.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
502832754,7/13/2014 21:41:15,,1322173325,7/13/2014 21:40:55,instagc,1.0,28301350,GBR,K4,Plymouth,89.242.63.62,[ASSOCIATED_WITH],[ASSOCIATED_WITH],to,N/A,40,69,64,81,1,RO-may_diagnose,906849-FS1,We compared the changes of non specific BRONCHIAL HYPERREACTIVITY to METHACHOLINE UNDW and exercise in 2 groups of patients with mite asthma treated with local immunotherapy (LIT group: 12 patients) and subcutaneous immunotherapy (SIT group: 8 patients) for 1 year.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
502832755,7/13/2014 18:43:40,,1322046395,7/13/2014 18:43:14,clixsense,1.0,19803139,NLD,11,Leiden,82.139.76.131,[IS_A],[IS_A],like illness:,N/A,175,147,181,160,1,RO-has_causative_agent,903979-FS1,"The specificity of these antibodies was tested by immunoblotting with a panel of crude protein antigens from 12 bacteria causing enteric fever and ENTERIC FEVER like illness: S TYPHI S. paratyphi A, S. paratyphi B, S. paratyphi C, S. choleraesuis, S. enteritidis, S. krefeld, S. panama, S. typhimurium, Escherichia coli, Pseudomonas pseudomallei, and Yersinia enterocolitica.",S TYPHI,ENTERIC FEVER
502832755,7/13/2014 18:47:12,,1322048165,7/13/2014 18:46:55,neodev,1.0,18517457,GBR,"","",86.29.147.112,[PART_OF],[PART_OF],like illness:,N/a,175,147,181,160,1,RO-has_causative_agent,903979-FS1,"The specificity of these antibodies was tested by immunoblotting with a panel of crude protein antigens from 12 bacteria causing enteric fever and ENTERIC FEVER like illness: S TYPHI S. paratyphi A, S. paratyphi B, S. paratyphi C, S. choleraesuis, S. enteritidis, S. krefeld, S. panama, S. typhimurium, Escherichia coli, Pseudomonas pseudomallei, and Yersinia enterocolitica.",S TYPHI,ENTERIC FEVER
502832755,7/13/2014 19:05:28,,1322056484,7/13/2014 19:04:59,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[CAUSES],[CAUSES],causing,N/A,175,147,181,160,1,RO-has_causative_agent,903979-FS1,"The specificity of these antibodies was tested by immunoblotting with a panel of crude protein antigens from 12 bacteria causing enteric fever and ENTERIC FEVER like illness: S TYPHI S. paratyphi A, S. paratyphi B, S. paratyphi C, S. choleraesuis, S. enteritidis, S. krefeld, S. panama, S. typhimurium, Escherichia coli, Pseudomonas pseudomallei, and Yersinia enterocolitica.",S TYPHI,ENTERIC FEVER
502832755,7/13/2014 19:05:29,,1322056488,7/13/2014 19:04:27,instagc,1.0,19686223,CAN,BC,Surrey,154.20.155.106,[DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]",The specificity of these antibodies was tested by immunoblotting with a panel of crude protein antigens from 12 bacteria causing enteric fever and ENTERIC FEVER like illness:,N/A,175,147,181,160,1,RO-has_causative_agent,903979-FS1,"The specificity of these antibodies was tested by immunoblotting with a panel of crude protein antigens from 12 bacteria causing enteric fever and ENTERIC FEVER like illness: S TYPHI S. paratyphi A, S. paratyphi B, S. paratyphi C, S. choleraesuis, S. enteritidis, S. krefeld, S. panama, S. typhimurium, Escherichia coli, Pseudomonas pseudomallei, and Yersinia enterocolitica.",S TYPHI,ENTERIC FEVER
502832755,7/13/2014 19:06:11,,1322056832,7/13/2014 19:06:02,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],"C,",N/A,175,147,181,160,1,RO-has_causative_agent,903979-FS1,"The specificity of these antibodies was tested by immunoblotting with a panel of crude protein antigens from 12 bacteria causing enteric fever and ENTERIC FEVER like illness: S TYPHI S. paratyphi A, S. paratyphi B, S. paratyphi C, S. choleraesuis, S. enteritidis, S. krefeld, S. panama, S. typhimurium, Escherichia coli, Pseudomonas pseudomallei, and Yersinia enterocolitica.",S TYPHI,ENTERIC FEVER
502832755,7/13/2014 19:30:33,,1322066459,7/13/2014 19:29:02,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[CAUSES],[CAUSES],causing,na,175,147,181,160,1,RO-has_causative_agent,903979-FS1,"The specificity of these antibodies was tested by immunoblotting with a panel of crude protein antigens from 12 bacteria causing enteric fever and ENTERIC FEVER like illness: S TYPHI S. paratyphi A, S. paratyphi B, S. paratyphi C, S. choleraesuis, S. enteritidis, S. krefeld, S. panama, S. typhimurium, Escherichia coli, Pseudomonas pseudomallei, and Yersinia enterocolitica.",S TYPHI,ENTERIC FEVER
502832755,7/13/2014 19:32:22,,1322067052,7/13/2014 19:32:03,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[ASSOCIATED_WITH],[ASSOCIATED_WITH],like,n/a,175,147,181,160,1,RO-has_causative_agent,903979-FS1,"The specificity of these antibodies was tested by immunoblotting with a panel of crude protein antigens from 12 bacteria causing enteric fever and ENTERIC FEVER like illness: S TYPHI S. paratyphi A, S. paratyphi B, S. paratyphi C, S. choleraesuis, S. enteritidis, S. krefeld, S. panama, S. typhimurium, Escherichia coli, Pseudomonas pseudomallei, and Yersinia enterocolitica.",S TYPHI,ENTERIC FEVER
502832755,7/13/2014 19:42:08,,1322071045,7/13/2014 19:41:34,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],like illness:,N/A,175,147,181,160,1,RO-has_causative_agent,903979-FS1,"The specificity of these antibodies was tested by immunoblotting with a panel of crude protein antigens from 12 bacteria causing enteric fever and ENTERIC FEVER like illness: S TYPHI S. paratyphi A, S. paratyphi B, S. paratyphi C, S. choleraesuis, S. enteritidis, S. krefeld, S. panama, S. typhimurium, Escherichia coli, Pseudomonas pseudomallei, and Yersinia enterocolitica.",S TYPHI,ENTERIC FEVER
502832755,7/13/2014 20:12:52,,1322099881,7/13/2014 20:11:51,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ENTERIC FEVER like illness:,n/a,175,147,181,160,1,RO-has_causative_agent,903979-FS1,"The specificity of these antibodies was tested by immunoblotting with a panel of crude protein antigens from 12 bacteria causing enteric fever and ENTERIC FEVER like illness: S TYPHI S. paratyphi A, S. paratyphi B, S. paratyphi C, S. choleraesuis, S. enteritidis, S. krefeld, S. panama, S. typhimurium, Escherichia coli, Pseudomonas pseudomallei, and Yersinia enterocolitica.",S TYPHI,ENTERIC FEVER
502832755,7/13/2014 20:17:16,,1322103809,7/13/2014 20:17:00,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[IS_A],[IS_A],illness:,N/A,175,147,181,160,1,RO-has_causative_agent,903979-FS1,"The specificity of these antibodies was tested by immunoblotting with a panel of crude protein antigens from 12 bacteria causing enteric fever and ENTERIC FEVER like illness: S TYPHI S. paratyphi A, S. paratyphi B, S. paratyphi C, S. choleraesuis, S. enteritidis, S. krefeld, S. panama, S. typhimurium, Escherichia coli, Pseudomonas pseudomallei, and Yersinia enterocolitica.",S TYPHI,ENTERIC FEVER
502832755,7/13/2014 20:46:03,,1322128036,7/13/2014 20:45:39,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ENTERIC FEVER like illness:,n/a,175,147,181,160,1,RO-has_causative_agent,903979-FS1,"The specificity of these antibodies was tested by immunoblotting with a panel of crude protein antigens from 12 bacteria causing enteric fever and ENTERIC FEVER like illness: S TYPHI S. paratyphi A, S. paratyphi B, S. paratyphi C, S. choleraesuis, S. enteritidis, S. krefeld, S. panama, S. typhimurium, Escherichia coli, Pseudomonas pseudomallei, and Yersinia enterocolitica.",S TYPHI,ENTERIC FEVER
502832755,7/13/2014 20:57:31,,1322138067,7/13/2014 20:56:33,elite,1.0,28397222,GBR,"","",31.49.231.211,[CAUSES],[CAUSES],causing,N/A,175,147,181,160,1,RO-has_causative_agent,903979-FS1,"The specificity of these antibodies was tested by immunoblotting with a panel of crude protein antigens from 12 bacteria causing enteric fever and ENTERIC FEVER like illness: S TYPHI S. paratyphi A, S. paratyphi B, S. paratyphi C, S. choleraesuis, S. enteritidis, S. krefeld, S. panama, S. typhimurium, Escherichia coli, Pseudomonas pseudomallei, and Yersinia enterocolitica.",S TYPHI,ENTERIC FEVER
502832755,7/13/2014 21:17:44,,1322155391,7/13/2014 21:16:46,clixsense,1.0,26649250,GBR,B7,Bristol,79.71.125.97,[SYMPTOM],[SYMPTOM],causing enteric fever and,n/a,175,147,181,160,1,RO-has_causative_agent,903979-FS1,"The specificity of these antibodies was tested by immunoblotting with a panel of crude protein antigens from 12 bacteria causing enteric fever and ENTERIC FEVER like illness: S TYPHI S. paratyphi A, S. paratyphi B, S. paratyphi C, S. choleraesuis, S. enteritidis, S. krefeld, S. panama, S. typhimurium, Escherichia coli, Pseudomonas pseudomallei, and Yersinia enterocolitica.",S TYPHI,ENTERIC FEVER
502832755,7/13/2014 21:43:59,,1322175451,7/13/2014 21:43:28,instagc,1.0,28301350,GBR,K4,Plymouth,89.242.63.62,[ASSOCIATED_WITH],[ASSOCIATED_WITH],causing ENTERIC FEVER S TYPHI,N/A,175,147,181,160,1,RO-has_causative_agent,903979-FS1,"The specificity of these antibodies was tested by immunoblotting with a panel of crude protein antigens from 12 bacteria causing enteric fever and ENTERIC FEVER like illness: S TYPHI S. paratyphi A, S. paratyphi B, S. paratyphi C, S. choleraesuis, S. enteritidis, S. krefeld, S. panama, S. typhimurium, Escherichia coli, Pseudomonas pseudomallei, and Yersinia enterocolitica.",S TYPHI,ENTERIC FEVER
502832755,7/13/2014 21:45:26,,1322176520,7/13/2014 21:44:56,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[IS_A],[IS_A],ENTERIC FEVER like illness:,N/A,175,147,181,160,1,RO-has_causative_agent,903979-FS1,"The specificity of these antibodies was tested by immunoblotting with a panel of crude protein antigens from 12 bacteria causing enteric fever and ENTERIC FEVER like illness: S TYPHI S. paratyphi A, S. paratyphi B, S. paratyphi C, S. choleraesuis, S. enteritidis, S. krefeld, S. panama, S. typhimurium, Escherichia coli, Pseudomonas pseudomallei, and Yersinia enterocolitica.",S TYPHI,ENTERIC FEVER
502832756,7/13/2014 18:48:06,,1322048573,7/13/2014 18:47:49,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[CAUSES],[CAUSES],caused,Na,44,7,65,24,1,RO-has_causative_agent,903737-FS1,Herpes ZOSTER (SHINGLES) is caused when the VARICELLA ZOSTER VIRUS that has remained latent since an earlier varicella infection (chicken pox) is reactivated.,VARICELLA ZOSTER VIRUS,ZOSTER (SHINGLES)
502832756,7/13/2014 18:48:53,,1322048931,7/13/2014 18:48:27,clixsense,1.0,19803139,NLD,11,Leiden,82.139.76.131,[CAUSES],[CAUSES],caused,N/A,44,7,65,24,1,RO-has_causative_agent,903737-FS1,Herpes ZOSTER (SHINGLES) is caused when the VARICELLA ZOSTER VIRUS that has remained latent since an earlier varicella infection (chicken pox) is reactivated.,VARICELLA ZOSTER VIRUS,ZOSTER (SHINGLES)
502832756,7/13/2014 18:54:52,,1322051691,7/13/2014 18:53:23,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[CAUSES],[CAUSES],caused,N/A,44,7,65,24,1,RO-has_causative_agent,903737-FS1,Herpes ZOSTER (SHINGLES) is caused when the VARICELLA ZOSTER VIRUS that has remained latent since an earlier varicella infection (chicken pox) is reactivated.,VARICELLA ZOSTER VIRUS,ZOSTER (SHINGLES)
502832756,7/13/2014 18:55:40,,1322052063,7/13/2014 18:54:36,neodev,1.0,18517457,GBR,"","",86.29.147.112,[CAUSES],[CAUSES],is caused when,N/a,44,7,65,24,1,RO-has_causative_agent,903737-FS1,Herpes ZOSTER (SHINGLES) is caused when the VARICELLA ZOSTER VIRUS that has remained latent since an earlier varicella infection (chicken pox) is reactivated.,VARICELLA ZOSTER VIRUS,ZOSTER (SHINGLES)
502832756,7/13/2014 19:01:59,,1322054992,7/13/2014 19:01:53,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[CAUSES],[CAUSES],VARICELLA,da,44,7,65,24,1,RO-has_causative_agent,903737-FS1,Herpes ZOSTER (SHINGLES) is caused when the VARICELLA ZOSTER VIRUS that has remained latent since an earlier varicella infection (chicken pox) is reactivated.,VARICELLA ZOSTER VIRUS,ZOSTER (SHINGLES)
502832756,7/13/2014 19:03:33,,1322055700,7/13/2014 19:03:23,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],remained,N/A,44,7,65,24,1,RO-has_causative_agent,903737-FS1,Herpes ZOSTER (SHINGLES) is caused when the VARICELLA ZOSTER VIRUS that has remained latent since an earlier varicella infection (chicken pox) is reactivated.,VARICELLA ZOSTER VIRUS,ZOSTER (SHINGLES)
502832756,7/13/2014 19:07:31,,1322057465,7/13/2014 19:07:03,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[CAUSES],[CAUSES],caused,N/A,44,7,65,24,1,RO-has_causative_agent,903737-FS1,Herpes ZOSTER (SHINGLES) is caused when the VARICELLA ZOSTER VIRUS that has remained latent since an earlier varicella infection (chicken pox) is reactivated.,VARICELLA ZOSTER VIRUS,ZOSTER (SHINGLES)
502832756,7/13/2014 19:19:55,,1322062620,7/13/2014 19:19:18,instagc,1.0,19686223,CAN,BC,Surrey,154.20.155.106,[CAUSES],[CAUSES],Herpes ZOSTER (SHINGLES) is caused when the VARICELLA ZOSTER VIRUS is reactivated.,N/A,44,7,65,24,1,RO-has_causative_agent,903737-FS1,Herpes ZOSTER (SHINGLES) is caused when the VARICELLA ZOSTER VIRUS that has remained latent since an earlier varicella infection (chicken pox) is reactivated.,VARICELLA ZOSTER VIRUS,ZOSTER (SHINGLES)
502832756,7/13/2014 19:22:06,,1322063335,7/13/2014 19:21:39,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[CAUSES],[CAUSES],is caused when,[CAUSES],44,7,65,24,1,RO-has_causative_agent,903737-FS1,Herpes ZOSTER (SHINGLES) is caused when the VARICELLA ZOSTER VIRUS that has remained latent since an earlier varicella infection (chicken pox) is reactivated.,VARICELLA ZOSTER VIRUS,ZOSTER (SHINGLES)
502832756,7/13/2014 19:26:56,,1322065158,7/13/2014 19:26:32,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[CAUSES],[CAUSES],ZOSTER (SHINGLES) is caused when the VARICELLA ZOSTER VIRUS,n/a,44,7,65,24,1,RO-has_causative_agent,903737-FS1,Herpes ZOSTER (SHINGLES) is caused when the VARICELLA ZOSTER VIRUS that has remained latent since an earlier varicella infection (chicken pox) is reactivated.,VARICELLA ZOSTER VIRUS,ZOSTER (SHINGLES)
502832756,7/13/2014 19:42:31,,1322071223,7/13/2014 19:42:09,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],caused when,N/A,44,7,65,24,1,RO-has_causative_agent,903737-FS1,Herpes ZOSTER (SHINGLES) is caused when the VARICELLA ZOSTER VIRUS that has remained latent since an earlier varicella infection (chicken pox) is reactivated.,VARICELLA ZOSTER VIRUS,ZOSTER (SHINGLES)
502832756,7/13/2014 20:05:53,,1322093609,7/13/2014 20:05:16,elite,1.0,28503042,USA,OK,Oakwood,64.250.220.169,[CAUSES],[CAUSES],is caused when the,N/A,44,7,65,24,1,RO-has_causative_agent,903737-FS1,Herpes ZOSTER (SHINGLES) is caused when the VARICELLA ZOSTER VIRUS that has remained latent since an earlier varicella infection (chicken pox) is reactivated.,VARICELLA ZOSTER VIRUS,ZOSTER (SHINGLES)
502832756,7/13/2014 20:51:12,,1322132633,7/13/2014 20:50:56,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[CAUSES],[CAUSES],is caused,n/a,44,7,65,24,1,RO-has_causative_agent,903737-FS1,Herpes ZOSTER (SHINGLES) is caused when the VARICELLA ZOSTER VIRUS that has remained latent since an earlier varicella infection (chicken pox) is reactivated.,VARICELLA ZOSTER VIRUS,ZOSTER (SHINGLES)
502832756,7/13/2014 21:04:54,,1322144548,7/13/2014 21:04:22,clixsense,1.0,26649250,GBR,B7,Bristol,79.71.125.97,[CAUSES],[CAUSES],is caused when the,n/a,44,7,65,24,1,RO-has_causative_agent,903737-FS1,Herpes ZOSTER (SHINGLES) is caused when the VARICELLA ZOSTER VIRUS that has remained latent since an earlier varicella infection (chicken pox) is reactivated.,VARICELLA ZOSTER VIRUS,ZOSTER (SHINGLES)
502832756,7/13/2014 21:26:52,,1322163098,7/13/2014 21:26:07,elite,1.0,28397222,GBR,"","",31.49.231.211,[CAUSES],[CAUSES],is caused when,N/A,44,7,65,24,1,RO-has_causative_agent,903737-FS1,Herpes ZOSTER (SHINGLES) is caused when the VARICELLA ZOSTER VIRUS that has remained latent since an earlier varicella infection (chicken pox) is reactivated.,VARICELLA ZOSTER VIRUS,ZOSTER (SHINGLES)
502832757,7/13/2014 18:41:46,,1322045241,7/13/2014 18:41:29,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SIDE_EFFECT],[SIDE_EFFECT],recurrence,Na,35,78,44,100,1,RO-may_prevent,907383-FS1,All patients have remained free of ARRHYTHMIA recurrence and have required no ANTIARRHYTHMIC THERAPY after a follow up of 5 to 28 months (mean 14.,ARRHYTHMIA,ANTIARRHYTHMIC THERAPY
502832757,7/13/2014 18:49:21,,1322049139,7/13/2014 18:49:06,neodev,1.0,18517457,GBR,"","",86.29.147.112,[TREATS],[TREATS],have required no,N/a,35,78,44,100,1,RO-may_prevent,907383-FS1,All patients have remained free of ARRHYTHMIA recurrence and have required no ANTIARRHYTHMIC THERAPY after a follow up of 5 to 28 months (mean 14.,ARRHYTHMIA,ANTIARRHYTHMIC THERAPY
502832757,7/13/2014 19:03:08,,1322055504,7/13/2014 19:00:46,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[TREATS],[TREATS],required no,na,35,78,44,100,1,RO-may_prevent,907383-FS1,All patients have remained free of ARRHYTHMIA recurrence and have required no ANTIARRHYTHMIC THERAPY after a follow up of 5 to 28 months (mean 14.,ARRHYTHMIA,ANTIARRHYTHMIC THERAPY
502832757,7/13/2014 19:06:41,,1322057054,7/13/2014 19:06:30,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],recurrence,N/A,35,78,44,100,1,RO-may_prevent,907383-FS1,All patients have remained free of ARRHYTHMIA recurrence and have required no ANTIARRHYTHMIC THERAPY after a follow up of 5 to 28 months (mean 14.,ARRHYTHMIA,ANTIARRHYTHMIC THERAPY
502832757,7/13/2014 19:09:19,,1322058258,7/13/2014 19:08:45,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],THERAPY,n/a,35,78,44,100,1,RO-may_prevent,907383-FS1,All patients have remained free of ARRHYTHMIA recurrence and have required no ANTIARRHYTHMIC THERAPY after a follow up of 5 to 28 months (mean 14.,ARRHYTHMIA,ANTIARRHYTHMIC THERAPY
502832757,7/13/2014 19:12:32,,1322059667,7/13/2014 19:11:49,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],required no THERAPY,N/A,35,78,44,100,1,RO-may_prevent,907383-FS1,All patients have remained free of ARRHYTHMIA recurrence and have required no ANTIARRHYTHMIC THERAPY after a follow up of 5 to 28 months (mean 14.,ARRHYTHMIA,ANTIARRHYTHMIC THERAPY
502832757,7/13/2014 19:15:20,,1322060706,7/13/2014 19:14:31,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PREVENTS],[PREVENTS],have required,N/A,35,78,44,100,1,RO-may_prevent,907383-FS1,All patients have remained free of ARRHYTHMIA recurrence and have required no ANTIARRHYTHMIC THERAPY after a follow up of 5 to 28 months (mean 14.,ARRHYTHMIA,ANTIARRHYTHMIC THERAPY
502832757,7/13/2014 19:17:56,,1322061809,7/13/2014 19:17:21,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[TREATS],[TREATS],remained free of ARRHYTHMIA required no ANTIARRHYTHMIC THERAPY,n/a,35,78,44,100,1,RO-may_prevent,907383-FS1,All patients have remained free of ARRHYTHMIA recurrence and have required no ANTIARRHYTHMIC THERAPY after a follow up of 5 to 28 months (mean 14.,ARRHYTHMIA,ANTIARRHYTHMIC THERAPY
502832757,7/13/2014 19:52:38,,1322079436,7/13/2014 19:52:01,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[TREATS],[TREATS],ARRHYTHMIA THERAPY,n/a,35,78,44,100,1,RO-may_prevent,907383-FS1,All patients have remained free of ARRHYTHMIA recurrence and have required no ANTIARRHYTHMIC THERAPY after a follow up of 5 to 28 months (mean 14.,ARRHYTHMIA,ANTIARRHYTHMIC THERAPY
502832757,7/13/2014 19:57:59,,1322084910,7/13/2014 19:56:41,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[OTHER],[OTHER],required,is treated by,35,78,44,100,1,RO-may_prevent,907383-FS1,All patients have remained free of ARRHYTHMIA recurrence and have required no ANTIARRHYTHMIC THERAPY after a follow up of 5 to 28 months (mean 14.,ARRHYTHMIA,ANTIARRHYTHMIC THERAPY
502832757,7/13/2014 20:14:55,,1322101725,7/13/2014 20:14:09,elite,1.0,28503042,USA,OK,Oakwood,64.250.220.169,[TREATS],[TREATS],ARRHYTHMIA have required no ANTIARRHYTHMIC THERAPY,N/A,35,78,44,100,1,RO-may_prevent,907383-FS1,All patients have remained free of ARRHYTHMIA recurrence and have required no ANTIARRHYTHMIC THERAPY after a follow up of 5 to 28 months (mean 14.,ARRHYTHMIA,ANTIARRHYTHMIC THERAPY
502832757,7/13/2014 21:08:24,,1322147540,7/13/2014 21:07:56,clixsense,1.0,26649250,GBR,B7,Bristol,79.71.125.97,[TREATS],[TREATS],required no,n/a,35,78,44,100,1,RO-may_prevent,907383-FS1,All patients have remained free of ARRHYTHMIA recurrence and have required no ANTIARRHYTHMIC THERAPY after a follow up of 5 to 28 months (mean 14.,ARRHYTHMIA,ANTIARRHYTHMIC THERAPY
502832757,7/13/2014 21:41:52,,1322173933,7/13/2014 21:41:38,instagc,1.0,28301350,GBR,K4,Plymouth,89.242.63.62,[TREATS],[TREATS],required no,N/A,35,78,44,100,1,RO-may_prevent,907383-FS1,All patients have remained free of ARRHYTHMIA recurrence and have required no ANTIARRHYTHMIC THERAPY after a follow up of 5 to 28 months (mean 14.,ARRHYTHMIA,ANTIARRHYTHMIC THERAPY
502832757,7/13/2014 21:43:57,,1322175410,7/13/2014 21:43:43,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],recurrence and have required no,N/A,35,78,44,100,1,RO-may_prevent,907383-FS1,All patients have remained free of ARRHYTHMIA recurrence and have required no ANTIARRHYTHMIC THERAPY after a follow up of 5 to 28 months (mean 14.,ARRHYTHMIA,ANTIARRHYTHMIC THERAPY
502832757,7/13/2014 21:46:59,,1322177766,7/13/2014 21:45:40,elite,1.0,28397222,GBR,"","",31.49.231.211,[OTHER],[OTHER],have required no,ARRHYTHMIA is treated by  ANTIARRHYTHMIC THERAPY,35,78,44,100,1,RO-may_prevent,907383-FS1,All patients have remained free of ARRHYTHMIA recurrence and have required no ANTIARRHYTHMIC THERAPY after a follow up of 5 to 28 months (mean 14.,ARRHYTHMIA,ANTIARRHYTHMIC THERAPY
502832758,7/13/2014 18:49:45,,1322049256,7/13/2014 18:48:37,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],were present,N/A,79,208,86,224,1,RO-disease_may_have_finding,902651-FS1,"Combinations of symptoms can be of value: 2 or more symptoms from the triad of HEADACHE palpitations, and diaphoresis were present in the majority of pheochromocytoma patients, but in a smaller number of non PHEOCHROMOCYTOMA patients.",HEADACHE,PHEOCHROMOCYTOMA
502832758,7/13/2014 19:03:42,,1322055753,7/13/2014 19:02:59,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[SYMPTOM],[SYMPTOM],symptoms from,N/A,79,208,86,224,1,RO-disease_may_have_finding,902651-FS1,"Combinations of symptoms can be of value: 2 or more symptoms from the triad of HEADACHE palpitations, and diaphoresis were present in the majority of pheochromocytoma patients, but in a smaller number of non PHEOCHROMOCYTOMA patients.",HEADACHE,PHEOCHROMOCYTOMA
502832758,7/13/2014 19:07:14,,1322057329,7/13/2014 19:07:01,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],number,N/A,79,208,86,224,1,RO-disease_may_have_finding,902651-FS1,"Combinations of symptoms can be of value: 2 or more symptoms from the triad of HEADACHE palpitations, and diaphoresis were present in the majority of pheochromocytoma patients, but in a smaller number of non PHEOCHROMOCYTOMA patients.",HEADACHE,PHEOCHROMOCYTOMA
502832758,7/13/2014 19:07:53,,1322057638,7/13/2014 19:07:24,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[NONE],[NONE],N/A,No clear relationship.,79,208,86,224,1,RO-disease_may_have_finding,902651-FS1,"Combinations of symptoms can be of value: 2 or more symptoms from the triad of HEADACHE palpitations, and diaphoresis were present in the majority of pheochromocytoma patients, but in a smaller number of non PHEOCHROMOCYTOMA patients.",HEADACHE,PHEOCHROMOCYTOMA
502832758,7/13/2014 19:22:05,,1322063332,7/13/2014 19:21:42,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",symptoms,n/a,79,208,86,224,1,RO-disease_may_have_finding,902651-FS1,"Combinations of symptoms can be of value: 2 or more symptoms from the triad of HEADACHE palpitations, and diaphoresis were present in the majority of pheochromocytoma patients, but in a smaller number of non PHEOCHROMOCYTOMA patients.",HEADACHE,PHEOCHROMOCYTOMA
502832758,7/13/2014 19:25:18,,1322064562,7/13/2014 19:24:42,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],were present,[DIAGNOSE_BY_TEST_OR_DRUG],79,208,86,224,1,RO-disease_may_have_finding,902651-FS1,"Combinations of symptoms can be of value: 2 or more symptoms from the triad of HEADACHE palpitations, and diaphoresis were present in the majority of pheochromocytoma patients, but in a smaller number of non PHEOCHROMOCYTOMA patients.",HEADACHE,PHEOCHROMOCYTOMA
502832758,7/13/2014 19:32:36,,1322067112,7/13/2014 19:31:55,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],symptoms from the triad of HEADACHE,N/A,79,208,86,224,1,RO-disease_may_have_finding,902651-FS1,"Combinations of symptoms can be of value: 2 or more symptoms from the triad of HEADACHE palpitations, and diaphoresis were present in the majority of pheochromocytoma patients, but in a smaller number of non PHEOCHROMOCYTOMA patients.",HEADACHE,PHEOCHROMOCYTOMA
502832758,7/13/2014 19:59:10,,1322086416,7/13/2014 19:58:00,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[SYMPTOM],[SYMPTOM],were present,n/a,79,208,86,224,1,RO-disease_may_have_finding,902651-FS1,"Combinations of symptoms can be of value: 2 or more symptoms from the triad of HEADACHE palpitations, and diaphoresis were present in the majority of pheochromocytoma patients, but in a smaller number of non PHEOCHROMOCYTOMA patients.",HEADACHE,PHEOCHROMOCYTOMA
502832758,7/13/2014 20:01:20,,1322088976,7/13/2014 20:00:22,clixsense,1.0,6365250,CAN,BC,Burnaby,70.79.16.165,[SYMPTOM],[SYMPTOM],symptoms HEADACHE smaller number non PHEOCHROMOCYTOMA patients.,symptom,79,208,86,224,1,RO-disease_may_have_finding,902651-FS1,"Combinations of symptoms can be of value: 2 or more symptoms from the triad of HEADACHE palpitations, and diaphoresis were present in the majority of pheochromocytoma patients, but in a smaller number of non PHEOCHROMOCYTOMA patients.",HEADACHE,PHEOCHROMOCYTOMA
502832758,7/13/2014 20:15:43,,1322102460,7/13/2014 20:14:56,elite,1.0,28503042,USA,OK,Oakwood,64.250.220.169,[SYMPTOM],[SYMPTOM],"palpitations, in a smaller number of non PHEOCHROMOCYTOMA patients.",N/A,79,208,86,224,1,RO-disease_may_have_finding,902651-FS1,"Combinations of symptoms can be of value: 2 or more symptoms from the triad of HEADACHE palpitations, and diaphoresis were present in the majority of pheochromocytoma patients, but in a smaller number of non PHEOCHROMOCYTOMA patients.",HEADACHE,PHEOCHROMOCYTOMA
502832758,7/13/2014 20:17:18,,1322103832,7/13/2014 20:16:55,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],smaller number,Na,79,208,86,224,1,RO-disease_may_have_finding,902651-FS1,"Combinations of symptoms can be of value: 2 or more symptoms from the triad of HEADACHE palpitations, and diaphoresis were present in the majority of pheochromocytoma patients, but in a smaller number of non PHEOCHROMOCYTOMA patients.",HEADACHE,PHEOCHROMOCYTOMA
502832758,7/13/2014 20:37:51,,1322121286,7/13/2014 20:36:25,elite,1.0,28397222,GBR,"","",31.49.231.211,[SYMPTOM],[SYMPTOM],symptoms from,N/A,79,208,86,224,1,RO-disease_may_have_finding,902651-FS1,"Combinations of symptoms can be of value: 2 or more symptoms from the triad of HEADACHE palpitations, and diaphoresis were present in the majority of pheochromocytoma patients, but in a smaller number of non PHEOCHROMOCYTOMA patients.",HEADACHE,PHEOCHROMOCYTOMA
502832758,7/13/2014 20:50:13,,1322131752,7/13/2014 20:49:51,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[SYMPTOM],[SYMPTOM],symptoms,n/a,79,208,86,224,1,RO-disease_may_have_finding,902651-FS1,"Combinations of symptoms can be of value: 2 or more symptoms from the triad of HEADACHE palpitations, and diaphoresis were present in the majority of pheochromocytoma patients, but in a smaller number of non PHEOCHROMOCYTOMA patients.",HEADACHE,PHEOCHROMOCYTOMA
502832758,7/13/2014 21:06:25,,1322145586,7/13/2014 21:05:50,clixsense,1.0,26649250,GBR,B7,Bristol,79.71.125.97,[ASSOCIATED_WITH],[ASSOCIATED_WITH],present in patients.,n/a,79,208,86,224,1,RO-disease_may_have_finding,902651-FS1,"Combinations of symptoms can be of value: 2 or more symptoms from the triad of HEADACHE palpitations, and diaphoresis were present in the majority of pheochromocytoma patients, but in a smaller number of non PHEOCHROMOCYTOMA patients.",HEADACHE,PHEOCHROMOCYTOMA
502832758,7/13/2014 21:43:27,,1322175132,7/13/2014 21:43:06,instagc,1.0,28301350,GBR,K4,Plymouth,89.242.63.62,[CAUSES],[CAUSES],were present,N/A,79,208,86,224,1,RO-disease_may_have_finding,902651-FS1,"Combinations of symptoms can be of value: 2 or more symptoms from the triad of HEADACHE palpitations, and diaphoresis were present in the majority of pheochromocytoma patients, but in a smaller number of non PHEOCHROMOCYTOMA patients.",HEADACHE,PHEOCHROMOCYTOMA
502832759,7/13/2014 18:47:34,,1322048337,7/13/2014 18:47:20,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[OTHER],[OTHER],and,Na,138,101,166,106,-1,RO-has_definitional_manifestation,904558-FS1,"All 6 had dual atrioventricular (AV) nodal pathway physiology, 4 had AV nodal reentrant tachycardia (AVNRT) induced, 1 had both AVNRT and RECIPROCATING AV TACHYCARDIAS and 1 had nonsustained AVNRT and an atrial tachycardia induced.",RECIPROCATING AV TACHYCARDIAS,AVNRT
502832759,7/13/2014 18:50:47,,1322049759,7/13/2014 18:50:33,neodev,1.0,18517457,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/a,138,101,166,106,-1,RO-has_definitional_manifestation,904558-FS1,"All 6 had dual atrioventricular (AV) nodal pathway physiology, 4 had AV nodal reentrant tachycardia (AVNRT) induced, 1 had both AVNRT and RECIPROCATING AV TACHYCARDIAS and 1 had nonsustained AVNRT and an atrial tachycardia induced.",RECIPROCATING AV TACHYCARDIAS,AVNRT
502832759,7/13/2014 18:53:05,,1322050903,7/13/2014 18:52:31,clixsense,1.0,19803139,NLD,11,Leiden,82.139.76.131,[OTHER],[OTHER],had nonsustained,N/A,138,101,166,106,-1,RO-has_definitional_manifestation,904558-FS1,"All 6 had dual atrioventricular (AV) nodal pathway physiology, 4 had AV nodal reentrant tachycardia (AVNRT) induced, 1 had both AVNRT and RECIPROCATING AV TACHYCARDIAS and 1 had nonsustained AVNRT and an atrial tachycardia induced.",RECIPROCATING AV TACHYCARDIAS,AVNRT
502832759,7/13/2014 19:02:42,,1322055289,7/13/2014 19:02:36,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[SYMPTOM],[SYMPTOM],pathway,da,138,101,166,106,-1,RO-has_definitional_manifestation,904558-FS1,"All 6 had dual atrioventricular (AV) nodal pathway physiology, 4 had AV nodal reentrant tachycardia (AVNRT) induced, 1 had both AVNRT and RECIPROCATING AV TACHYCARDIAS and 1 had nonsustained AVNRT and an atrial tachycardia induced.",RECIPROCATING AV TACHYCARDIAS,AVNRT
502832759,7/13/2014 19:04:25,,1322056092,7/13/2014 19:04:09,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],atrial,N/A,138,101,166,106,-1,RO-has_definitional_manifestation,904558-FS1,"All 6 had dual atrioventricular (AV) nodal pathway physiology, 4 had AV nodal reentrant tachycardia (AVNRT) induced, 1 had both AVNRT and RECIPROCATING AV TACHYCARDIAS and 1 had nonsustained AVNRT and an atrial tachycardia induced.",RECIPROCATING AV TACHYCARDIAS,AVNRT
502832759,7/13/2014 19:21:35,,1322063132,7/13/2014 19:20:50,instagc,1.0,19686223,CAN,BC,Surrey,154.20.155.106,[PART_OF],[PART_OF],"All 6 had dual atrioventricular (AV) nodal pathway physiology,",N/A,138,101,166,106,-1,RO-has_definitional_manifestation,904558-FS1,"All 6 had dual atrioventricular (AV) nodal pathway physiology, 4 had AV nodal reentrant tachycardia (AVNRT) induced, 1 had both AVNRT and RECIPROCATING AV TACHYCARDIAS and 1 had nonsustained AVNRT and an atrial tachycardia induced.",RECIPROCATING AV TACHYCARDIAS,AVNRT
502832759,7/13/2014 19:25:44,,1322064686,7/13/2014 19:25:25,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,138,101,166,106,-1,RO-has_definitional_manifestation,904558-FS1,"All 6 had dual atrioventricular (AV) nodal pathway physiology, 4 had AV nodal reentrant tachycardia (AVNRT) induced, 1 had both AVNRT and RECIPROCATING AV TACHYCARDIAS and 1 had nonsustained AVNRT and an atrial tachycardia induced.",RECIPROCATING AV TACHYCARDIAS,AVNRT
502832759,7/13/2014 19:27:04,,1322065200,7/13/2014 19:26:36,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]","induced,",[DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH],138,101,166,106,-1,RO-has_definitional_manifestation,904558-FS1,"All 6 had dual atrioventricular (AV) nodal pathway physiology, 4 had AV nodal reentrant tachycardia (AVNRT) induced, 1 had both AVNRT and RECIPROCATING AV TACHYCARDIAS and 1 had nonsustained AVNRT and an atrial tachycardia induced.",RECIPROCATING AV TACHYCARDIAS,AVNRT
502832759,7/13/2014 19:50:52,,1322077762,7/13/2014 19:50:14,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],AVNRT RECIPROCATING AV TACHYCARDIAS,n/a,138,101,166,106,-1,RO-has_definitional_manifestation,904558-FS1,"All 6 had dual atrioventricular (AV) nodal pathway physiology, 4 had AV nodal reentrant tachycardia (AVNRT) induced, 1 had both AVNRT and RECIPROCATING AV TACHYCARDIAS and 1 had nonsustained AVNRT and an atrial tachycardia induced.",RECIPROCATING AV TACHYCARDIAS,AVNRT
502832759,7/13/2014 20:01:39,,1322089426,7/13/2014 20:01:09,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],had both,n/a,138,101,166,106,-1,RO-has_definitional_manifestation,904558-FS1,"All 6 had dual atrioventricular (AV) nodal pathway physiology, 4 had AV nodal reentrant tachycardia (AVNRT) induced, 1 had both AVNRT and RECIPROCATING AV TACHYCARDIAS and 1 had nonsustained AVNRT and an atrial tachycardia induced.",RECIPROCATING AV TACHYCARDIAS,AVNRT
502832759,7/13/2014 20:08:23,,1322096071,7/13/2014 20:08:05,elite,1.0,28503042,USA,OK,Oakwood,64.250.220.169,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,138,101,166,106,-1,RO-has_definitional_manifestation,904558-FS1,"All 6 had dual atrioventricular (AV) nodal pathway physiology, 4 had AV nodal reentrant tachycardia (AVNRT) induced, 1 had both AVNRT and RECIPROCATING AV TACHYCARDIAS and 1 had nonsustained AVNRT and an atrial tachycardia induced.",RECIPROCATING AV TACHYCARDIAS,AVNRT
502832759,7/13/2014 20:11:12,,1322098461,7/13/2014 20:10:11,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,138,101,166,106,-1,RO-has_definitional_manifestation,904558-FS1,"All 6 had dual atrioventricular (AV) nodal pathway physiology, 4 had AV nodal reentrant tachycardia (AVNRT) induced, 1 had both AVNRT and RECIPROCATING AV TACHYCARDIAS and 1 had nonsustained AVNRT and an atrial tachycardia induced.",RECIPROCATING AV TACHYCARDIAS,AVNRT
502832759,7/13/2014 20:33:07,,1322117436,7/13/2014 20:32:45,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],AVNRT and RECIPROCATING AV TACHYCARDIAS,N/A,138,101,166,106,-1,RO-has_definitional_manifestation,904558-FS1,"All 6 had dual atrioventricular (AV) nodal pathway physiology, 4 had AV nodal reentrant tachycardia (AVNRT) induced, 1 had both AVNRT and RECIPROCATING AV TACHYCARDIAS and 1 had nonsustained AVNRT and an atrial tachycardia induced.",RECIPROCATING AV TACHYCARDIAS,AVNRT
502832759,7/13/2014 20:59:08,,1322139667,7/13/2014 20:58:27,clixsense,1.0,26649250,GBR,B7,Bristol,79.71.125.97,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,138,101,166,106,-1,RO-has_definitional_manifestation,904558-FS1,"All 6 had dual atrioventricular (AV) nodal pathway physiology, 4 had AV nodal reentrant tachycardia (AVNRT) induced, 1 had both AVNRT and RECIPROCATING AV TACHYCARDIAS and 1 had nonsustained AVNRT and an atrial tachycardia induced.",RECIPROCATING AV TACHYCARDIAS,AVNRT
502832759,7/13/2014 21:42:31,,1322174370,7/13/2014 21:42:10,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],AVNRT RECIPROCATING AV TACHYCARDIAS,N/A,138,101,166,106,-1,RO-has_definitional_manifestation,904558-FS1,"All 6 had dual atrioventricular (AV) nodal pathway physiology, 4 had AV nodal reentrant tachycardia (AVNRT) induced, 1 had both AVNRT and RECIPROCATING AV TACHYCARDIAS and 1 had nonsustained AVNRT and an atrial tachycardia induced.",RECIPROCATING AV TACHYCARDIAS,AVNRT
502832760,7/13/2014 18:46:29,,1322047774,7/13/2014 18:46:02,neodev,1.0,18517457,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],clinical suspicion of,N/a,151,64,166,67,-1,RO-has_manifestation,906417-FS1,"Antinuclear antibody  Order when there is clinical suspicion of SLE (or unexplained serositis, glomerulonephritis, alveolar hemorrhage, leukopenia, or THROMBOCYTOPENIA not as a general screening test for sick patients; negative test makes SLE unlikely ANCA  Order when there is clinical suspicion of WG or MPA or drug induced vasculitis; test should be performed by both IF and ELISA Drug screen  Order for unexplained CNS symptoms, myocardial ischemia, vascular spasm, panic attacks with systemic features, tachycardia, nasal perforation; urine screen should be done Blood cultures  Useful.",THROMBOCYTOPENIA,SLE
502832760,7/13/2014 18:54:46,,1322051649,7/13/2014 18:53:34,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[NONE],[NONE],N/A,No clear relationship.,151,64,166,67,-1,RO-has_manifestation,906417-FS1,"Antinuclear antibody  Order when there is clinical suspicion of SLE (or unexplained serositis, glomerulonephritis, alveolar hemorrhage, leukopenia, or THROMBOCYTOPENIA not as a general screening test for sick patients; negative test makes SLE unlikely ANCA  Order when there is clinical suspicion of WG or MPA or drug induced vasculitis; test should be performed by both IF and ELISA Drug screen  Order for unexplained CNS symptoms, myocardial ischemia, vascular spasm, panic attacks with systemic features, tachycardia, nasal perforation; urine screen should be done Blood cultures  Useful.",THROMBOCYTOPENIA,SLE
502832760,7/13/2014 19:03:49,,1322055823,7/13/2014 19:02:38,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[ASSOCIATED_WITH],[ASSOCIATED_WITH],suspicion of SLE or THROMBOCYTOPENIA,n/a,151,64,166,67,-1,RO-has_manifestation,906417-FS1,"Antinuclear antibody  Order when there is clinical suspicion of SLE (or unexplained serositis, glomerulonephritis, alveolar hemorrhage, leukopenia, or THROMBOCYTOPENIA not as a general screening test for sick patients; negative test makes SLE unlikely ANCA  Order when there is clinical suspicion of WG or MPA or drug induced vasculitis; test should be performed by both IF and ELISA Drug screen  Order for unexplained CNS symptoms, myocardial ischemia, vascular spasm, panic attacks with systemic features, tachycardia, nasal perforation; urine screen should be done Blood cultures  Useful.",THROMBOCYTOPENIA,SLE
502832760,7/13/2014 19:05:52,,1322056665,7/13/2014 19:05:33,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],"tachycardia,",N/A,151,64,166,67,-1,RO-has_manifestation,906417-FS1,"Antinuclear antibody  Order when there is clinical suspicion of SLE (or unexplained serositis, glomerulonephritis, alveolar hemorrhage, leukopenia, or THROMBOCYTOPENIA not as a general screening test for sick patients; negative test makes SLE unlikely ANCA  Order when there is clinical suspicion of WG or MPA or drug induced vasculitis; test should be performed by both IF and ELISA Drug screen  Order for unexplained CNS symptoms, myocardial ischemia, vascular spasm, panic attacks with systemic features, tachycardia, nasal perforation; urine screen should be done Blood cultures  Useful.",THROMBOCYTOPENIA,SLE
502832760,7/13/2014 19:40:11,,1322069959,7/13/2014 19:39:20,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],suspicion of SLE or THROMBOCYTOPENIA,N/A,151,64,166,67,-1,RO-has_manifestation,906417-FS1,"Antinuclear antibody  Order when there is clinical suspicion of SLE (or unexplained serositis, glomerulonephritis, alveolar hemorrhage, leukopenia, or THROMBOCYTOPENIA not as a general screening test for sick patients; negative test makes SLE unlikely ANCA  Order when there is clinical suspicion of WG or MPA or drug induced vasculitis; test should be performed by both IF and ELISA Drug screen  Order for unexplained CNS symptoms, myocardial ischemia, vascular spasm, panic attacks with systemic features, tachycardia, nasal perforation; urine screen should be done Blood cultures  Useful.",THROMBOCYTOPENIA,SLE
502832760,7/13/2014 19:56:48,,1322083541,7/13/2014 19:55:24,clixsense,1.0,6365250,CAN,BC,Burnaby,70.79.16.165,[IS_A] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[IS_A]","clinical suspicion SLE (or unexplained serositis, glomerulonephritis, alveolar hemorrhage, leukopenia, THROMBOCYTOPENIA",is a/ associated with,151,64,166,67,-1,RO-has_manifestation,906417-FS1,"Antinuclear antibody  Order when there is clinical suspicion of SLE (or unexplained serositis, glomerulonephritis, alveolar hemorrhage, leukopenia, or THROMBOCYTOPENIA not as a general screening test for sick patients; negative test makes SLE unlikely ANCA  Order when there is clinical suspicion of WG or MPA or drug induced vasculitis; test should be performed by both IF and ELISA Drug screen  Order for unexplained CNS symptoms, myocardial ischemia, vascular spasm, panic attacks with systemic features, tachycardia, nasal perforation; urine screen should be done Blood cultures  Useful.",THROMBOCYTOPENIA,SLE
502832760,7/13/2014 20:16:32,,1322103054,7/13/2014 20:15:45,elite,1.0,28503042,USA,OK,Oakwood,64.250.220.169,[PART_OF],[PART_OF],SLE or THROMBOCYTOPENIA,N/A,151,64,166,67,-1,RO-has_manifestation,906417-FS1,"Antinuclear antibody  Order when there is clinical suspicion of SLE (or unexplained serositis, glomerulonephritis, alveolar hemorrhage, leukopenia, or THROMBOCYTOPENIA not as a general screening test for sick patients; negative test makes SLE unlikely ANCA  Order when there is clinical suspicion of WG or MPA or drug induced vasculitis; test should be performed by both IF and ELISA Drug screen  Order for unexplained CNS symptoms, myocardial ischemia, vascular spasm, panic attacks with systemic features, tachycardia, nasal perforation; urine screen should be done Blood cultures  Useful.",THROMBOCYTOPENIA,SLE
502832760,7/13/2014 20:18:15,,1322104615,7/13/2014 20:17:51,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[IS_A],[IS_A],or,N/A,151,64,166,67,-1,RO-has_manifestation,906417-FS1,"Antinuclear antibody  Order when there is clinical suspicion of SLE (or unexplained serositis, glomerulonephritis, alveolar hemorrhage, leukopenia, or THROMBOCYTOPENIA not as a general screening test for sick patients; negative test makes SLE unlikely ANCA  Order when there is clinical suspicion of WG or MPA or drug induced vasculitis; test should be performed by both IF and ELISA Drug screen  Order for unexplained CNS symptoms, myocardial ischemia, vascular spasm, panic attacks with systemic features, tachycardia, nasal perforation; urine screen should be done Blood cultures  Useful.",THROMBOCYTOPENIA,SLE
502832760,7/13/2014 20:21:58,,1322107947,7/13/2014 20:21:40,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],negative test,Na,151,64,166,67,-1,RO-has_manifestation,906417-FS1,"Antinuclear antibody  Order when there is clinical suspicion of SLE (or unexplained serositis, glomerulonephritis, alveolar hemorrhage, leukopenia, or THROMBOCYTOPENIA not as a general screening test for sick patients; negative test makes SLE unlikely ANCA  Order when there is clinical suspicion of WG or MPA or drug induced vasculitis; test should be performed by both IF and ELISA Drug screen  Order for unexplained CNS symptoms, myocardial ischemia, vascular spasm, panic attacks with systemic features, tachycardia, nasal perforation; urine screen should be done Blood cultures  Useful.",THROMBOCYTOPENIA,SLE
502832760,7/13/2014 20:32:43,,1322117111,7/13/2014 20:32:07,gifthulk,1.0,21916793,GBR,"","",87.113.87.199,[CONTRAINDICATES],[CONTRAINDICATES],negative test makes SLE unlikely,N/A,151,64,166,67,-1,RO-has_manifestation,906417-FS1,"Antinuclear antibody  Order when there is clinical suspicion of SLE (or unexplained serositis, glomerulonephritis, alveolar hemorrhage, leukopenia, or THROMBOCYTOPENIA not as a general screening test for sick patients; negative test makes SLE unlikely ANCA  Order when there is clinical suspicion of WG or MPA or drug induced vasculitis; test should be performed by both IF and ELISA Drug screen  Order for unexplained CNS symptoms, myocardial ischemia, vascular spasm, panic attacks with systemic features, tachycardia, nasal perforation; urine screen should be done Blood cultures  Useful.",THROMBOCYTOPENIA,SLE
502832760,7/13/2014 20:53:08,,1322134111,7/13/2014 20:52:34,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[IS_A],[IS_A],or,n/a,151,64,166,67,-1,RO-has_manifestation,906417-FS1,"Antinuclear antibody  Order when there is clinical suspicion of SLE (or unexplained serositis, glomerulonephritis, alveolar hemorrhage, leukopenia, or THROMBOCYTOPENIA not as a general screening test for sick patients; negative test makes SLE unlikely ANCA  Order when there is clinical suspicion of WG or MPA or drug induced vasculitis; test should be performed by both IF and ELISA Drug screen  Order for unexplained CNS symptoms, myocardial ischemia, vascular spasm, panic attacks with systemic features, tachycardia, nasal perforation; urine screen should be done Blood cultures  Useful.",THROMBOCYTOPENIA,SLE
502832760,7/13/2014 21:10:20,,1322149215,7/13/2014 21:09:43,clixsense,1.0,26649250,GBR,B7,Bristol,79.71.125.97,[ASSOCIATED_WITH],[ASSOCIATED_WITH],(or,n/a,151,64,166,67,-1,RO-has_manifestation,906417-FS1,"Antinuclear antibody  Order when there is clinical suspicion of SLE (or unexplained serositis, glomerulonephritis, alveolar hemorrhage, leukopenia, or THROMBOCYTOPENIA not as a general screening test for sick patients; negative test makes SLE unlikely ANCA  Order when there is clinical suspicion of WG or MPA or drug induced vasculitis; test should be performed by both IF and ELISA Drug screen  Order for unexplained CNS symptoms, myocardial ischemia, vascular spasm, panic attacks with systemic features, tachycardia, nasal perforation; urine screen should be done Blood cultures  Useful.",THROMBOCYTOPENIA,SLE
502832760,7/13/2014 21:34:12,,1322168480,7/13/2014 21:31:30,elite,1.0,28397222,GBR,"","",31.49.231.211,[OTHER],[OTHER],(or,The two are associated by being tested by Antinuclear antibody Order where either is indicated,151,64,166,67,-1,RO-has_manifestation,906417-FS1,"Antinuclear antibody  Order when there is clinical suspicion of SLE (or unexplained serositis, glomerulonephritis, alveolar hemorrhage, leukopenia, or THROMBOCYTOPENIA not as a general screening test for sick patients; negative test makes SLE unlikely ANCA  Order when there is clinical suspicion of WG or MPA or drug induced vasculitis; test should be performed by both IF and ELISA Drug screen  Order for unexplained CNS symptoms, myocardial ischemia, vascular spasm, panic attacks with systemic features, tachycardia, nasal perforation; urine screen should be done Blood cultures  Useful.",THROMBOCYTOPENIA,SLE
502832760,7/13/2014 21:41:00,,1322173150,7/13/2014 21:40:30,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[PART_OF],[PART_OF],"(or unexplained serositis, glomerulonephritis, alveolar hemorrhage, leukopenia, or THROMBOCYTOPENIA",N/A,151,64,166,67,-1,RO-has_manifestation,906417-FS1,"Antinuclear antibody  Order when there is clinical suspicion of SLE (or unexplained serositis, glomerulonephritis, alveolar hemorrhage, leukopenia, or THROMBOCYTOPENIA not as a general screening test for sick patients; negative test makes SLE unlikely ANCA  Order when there is clinical suspicion of WG or MPA or drug induced vasculitis; test should be performed by both IF and ELISA Drug screen  Order for unexplained CNS symptoms, myocardial ischemia, vascular spasm, panic attacks with systemic features, tachycardia, nasal perforation; urine screen should be done Blood cultures  Useful.",THROMBOCYTOPENIA,SLE
502832760,7/13/2014 21:42:49,,1322174638,7/13/2014 21:42:31,instagc,1.0,28301350,GBR,K4,Plymouth,89.242.63.62,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,N/A,151,64,166,67,-1,RO-has_manifestation,906417-FS1,"Antinuclear antibody  Order when there is clinical suspicion of SLE (or unexplained serositis, glomerulonephritis, alveolar hemorrhage, leukopenia, or THROMBOCYTOPENIA not as a general screening test for sick patients; negative test makes SLE unlikely ANCA  Order when there is clinical suspicion of WG or MPA or drug induced vasculitis; test should be performed by both IF and ELISA Drug screen  Order for unexplained CNS symptoms, myocardial ischemia, vascular spasm, panic attacks with systemic features, tachycardia, nasal perforation; urine screen should be done Blood cultures  Useful.",THROMBOCYTOPENIA,SLE
502832761,7/13/2014 18:44:02,,1322046595,7/13/2014 18:43:41,clixsense,1.0,19803139,NLD,11,Leiden,82.139.76.131,[LOCATION],[LOCATION],acquired from,N/A,43,89,64,103,-1,RO-has_causative_agent,903988-FS1,"Knowledge of the physiological function of CELLULAR PRION PROTEIN has been acquired from PRION DISEASES such as Creutzfeldt Jakob disease, as well as PRNP knock out and transgenic mice.",CELLULAR PRION PROTEIN,PRION DISEASES
502832761,7/13/2014 18:54:19,,1322051433,7/13/2014 18:53:53,neodev,1.0,18517457,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Knowledge of,N/a,43,89,64,103,-1,RO-has_causative_agent,903988-FS1,"Knowledge of the physiological function of CELLULAR PRION PROTEIN has been acquired from PRION DISEASES such as Creutzfeldt Jakob disease, as well as PRNP knock out and transgenic mice.",CELLULAR PRION PROTEIN,PRION DISEASES
502832761,7/13/2014 18:59:05,,1322053719,7/13/2014 18:56:56,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],acquired,N/A,43,89,64,103,-1,RO-has_causative_agent,903988-FS1,"Knowledge of the physiological function of CELLULAR PRION PROTEIN has been acquired from PRION DISEASES such as Creutzfeldt Jakob disease, as well as PRNP knock out and transgenic mice.",CELLULAR PRION PROTEIN,PRION DISEASES
502832761,7/13/2014 19:02:09,,1322055047,7/13/2014 19:02:01,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],physiological,da,43,89,64,103,-1,RO-has_causative_agent,903988-FS1,"Knowledge of the physiological function of CELLULAR PRION PROTEIN has been acquired from PRION DISEASES such as Creutzfeldt Jakob disease, as well as PRNP knock out and transgenic mice.",CELLULAR PRION PROTEIN,PRION DISEASES
502832761,7/13/2014 19:10:39,,1322058822,7/13/2014 19:09:33,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],has acquired,N/A,43,89,64,103,-1,RO-has_causative_agent,903988-FS1,"Knowledge of the physiological function of CELLULAR PRION PROTEIN has been acquired from PRION DISEASES such as Creutzfeldt Jakob disease, as well as PRNP knock out and transgenic mice.",CELLULAR PRION PROTEIN,PRION DISEASES
502832761,7/13/2014 19:10:53,,1322058892,7/13/2014 19:10:04,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],been acquired,na,43,89,64,103,-1,RO-has_causative_agent,903988-FS1,"Knowledge of the physiological function of CELLULAR PRION PROTEIN has been acquired from PRION DISEASES such as Creutzfeldt Jakob disease, as well as PRNP knock out and transgenic mice.",CELLULAR PRION PROTEIN,PRION DISEASES
502832761,7/13/2014 19:12:20,,1322059551,7/13/2014 19:11:12,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[LOCATION],[LOCATION],PRION,N/A,43,89,64,103,-1,RO-has_causative_agent,903988-FS1,"Knowledge of the physiological function of CELLULAR PRION PROTEIN has been acquired from PRION DISEASES such as Creutzfeldt Jakob disease, as well as PRNP knock out and transgenic mice.",CELLULAR PRION PROTEIN,PRION DISEASES
502832761,7/13/2014 19:13:46,,1322060100,7/13/2014 19:12:44,instagc,1.0,19686223,CAN,BC,Surrey,154.20.155.106,[OTHER],[OTHER],Knowledge of physiological function of CELLULAR PRION PROTEIN has been acquired from PRION DISEASES,N/A,43,89,64,103,-1,RO-has_causative_agent,903988-FS1,"Knowledge of the physiological function of CELLULAR PRION PROTEIN has been acquired from PRION DISEASES such as Creutzfeldt Jakob disease, as well as PRNP knock out and transgenic mice.",CELLULAR PRION PROTEIN,PRION DISEASES
502832761,7/13/2014 19:15:34,,1322060782,7/13/2014 19:14:41,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],physiological function acquired from,N/A,43,89,64,103,-1,RO-has_causative_agent,903988-FS1,"Knowledge of the physiological function of CELLULAR PRION PROTEIN has been acquired from PRION DISEASES such as Creutzfeldt Jakob disease, as well as PRNP knock out and transgenic mice.",CELLULAR PRION PROTEIN,PRION DISEASES
502832761,7/13/2014 19:20:18,,1322062735,7/13/2014 19:19:43,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[TREATS],[TREATS],function of CELLULAR PRION PROTEIN has been acquired from PRION DISEASES,n/a,43,89,64,103,-1,RO-has_causative_agent,903988-FS1,"Knowledge of the physiological function of CELLULAR PRION PROTEIN has been acquired from PRION DISEASES such as Creutzfeldt Jakob disease, as well as PRNP knock out and transgenic mice.",CELLULAR PRION PROTEIN,PRION DISEASES
502832761,7/13/2014 19:29:20,,1322066037,7/13/2014 19:28:53,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],has been acquired,[DIAGNOSE_BY_TEST_OR_DRUG],43,89,64,103,-1,RO-has_causative_agent,903988-FS1,"Knowledge of the physiological function of CELLULAR PRION PROTEIN has been acquired from PRION DISEASES such as Creutzfeldt Jakob disease, as well as PRNP knock out and transgenic mice.",CELLULAR PRION PROTEIN,PRION DISEASES
502832761,7/13/2014 19:33:09,,1322067324,7/13/2014 19:32:37,instagc,1.0,13763729,USA,"","",75.182.89.225,[PART_OF],[PART_OF],has been acquired from,N/A,43,89,64,103,-1,RO-has_causative_agent,903988-FS1,"Knowledge of the physiological function of CELLULAR PRION PROTEIN has been acquired from PRION DISEASES such as Creutzfeldt Jakob disease, as well as PRNP knock out and transgenic mice.",CELLULAR PRION PROTEIN,PRION DISEASES
502832761,7/13/2014 19:45:00,,1322073165,7/13/2014 19:44:26,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CELLULAR PRION PROTEIN PRION DISEASES,n/a,43,89,64,103,-1,RO-has_causative_agent,903988-FS1,"Knowledge of the physiological function of CELLULAR PRION PROTEIN has been acquired from PRION DISEASES such as Creutzfeldt Jakob disease, as well as PRNP knock out and transgenic mice.",CELLULAR PRION PROTEIN,PRION DISEASES
502832761,7/13/2014 20:00:29,,1322088079,7/13/2014 19:59:12,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[SYMPTOM],[SYMPTOM],acquired,n/a,43,89,64,103,-1,RO-has_causative_agent,903988-FS1,"Knowledge of the physiological function of CELLULAR PRION PROTEIN has been acquired from PRION DISEASES such as Creutzfeldt Jakob disease, as well as PRNP knock out and transgenic mice.",CELLULAR PRION PROTEIN,PRION DISEASES
502832761,7/13/2014 20:15:50,,1322102537,7/13/2014 20:15:27,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Knowledge,Na,43,89,64,103,-1,RO-has_causative_agent,903988-FS1,"Knowledge of the physiological function of CELLULAR PRION PROTEIN has been acquired from PRION DISEASES such as Creutzfeldt Jakob disease, as well as PRNP knock out and transgenic mice.",CELLULAR PRION PROTEIN,PRION DISEASES
502832762,7/13/2014 18:42:29,,1322045693,7/13/2014 18:42:13,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SIDE_EFFECT],[SIDE_EFFECT],opposed,Na,185,208,199,226,-1,RO-cause_of,900437-FS1,"In our population CPI does not associate directly with asthma and allergy, but chronic or recurrent infection is associated with allergic asthma and inhalative allergy as opposed to nonALLERGIC ASTHMA and nonINHALATIVE ALLERGY.",ALLERGIC ASTHMA,INHALATIVE ALLERGY
502832762,7/13/2014 18:47:07,,1322048119,7/13/2014 18:46:40,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,185,208,199,226,-1,RO-cause_of,900437-FS1,"In our population CPI does not associate directly with asthma and allergy, but chronic or recurrent infection is associated with allergic asthma and inhalative allergy as opposed to nonALLERGIC ASTHMA and nonINHALATIVE ALLERGY.",ALLERGIC ASTHMA,INHALATIVE ALLERGY
502832762,7/13/2014 19:07:00,,1322057195,7/13/2014 19:06:52,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],"allergy,",N/A,185,208,199,226,-1,RO-cause_of,900437-FS1,"In our population CPI does not associate directly with asthma and allergy, but chronic or recurrent infection is associated with allergic asthma and inhalative allergy as opposed to nonALLERGIC ASTHMA and nonINHALATIVE ALLERGY.",ALLERGIC ASTHMA,INHALATIVE ALLERGY
502832762,7/13/2014 19:07:42,,1322057535,7/13/2014 19:07:19,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associate with,N/A,185,208,199,226,-1,RO-cause_of,900437-FS1,"In our population CPI does not associate directly with asthma and allergy, but chronic or recurrent infection is associated with allergic asthma and inhalative allergy as opposed to nonALLERGIC ASTHMA and nonINHALATIVE ALLERGY.",ALLERGIC ASTHMA,INHALATIVE ALLERGY
502832762,7/13/2014 19:11:09,,1322059022,7/13/2014 19:09:51,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[OTHER],[OTHER],nonINHALATIVE,N/A,185,208,199,226,-1,RO-cause_of,900437-FS1,"In our population CPI does not associate directly with asthma and allergy, but chronic or recurrent infection is associated with allergic asthma and inhalative allergy as opposed to nonALLERGIC ASTHMA and nonINHALATIVE ALLERGY.",ALLERGIC ASTHMA,INHALATIVE ALLERGY
502832762,7/13/2014 19:11:49,,1322059300,7/13/2014 19:11:13,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],and,N/A,185,208,199,226,-1,RO-cause_of,900437-FS1,"In our population CPI does not associate directly with asthma and allergy, but chronic or recurrent infection is associated with allergic asthma and inhalative allergy as opposed to nonALLERGIC ASTHMA and nonINHALATIVE ALLERGY.",ALLERGIC ASTHMA,INHALATIVE ALLERGY
502832762,7/13/2014 19:20:49,,1322062880,7/13/2014 19:19:56,instagc,1.0,19686223,CAN,BC,Surrey,154.20.155.106,[ASSOCIATED_WITH],[ASSOCIATED_WITH],chronic or recurrent infection is associated with allergic asthma and inhalative allergy as opposed to nonALLERGIC ASTHMA and nonINHALATIVE ALLERGY.,N/A,185,208,199,226,-1,RO-cause_of,900437-FS1,"In our population CPI does not associate directly with asthma and allergy, but chronic or recurrent infection is associated with allergic asthma and inhalative allergy as opposed to nonALLERGIC ASTHMA and nonINHALATIVE ALLERGY.",ALLERGIC ASTHMA,INHALATIVE ALLERGY
502832762,7/13/2014 19:20:52,,1322062902,7/13/2014 19:20:20,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[ASSOCIATED_WITH],[ASSOCIATED_WITH],nonALLERGIC ASTHMA and nonINHALATIVE ALLERGY.,n/a,185,208,199,226,-1,RO-cause_of,900437-FS1,"In our population CPI does not associate directly with asthma and allergy, but chronic or recurrent infection is associated with allergic asthma and inhalative allergy as opposed to nonALLERGIC ASTHMA and nonINHALATIVE ALLERGY.",ALLERGIC ASTHMA,INHALATIVE ALLERGY
502832762,7/13/2014 19:27:54,,1322065495,7/13/2014 19:27:31,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,n/a,185,208,199,226,-1,RO-cause_of,900437-FS1,"In our population CPI does not associate directly with asthma and allergy, but chronic or recurrent infection is associated with allergic asthma and inhalative allergy as opposed to nonALLERGIC ASTHMA and nonINHALATIVE ALLERGY.",ALLERGIC ASTHMA,INHALATIVE ALLERGY
502832762,7/13/2014 19:31:28,,1322066732,7/13/2014 19:30:39,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with allergic asthma inhalative allergy,N/A,185,208,199,226,-1,RO-cause_of,900437-FS1,"In our population CPI does not associate directly with asthma and allergy, but chronic or recurrent infection is associated with allergic asthma and inhalative allergy as opposed to nonALLERGIC ASTHMA and nonINHALATIVE ALLERGY.",ALLERGIC ASTHMA,INHALATIVE ALLERGY
502832762,7/13/2014 19:33:41,,1322067480,7/13/2014 19:33:03,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,na,185,208,199,226,-1,RO-cause_of,900437-FS1,"In our population CPI does not associate directly with asthma and allergy, but chronic or recurrent infection is associated with allergic asthma and inhalative allergy as opposed to nonALLERGIC ASTHMA and nonINHALATIVE ALLERGY.",ALLERGIC ASTHMA,INHALATIVE ALLERGY
502832762,7/13/2014 19:35:23,,1322068104,7/13/2014 19:34:58,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,[ASSOCIATED_WITH],185,208,199,226,-1,RO-cause_of,900437-FS1,"In our population CPI does not associate directly with asthma and allergy, but chronic or recurrent infection is associated with allergic asthma and inhalative allergy as opposed to nonALLERGIC ASTHMA and nonINHALATIVE ALLERGY.",ALLERGIC ASTHMA,INHALATIVE ALLERGY
502832762,7/13/2014 19:43:39,,1322072056,7/13/2014 19:43:04,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],nonALLERGIC ASTHMA nonINHALATIVE ALLERGY.,n/a,185,208,199,226,-1,RO-cause_of,900437-FS1,"In our population CPI does not associate directly with asthma and allergy, but chronic or recurrent infection is associated with allergic asthma and inhalative allergy as opposed to nonALLERGIC ASTHMA and nonINHALATIVE ALLERGY.",ALLERGIC ASTHMA,INHALATIVE ALLERGY
502832762,7/13/2014 20:09:28,,1322097001,7/13/2014 20:08:59,elite,1.0,28503042,USA,OK,Oakwood,64.250.220.169,[OTHER],[OTHER],nonALLERGIC ASTHMA and nonINHALATIVE ALLERGY.,N/A,185,208,199,226,-1,RO-cause_of,900437-FS1,"In our population CPI does not associate directly with asthma and allergy, but chronic or recurrent infection is associated with allergic asthma and inhalative allergy as opposed to nonALLERGIC ASTHMA and nonINHALATIVE ALLERGY.",ALLERGIC ASTHMA,INHALATIVE ALLERGY
502832762,7/13/2014 20:15:37,,1322102358,7/13/2014 20:15:22,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,185,208,199,226,-1,RO-cause_of,900437-FS1,"In our population CPI does not associate directly with asthma and allergy, but chronic or recurrent infection is associated with allergic asthma and inhalative allergy as opposed to nonALLERGIC ASTHMA and nonINHALATIVE ALLERGY.",ALLERGIC ASTHMA,INHALATIVE ALLERGY
502832763,7/13/2014 18:48:45,,1322048870,7/13/2014 18:48:17,neodev,1.0,18517457,GBR,"","",86.29.147.112,[MANIFESTATION],[MANIFESTATION],are,N/a,31,0,78,26,1,RO-disease_has_finding,901845-FS1,"GRANULOCYTIC SARCOMAS (GS) are EXTRAMEDULLARY TUMOUR MASSES OF IMMATURE MYELOID cells, also known as chloroma and extramedullary myeloid cell tumour.",EXTRAMEDULLARY TUMOUR MASSES OF IMMATURE MYELOID,GRANULOCYTIC SARCOMAS (GS)
502832763,7/13/2014 18:55:44,,1322052099,7/13/2014 18:55:27,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[LOCATION],[LOCATION],are,N/A,31,0,78,26,1,RO-disease_has_finding,901845-FS1,"GRANULOCYTIC SARCOMAS (GS) are EXTRAMEDULLARY TUMOUR MASSES OF IMMATURE MYELOID cells, also known as chloroma and extramedullary myeloid cell tumour.",EXTRAMEDULLARY TUMOUR MASSES OF IMMATURE MYELOID,GRANULOCYTIC SARCOMAS (GS)
502832763,7/13/2014 19:00:31,,1322054356,7/13/2014 19:00:04,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[IS_A],[IS_A],are,N/A,31,0,78,26,1,RO-disease_has_finding,901845-FS1,"GRANULOCYTIC SARCOMAS (GS) are EXTRAMEDULLARY TUMOUR MASSES OF IMMATURE MYELOID cells, also known as chloroma and extramedullary myeloid cell tumour.",EXTRAMEDULLARY TUMOUR MASSES OF IMMATURE MYELOID,GRANULOCYTIC SARCOMAS (GS)
502832763,7/13/2014 19:19:08,,1322062256,7/13/2014 19:18:22,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],are,N/A,31,0,78,26,1,RO-disease_has_finding,901845-FS1,"GRANULOCYTIC SARCOMAS (GS) are EXTRAMEDULLARY TUMOUR MASSES OF IMMATURE MYELOID cells, also known as chloroma and extramedullary myeloid cell tumour.",EXTRAMEDULLARY TUMOUR MASSES OF IMMATURE MYELOID,GRANULOCYTIC SARCOMAS (GS)
502832763,7/13/2014 19:19:53,,1322062607,7/13/2014 19:19:39,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],are,N/A,31,0,78,26,1,RO-disease_has_finding,901845-FS1,"GRANULOCYTIC SARCOMAS (GS) are EXTRAMEDULLARY TUMOUR MASSES OF IMMATURE MYELOID cells, also known as chloroma and extramedullary myeloid cell tumour.",EXTRAMEDULLARY TUMOUR MASSES OF IMMATURE MYELOID,GRANULOCYTIC SARCOMAS (GS)
502832763,7/13/2014 19:29:50,,1322066249,7/13/2014 19:29:36,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[ASSOCIATED_WITH],[ASSOCIATED_WITH],also,n/a,31,0,78,26,1,RO-disease_has_finding,901845-FS1,"GRANULOCYTIC SARCOMAS (GS) are EXTRAMEDULLARY TUMOUR MASSES OF IMMATURE MYELOID cells, also known as chloroma and extramedullary myeloid cell tumour.",EXTRAMEDULLARY TUMOUR MASSES OF IMMATURE MYELOID,GRANULOCYTIC SARCOMAS (GS)
502832763,7/13/2014 19:56:29,,1322083179,7/13/2014 19:55:56,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],GRANULOCYTIC SARCOMAS (GS) EXTRAMEDULLARY TUMOUR MASSES OF IMMATURE MYELOID,n/a,31,0,78,26,1,RO-disease_has_finding,901845-FS1,"GRANULOCYTIC SARCOMAS (GS) are EXTRAMEDULLARY TUMOUR MASSES OF IMMATURE MYELOID cells, also known as chloroma and extramedullary myeloid cell tumour.",EXTRAMEDULLARY TUMOUR MASSES OF IMMATURE MYELOID,GRANULOCYTIC SARCOMAS (GS)
502832763,7/13/2014 20:07:20,,1322095043,7/13/2014 20:06:33,elite,1.0,28397222,GBR,"","",31.49.231.211,[IS_A],[IS_A],are,N/A,31,0,78,26,1,RO-disease_has_finding,901845-FS1,"GRANULOCYTIC SARCOMAS (GS) are EXTRAMEDULLARY TUMOUR MASSES OF IMMATURE MYELOID cells, also known as chloroma and extramedullary myeloid cell tumour.",EXTRAMEDULLARY TUMOUR MASSES OF IMMATURE MYELOID,GRANULOCYTIC SARCOMAS (GS)
502832763,7/13/2014 20:07:45,,1322095474,7/13/2014 20:06:50,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[IS_A],[IS_A],are,N/A,31,0,78,26,1,RO-disease_has_finding,901845-FS1,"GRANULOCYTIC SARCOMAS (GS) are EXTRAMEDULLARY TUMOUR MASSES OF IMMATURE MYELOID cells, also known as chloroma and extramedullary myeloid cell tumour.",EXTRAMEDULLARY TUMOUR MASSES OF IMMATURE MYELOID,GRANULOCYTIC SARCOMAS (GS)
502832763,7/13/2014 20:19:35,,1322105856,7/13/2014 20:19:13,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],are,Na,31,0,78,26,1,RO-disease_has_finding,901845-FS1,"GRANULOCYTIC SARCOMAS (GS) are EXTRAMEDULLARY TUMOUR MASSES OF IMMATURE MYELOID cells, also known as chloroma and extramedullary myeloid cell tumour.",EXTRAMEDULLARY TUMOUR MASSES OF IMMATURE MYELOID,GRANULOCYTIC SARCOMAS (GS)
502832763,7/13/2014 21:13:32,,1322151832,7/13/2014 21:13:02,clixsense,1.0,26649250,GBR,B7,Bristol,79.71.125.97,[IS_A],[IS_A],are,n/a,31,0,78,26,1,RO-disease_has_finding,901845-FS1,"GRANULOCYTIC SARCOMAS (GS) are EXTRAMEDULLARY TUMOUR MASSES OF IMMATURE MYELOID cells, also known as chloroma and extramedullary myeloid cell tumour.",EXTRAMEDULLARY TUMOUR MASSES OF IMMATURE MYELOID,GRANULOCYTIC SARCOMAS (GS)
502832763,7/13/2014 21:44:09,,1322175556,7/13/2014 21:43:58,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[IS_A],[IS_A],are,N/A,31,0,78,26,1,RO-disease_has_finding,901845-FS1,"GRANULOCYTIC SARCOMAS (GS) are EXTRAMEDULLARY TUMOUR MASSES OF IMMATURE MYELOID cells, also known as chloroma and extramedullary myeloid cell tumour.",EXTRAMEDULLARY TUMOUR MASSES OF IMMATURE MYELOID,GRANULOCYTIC SARCOMAS (GS)
502832763,7/13/2014 21:45:28,,1322176574,7/13/2014 21:45:09,instagc,1.0,28301350,GBR,K4,Plymouth,89.242.63.62,[PART_OF],[PART_OF],are,N/A,31,0,78,26,1,RO-disease_has_finding,901845-FS1,"GRANULOCYTIC SARCOMAS (GS) are EXTRAMEDULLARY TUMOUR MASSES OF IMMATURE MYELOID cells, also known as chloroma and extramedullary myeloid cell tumour.",EXTRAMEDULLARY TUMOUR MASSES OF IMMATURE MYELOID,GRANULOCYTIC SARCOMAS (GS)
502832763,7/13/2014 22:56:14,,1322237549,7/13/2014 22:55:53,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[PART_OF],[PART_OF],are,n/a,31,0,78,26,1,RO-disease_has_finding,901845-FS1,"GRANULOCYTIC SARCOMAS (GS) are EXTRAMEDULLARY TUMOUR MASSES OF IMMATURE MYELOID cells, also known as chloroma and extramedullary myeloid cell tumour.",EXTRAMEDULLARY TUMOUR MASSES OF IMMATURE MYELOID,GRANULOCYTIC SARCOMAS (GS)
502832763,7/13/2014 23:04:42,,1322245401,7/13/2014 23:03:36,prizerebel,1,16316481,CAN,ON,Toronto,99.244.116.246,[ASSOCIATED_WITH],[ASSOCIATED_WITH],are,N/A,31,0,78,26,1,RO-disease_has_finding,901845-FS1,"GRANULOCYTIC SARCOMAS (GS) are EXTRAMEDULLARY TUMOUR MASSES OF IMMATURE MYELOID cells, also known as chloroma and extramedullary myeloid cell tumour.",EXTRAMEDULLARY TUMOUR MASSES OF IMMATURE MYELOID,GRANULOCYTIC SARCOMAS (GS)
